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Abstract 
Aims 
The aim of my research was to evaluate a novel way to empower patients 
with inflammatory bowel disease by giving them access to personalised information 
about their condition and management. I also reviewed the literature relating to 
personal health records and have reflected on my experience of conducting research 
from my perspective as a nurse practitioner.  
Methods 
We took a pragmatic mixed methods approach to the study. We convened a 
local focus group and employed a summative analysis technique to explore the topic.  
Based on the outcomes of the focus group we developed an intervention 
(ELIJAH) that extended the local IBD electronic health record to enable the creation 
of individualised IBD health reports that were educationally enriched. We tested this 
intervention in a pragmatic randomised controlled feasibility study with 61 patients 
from one District General Hospital in South Wales.   
From the learning and recommended modifications of the feasibility study 
we drew up a protocol for a fully powered phase III trial of the intervention.  
Results 
The focus group showed that patients wanted more access to their IBD health 
records and individualised education about their disease.  
The randomised controlled feasibility study of the ELIJAH intervention 
showed that the intervention met the clinical and feasibility criteria, and the 
intervention with modifications could be progressed for a fully powered phase III 
trial.  
Conclusion 
The ELIJAH intervention is wanted by patients and is feasible to produce and 
test.  
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Chapter one: Introduction 
Chronic disease is a major cause of health problems in the U.K. Finding ways 
to best serve chronically ill patients is amongst the most important challenges facing 
the health care system. Self-management programmes and open access to specialist 
services at times of need can offer new models of care, but heavily rely on well 
educated patients who are able to take responsibility for their care and have effective 
communication with health care providers.  
In Gastroenterology, Inflammatory Bowel Disease (IBD) is an example of a 
chronic disease of unpredictable pattern that heavily uses primary and secondary 
care resources, and may be better managed by empowering patients to take increased 
responsibility for their own care (Hall 2007).  For patients to be more able to self-
manage, they need to have increased individualised information and education about 
their condition, their individual care pathway including agreed plans for care, and 
easy and effective ways to communicate with the multi-disciplinary team. 
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 1.1 Background 
Inflammatory bowel disease 
Inflammatory Bowel Disease (IBD) encompasses many chronic, 
unpredictable, relapsing disorders that originate within the bowel or gastro-intestinal 
tract. The two most common forms: Ulcerative Colitis and Crohn’s disease often 
require powerful medical treatments: steroid, immunosuppressive or more powerful 
biologic therapy and / or major surgery (Travis et al 2008) in order to treat the often 
debilitating and distressing symptoms and establish maintenance. The treatments 
also can cause additional symptoms and complications (Carter et al 2004). As with 
many chronic diseases there is no known cure (Stange et al 2008), and patients can 
experience an exacerbation of their symptoms which could include defecation of up 
to 20 times a day with diarrhoea, mucus, pus and blood, nutritional depletion and 
weight loss, anaemia, abdominal pain, vomiting and emergency situations such as 
bowel narrowing, blocking and stasis (stricturing and obstructing), septicaemia (from 
toxic megacolon) without reason or warning. IBD is a major cause of morbidity 
(British Society of Gastroenterology 2005), but has no raised mortality rate 
(Williams et al 2006), for men and women equally and affects an age range of early 
teens to old age.  
Overview of UK patient management of inflammatory bowel disease 
There are about 150,000 cases of IBD within the United Kingdom (Mowat et 
al 2011), mostly cared for within the National Health Service (NHS) in secondary 
care settings (Robinson et al 2001). There are approximately 8,500 new diagnoses 
made each year (British Society of Gastroenterology 2005). Care of IBD has 
traditionally mostly been based in secondary care with little involvement from the 
primary sector principally because of the unpredictable nature of the disease, 
potential complications, powerful treatments and subsequent medication monitoring 
regimes. Both newly diagnosed, and patients with a long history of IBD, may make 
frequent demands on health services from both their secondary care provider 
(Williams et al 2007) and GPs as patients often require close communication with 
long-term specialist follow-up and seek significant involvement with their care-
providers to make important decisions regarding their care.   
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Within secondary care, patients regularly access services offered to 
investigate or follow up their care according to their presenting symptoms, and up to 
half of patients experience a flare of their IBD symptoms annually (Mowat et al 
2011). Secondary care providers usually offer scheduled care in gastroenterology or 
surgical outpatient clinic, some offer joint clinic between these two specialities, as 
well as endoscopy and inpatient care, and emergency care as needed. Patients with 
non-acute disease are often provided routine follow-up appointments of typically 
three month to annual frequency to assess their disease, alongside open access 
opportunities via a telephone helpline. However, this arrangement for an 
unpredictable disease process often misses the opportunity to provide rapid 
appropriate specialist intervention at time of need, or misuses resources by assessing 
a well patient. Increasingly services have recognised these issues and have provided 
open access services such as telephone helplines and email, alongside scheduled 
care, that have provided remote access to clinical advice, information and triage to 
specialist care at time of need (Rogers et al 2004). These open access services are 
usually staffed by IBD Clinical Nurse Specialists working with the multi-
disciplinary IBD team.  
A patient’s’ IBD clinical team is usually multi-disciplinary consisting of 
Gastroenterologists (who usually lead care), Gastro-Intestinal Surgeons, 
Endoscopists, Clinical Nurse Specialists or Nurse Practitioners in IBD, Radiologists, 
Dieticians and Nutritionists, Pharmacists, Histo-pathologist, and ward staff amongst 
others (Williams et al 2006). The tertiary sector of care is very active in supporting 
patients with IBD, and in the U.K. the charity Crohn’s and Colitis UK provides 
advice, support and helplines alongside research grants and professional and patient 
led forums.  
IBD care, due to its unpredictability, is costly to provide because of the 
intense demands upon healthcare resources. The IBD Standards 2009, reported that 
the cost of IBD care to the NHS per annum is approximately £720 million of which 
half some £360 million is directed toward the small proportion of IBD in-patient 
based care. They recommended that responsive outpatient care with the resulting 
effective assessment and management of symptoms at time of need and efficient 
maintenance of remission could prove cost effective and for the patient clinically 
optimal.  
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Our service 
Since our records began in 1990 till 2015 when I left the service, we had 
looked after 860 patients with IBD in the Gastroenterology and Endoscopy 
Department of Neath Port Talbot Hospital, a small District General Hospital within 
the Health Board organisation of services in South Wales.  
I joined the Gastroenterology team in 2002, and was appointed as an 
Advanced Nurse Practitioner in Gastroenterology and Endoscopy. My appointment 
was made as a direct result of a research study, carried out within the Neath Port 
Talbot area that looked at the opportunities open access follow up could have for 
IBD patients (Williams et al 2000). The randomised trial concluded that open access 
follow-up of patients with IBD reduced demand on overall health resources due to 
lower outpatient clinic and investigative contacts. The study found that patients and 
GPs both preferred open access i.e. patients receiving secondary care clinic 
appointments and investigations during time of symptoms rather than in a 
prescriptive pre-determined way, but both groups reported issues with the system.  
Patients reported “difficulty in obtaining an urgent appointment” (Williams et al 
2000 p.544), so negating the premise of open access, and 64% of participating GP’s 
“favoured a gastrointestinal nurse practitioner as a point of contact” (Williams et al 
2000 p.546) based within the secondary care setting and allied to a medical 
gastroenterology team, rather than primary care contact. 
The additional benefit of educating patients to manage their own care was 
reported in a similar study at around the same time as the Williams study in 2000. 
Robinson et al 2001 demonstrated reduced hospital and GP visits if patients were 
given education of how to deal with increased symptoms, however they noted that 
wide-spread implementation of the scheme would require “radical reorganisation of 
most outpatient clinics … available at short notice” (P976).   
These two studies, Williams et al, and Robinson et al helped fundamentally 
shape my role in 2002. I was tasked primarily to help provide scheduled follow up 
and investigations for IBD patients, postal review follow up for stable patients, and 
establish a telephone helpline that patients could contact at time of need. Each of 
these activities was underpinned by an electronic patient record (GeneCIS), that 
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provided immediate access to relevant demographic, and clinical coded and free-text 
details (Williams 1999).  
These innovations lead to a stabilisation of rising demand initially, improved 
the variety of access for patients and extended use of the electronic patient record. 
However, outpatient workload rose steadily from 2005, and the telephone helpline in 
particular constituted a significant portion of the clinical activity of my role. The 
department of gastroenterology had also expanded during the late 2000’s, and 
provided increasing numbers of diagnostic, therapeutic, and rapid access services for 
more chronic and complex inflammatory bowel disease patients who required long-
term and sometimes life-long follow up.  Our experience was not unique, and was a 
reflection of the UK-wide IBD service provision (BSG 2006). 
The issue 
By 2010 we had approximately 600 IBD patients actively under our care, and 
the innovations implemented to try to divert pressure upon clinics such as the 
telephone helpline service had not helped quell demand for outpatient services. My 
service had seen growth since 2002 (see figure 1. ANP service activity 2002-2010). 
The rising demand from 2002 to 2010 threatened to outstrip the capacity of the 
service to provide responsive IBD patient centred services, especially at time of 
patient need.  
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Figure 1. ANP service activity 2002-2010 
 
Note: data from 2008 is taken from six months of activity only due to maternity 
leave.  
Our clinical team met in late 2009 to discuss the rising pressures on the IBD 
service. We considered how best we could meet the rising patient demand for 
services, while maintaining a vision of care delivery that provided safe, cost-
effective, and flexible services to meet each individual patient need. We did not want 
to compromise on the quality of care afforded to our IBD patients and felt it 
important to maintain patient empowerment and open access to services especially at 
time of exacerbation of symptoms when rapid access to specialist care is essential. 
In previous times of increased demand we had expanded the clinical team by 
recruiting additional doctors or specialist nurses, enlarged the involvement of 
primary care and implemented innovations such as open access to services.  
Our first option of increasing the clinical team was not feasible as in 2010 the 
UK and healthcare was in an age of recession and austerity (Department of Health 
2010). There was an appreciated lack of opportunity to bid for additional funds. We 
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were advised we had to look at ways of providing expansion of clinical services 
within our budget and any innovation was required to be cost-neutral.  
Enlarging the involvement of primary care in the management of IBD 
patients was not popular with primary care as shown in the Williams et al study 
(2001), and there did not exist the specialist knowledge in primary care of IBD to 
facilitate this.  
Our approach to the issue 
We considered improving our clinical processes and discussed whether we 
could further innovate our existing open access patient provision. From data gathered 
from the telephone helpline and anecdotally in outpatient clinic we understood that 
patients wanted more information about their IBD and about their own disease 
process and pathway. One way patients tried to achieve this was by gathering 
information from a wide variety of resources outside their main care providers 
including patient forums, charities, the internet and support from other patients. We 
understood that collectively available patients’ information about IBD was largely 
generic, mass produced and wide-ranging in terms of quality and reliability.  Much 
of it was, therefore not applicable to the idiosyncratic individual patient disease 
pathway. 
We hypothesised that if we could provide patients with their own IBD 
information they may be empowered to better self care as they could hold clinically 
accurate information, understand their medical history more fully, and implement 
care-plans at time of need to treat mild to moderate symptoms quickly and 
effectively without attending outpatient clinic or contacting the telephone helpline. 
We considered whether patients should simply have access to their whole IBD 
record as it was held in secondary care. However, we realised that the records were 
sometimes complex, disordered, incomplete, and the medical terminology used in 
correspondence and reports held in the patient records i.e. clinic letters, endoscopy 
reports or discharge notification, could be confusing or cause misunderstanding for 
patients. We also debated whether patients should have direct access to their 
information held in GeneCIS, but found this approach to be too technically 
challenging and costly.  
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Our use of the EPR in endoscopy told us that we could produce summary 
reports by completing a multi-levelled questionnaire. The endoscopy report was 
routinely given to patients and consisted of a short précis of the examination that had 
taken place, we recognised that an IBD patient report would need to be more 
detailed, but the endoscopy report concept could be transferrable. We keenly 
understood that we would need to electronically attach portions of educationally 
explanatory information to the clinical facts relayed to ensure patient understanding 
of the clinical terminology and provide clear information regarding patients’ 
individual care pathways and inform patients how to access care when needed.  
We envisaged improved patient empowerment and self management through 
this method of sharing the clinical information held within our EPR and providing 
the information in the form of a personalised and educationally enriched IBD report. 
We wanted to provide this new patient service in conjunction with traditional 
outpatient clinics and open access services to provide a realistic complementary 
approach to traditional follow up services. We postulated that via this approach we 
could reduce the load on clinics, and free up clinical time to allow patients who did 
need to be seen quickly have rapid access to outpatient appointments.  
In 2010 we found little evidence of the cost or effectiveness of our proposed 
approach. There were some studies, mainly from primary care, of the experience of 
primary care teams enabling patient access to medical records (Bhavnani et al 2010, 
Cimino et al 2000, Fisher 2009, McKinstry 2006), but few from secondary care and 
none looked at these type of innovations with IBD patients.  
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1.2 Aims and objectives 
As a result of our deliberations we proposed to pragmatically extend the 
capabilities of our electronic patient record system (GeneCIS) to produce 
individualised, educationally enhanced IBD reports, and added email to our existing 
repertoire of methods of contact for GPs and patients. We researched these 
innovations within a funded mixed methods trial utilising qualitative and quantitative 
research techniques.   
Our stated aims were:  
 To understand what patients want from access to their information 
and from an IBD report.  
 To understand the pertinent factors when providing patients access to 
their health records. 
 To develop an intervention to produce individualised, educationally 
enriched IBD patient information.  
 To determine the feasibility of undertaking a trial of the intervention.    
Our objectives were: 
 To undertake a focus group to determine whether patients want access 
to their personalised health reports, and, if so how these should look and the 
content.  
 To use the results of the focus group to inform the development of the 
intervention   
 To create a facility within our existing EPR to produce individualised 
and educationally enriched IBD reports, and make these available to patients and 
GPs. 
 To use the IBD reports to facilitate greater understanding of a 
patient’s IBD history and care plan, and enable patients to take greater 
responsibility for their healthcare through better communication between patients 
and clinicians 
  To evaluate whether the approach was feasible to test in a fully 
powered randomised controlled trial.  
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 To undertake a literature review to identify the most appropriate way 
of providing patients with access to their own medical health records, and to 
identify gaps in the research literature.  
Within this thesis I will describe how we met our stated aims and 
objectives.  
In chapter two, I will discuss the findings of a patient focus group held to 
explore the views of IBD patients’ regarding access to their healthcare information, 
and to elicit patient views on the development of an intervention to deliver patients 
their IBD information. How this valuable patient insight was used to develop the 
intervention is described within chapter three.  The pragmatic randomised controlled 
feasibility trial to determine feasibility of testing the intervention is examined in 
chapter four. In chapter five I relay a reflection of my experiences whilst conducting 
the trial and in chapter six a systematic literature review of the pertinent evidence 
used to develop the trial in 2010, and developments to the present day are presented. 
The systematic literature review is placed within chapter six as it reflects on the 
findings of the focus group and feasibility trial and informs a protocol for further 
study. The final chapter draws on all of the examination of the development and 
testing of the intervention and sets out a protocol for a fully powered randomised 
controlled trial of a modified ELIJAH intervention.  
 
 
 
 
 
 
 
 
 
 
 21 
 
Chapter two: The Focus group 
In the introduction, I discussed how we had noted an increase in the number 
of patients with IBD attending outpatient clinics and seeking advice from the 
telephone helpline.  We recognised that traditional methods of increasing the 
capacity of the IBD outpatient service were not feasible and so we considered further 
developing our EPR: GeneCIS, to develop individualised and educationally enriched 
IBD reports.  
We thought that these reports could be shared between patients, their GPs 
and secondary care, and that the reports could be used to by patients to enable them 
to better self manage their symptoms. We hypothesised that having these structured, 
detailed and individualised IBD reports could empower patients to better self-care 
through a raised understanding of their disease process, and by patients’ initiating  an 
agreed plan of action in the event of increased symptoms. But we recognised that 
this potential innovation was the vision of the clinical team. We needed input from 
patients to ensure the IBD reports were what patients wanted based on their previous 
experiences of access to their IBD information.   
In this chapter I will relay how we convened a local IBD focus group, and 
employed a summative analysis technique to gather and explore patients’ views of 
their previous IBD education, care planning, communication, and their opinions of 
our proposed intervention. 
The methods used in this explanation of the focus group follow the COREQ 
(COnsolidated criteria for REporting Qualitative studies checklist and guide (Tong et 
al 2007), appendix 1.  
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2.1 Background and objectives 
In 2010 there was little published evidence on patients’ views of access to 
their IBD information and how this access could affect patients’ health outcomes.   
Cimino et al (2001, 2002) reported that when patients in the U.S. were given 
access to their medical records they reported better knowledge and understanding of 
their condition and had an improved relationship with their clinicians. However, the 
study was small and had few participants: thirteen. Of these thirteen patients many 
had used the system infrequently, and only five patients remained in the study until 
completion of the trial. The research was of limited quality because of the low 
number of participants and high number of trial drop-outs. 
McKinstry et al (2006), in a seminal paper, looked at the clinical effects on 
known hypertensive patients of an individualised care plan. This high quality, large, 
randomised study of over 200 U.K. patients found no statistically significant effect 
of the intervention on blood pressure readings, and this quantitative trial did not 
include patients’ views of the intervention. Fisher et al (2009) did explore primary 
care patients’ views of access to their records and again found this had the potential 
to improve the Dr - patient relationship. Three themes emerged from their findings of 
how patients used the additional information offered to them through access to their 
records; “participation in care, quality of care and self-care strategies” (p 77). There 
was some evidence that if patients used the system frequently then over time this 
could have a positive effect on their health outcomes, but this was not proved by the 
results presented.  
There were few U.K. based papers showing evidence of patients’ views, 
opinions or outcomes of having greater access to their health information. Honeyman 
et al 2005, conducted interviews with over 100 primary care patients questioning 
whether they wanted more access to their health records and what potential benefit 
they believed they may gain if they were given access. They reported that the 
participants did want to see their information and, in a reflection of the Cimino et al 
(2001, 2002) findings, thought this would enhance the patient/ clinician dynamic. 
The patients acknowledged that there could be errors in the records but were 
enthusiastic to have the opportunity to correct these and up-date the record to include 
current issues or problems. However, the Honeyman et al research explored the 
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potential of enhanced access to the record without giving the patients the opportunity 
to try a system designed to achieve improved access, nor gave examples of what the 
access could look like.  
There were a limited number of literature reviews looking at patient views of 
access to their health information. Ross et al 2003 reported that patients liked having 
access to their health information and benefits included better communication with 
their clinicians. Ferreira et al 2007, concurred with the findings of Ross et al, and 
they concluded there were few drawbacks or risks of enabling patients to view or 
hold their information. However, the assessment of quality of the articles appraised 
within the literature reviews revealed that many of the studies examined were of low 
quality and none demonstrated an improvement in clinical outcomes (Ko et al 2010).  
There was a paucity of evidence looking at what IBD patients wanted from 
access to their records. None of the papers, in 2010, included IBD patients in their 
participant cohorts but there were calls from professional and patient representative 
IBD groups, at this time, for patients to be given greater access to their health 
information. Politi et al (2008), in a pan-European and Israeli study, provided a 
questionnaire to nearly 1000 patients, asking how they best they liked receiving 
information about general IBD issues. The study did not ask whether or how patients 
received their own individualised information. The majority of patients (over two-
thirds) reported they preferred information via their countries IBD information 
channels and in paper form. However, the study concluded that patients should have 
more access to information in the way that they individually prefer and electronic 
means of communicating the information should be increased.  
We concluded from a review of the above literature that the evidence base for 
our intervention development was mostly of poor quality and there was little usable 
data that we could apply to the development of our intervention. We decided to 
conduct an IBD focus group to enable us to gather useful and insightful data that 
could plug the gaps in the evidence base.  
Aims 
Our aims were to:  
 To understand what patients want from access to their information and from 
an IBD report.  
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Objectives 
 To undertake a focus group to determine whether patients want access 
to their personalised health reports, and, if so how these should look and the 
content.  
 To use the results of the focus group to inform the development of the 
intervention   
 To ascertain whether patients think that the IBD information they 
have received is adequate, appropriate and can be utilised effectively especially 
at time of need. 
 To determine how patients communicate with health professionals 
and discover where improvements can be made. 
 To identify whether an intervention output that would deliver 
individualised and educationally enriched patient reports is wanted by patients.  
 To gather opinions and views to inform the construction and content 
of the intervention.  
We decided to carry out a focus group to collect the data, rather than harvest 
patients views via alternative means such as questionnaires or structured interviews, 
because we wanted to quickly and conveniently gather the information as our trial 
period in total was limited to one year only. We also believed that a focus group 
could allow us to pick on richer data through the interaction of participants and the 
interplay between them and the use of open questions (Kitzinger 1995). We wanted 
to allow the focus group participants to explore the broad themes and were interested 
if themes arose that we had not envisaged. 
Focus group methodology has been used extensively within healthcare 
research to explore patients’ views and understanding of health and we wanted to 
exploit the potential advantages of this methodology; effective and efficient data 
collection, easy identification of themes, easy-going environment to create 
productive discussion and empowerment of patients to give their views in a 
collective of similar patients (Robinson 1999).  
Within this chapter I will describe how we held a focus group that comprised 
of IBD patients, and how we met our stated aims and objectives.  
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3.2 Methods 
We designed this study to amass IBD patient views of their IBD information 
and education that they had received since their diagnosis, care planning and how 
they communicate with their healthcare providers. We also gathered opinions on the 
design and content of an intervention to deliver individualised IBD information.  
Research team 
I conducted the focus group, and invited patients to take part in the focus 
group. Some of the ten patients who attended the focus group had been under my 
care and had attended the IBD clinic or endoscopy sessions that I carried out as part 
of my role as an Advanced Nurse Practitioner. The trial manager and a lecturer from 
Swansea University were also present at the focus group to take notes and help in the 
organisation of the group if required. Each of the research team present at the focus 
group introduced themselves to the participants at the start of the focus group.  
Participants 
Participants from Neath Port Talbot Hospital, ABMUHB were invited to 
participate in the focus group. We recruited the patients in March 2010 and the focus 
group was held in May 2010 (see figure 2. Summary of ELIJAH timeline: focus 
group).  
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Figure 2. Summary of ELIJAH timeline: focus group 
Summary of timeline 
TASK ACTION FINISH 
ETHICS.R&D APPLICATION 24.12.09 
 INTERVIEW 22.01.10 
 PT LEAFLET & CONSENT 05.02.10 
 NHS R&D 05.02.10 
SHINE FUNDING APPLICATION 02.11.09 
 INTERVIEW 09.12.09 
 MEET SPRINGFIELD CONSULTANCY 08.01.10 
 HEALTH CHECK 04.02.10 
 CONTRACT 03.02.10 
 APPOINT PROJECT MANAGER 0.4 01.02.10 
 CONFERENCE AWARD 25.02.10 
 DASHBOARD 01.02.11 
OUTCOMES PT SATISFACTION QUESTIONNAIRE 26.03.10 
 TESTING Q 12.03.10 
 ADVERSE EVENTS 15.04.10 
 COST 09.02.10 
 TIMELINESS 19.03.10 
 EQUITY 19.03.10 
INTERVENTION AGREE SPECIFICS & CUSTOMISE 25.06.10 
 REVISE INTERVENTION & PILOT 07.07.10 
RECRUITMENT IBD PT LIST GENECIS 17.12.09 
 IBD PT LIST BY GP 20.12.09 
 GP RECRUITMENT 12.02.10 
 GP INFORMATION LETTER 06.02.10 
FOCUS GROUP ADVICE RE FOCUS GROUP QUESTIONS 10.02.10 
 PATIENT RECRUITMENT 10.03.10 
 HOLD FOCUS GROUP 26.05.10 
 FULL TRANSCRIPTION                                           10.11.10                
 ANALYSES 13.02.11   
 REPORT 12.04.11   
PATIENT EDUCATION SOURCE EDUCATION PACKAGES 28.02.10   
 NACC VISIT TO NPTH 29.01.10   
 REVIEW EDUCATIONAL PACKAGES 12.03.10   
PATIENT RECRUITMENT SEND LETTERS 02.06.10   
PATIENT RANDOMISATION 30.06.10   
TRIAL START 
 
01.12.10   
EXTRACT GP NOTES 22.02.11   
FINAL FOLLOW UP 31.03.11   
FULL ANALYSIS & REPORT 31.08.11 
 
 
 
PUBLICATIONS  
31.08.11  
       
 
 
 
 
We identified patients with a secure diagnosis of IBD by searching within the 
GeneCIS EPR for coded IBD terms and verified these by cross-checking the 
information with endoscopic and histological evidence of IBD found in the 
electronic and paper hospital records. We checked whether patients were currently 
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under the care of the gastroenterology team at Neath Port Talbot by identifying the 
date of the last admission to clinic or endoscopy and noted the patients’ registered 
GP practice.  
The eligibility criteria for inclusion for patients were: 
 Confirmed diagnosis of IBD 
 Recent review (within 18 months) of IBD care at Neath Port Talbot Hospital 
Patient ineligible for inclusion included those who did not meet the inclusion 
criteria in terms of diagnosis and IBD care, and those who could not understand the 
study.  
We stratified the patients by GP practice and created a database of patients 
listed alphabetically by GP, and under each GP listed the patients numerically 
according to their hospital number. We randomly invited every tenth patient in the 
list to take part in the focus group on 10th March 2010 (see figure 1). This method of 
randomisation was undertaken to reduce the potential bias of the focus group, and to 
ensure equal representation from the wide geographical areas of the patients.  
A total of number of 23 patients were invited from 35 GP practices. Patients 
were sent a letter and a consent form outlining the purpose of the focus group and 
detailing that ethical approval for the focus group had been obtained. Patients were 
asked to consider the invitation and inform us of their choice to attend or not.  
One patient did not respond to the invitation call and the GP informed us that 
the patient was immobile and so would not be able to attend. In total nine patients of 
the 23 patients invited could not attend the meeting or did not want to. Reasons for 
not attending varied and included being busy on the evening of the focus group, not 
wanting be a participant, having hospital appointments that day already and side 
effects from treatment that could affect the wellness of the patient to attend. One 
patient stated their IBD was so unpredictable that they did not think they could 
participate for the two hours required as they had frequent requirement to use the 
toilet. Of the 14 patients who replied that they would attend the focus group, ten 
attended the evening meeting.  
The participants consisted of seven female and three male participants. The 
ages of the participants ranged from 23 to 71 years of age, and there was an equal 
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split of IBD with five patients having a diagnosis of ulcerative colitis and five with 
Crohn’s disease. 
Setting 
We held the focus group in a conference room in the Post Graduate Centre of 
Neath Port Talbot Hospital on the 26th March 2010 from five till seven PM with a 20 
minute break for refreshments provided by the research team. We chose to hold the 
focus group in the hospital as we thought this would make travel easy for patients as 
they had had appointments within the building previously, and there were good 
parking and public transport links available. We reimbursed the patients £50.00 each 
to cover their travel costs.  
Before the focus group started the trial manager who was attending the focus 
group, answered any participant questions about the focus group and obtained 
written informed consent from each participant. 
At the start of the focus group we welcomed the group, and I introduced the 
other two researchers in attendance. The total number of people therefore in 
attendance was 13 – ten participants and three researchers. We reassured the 
participants that confidentiality of their inclusion in the focus group would be 
maintained and that any quotes used from them would be anonymised. We also 
implored the group to not discuss the focus group with anyone to maintain the 
privacy of the group members. 
We asked that participants write their names on a card and place it in front of 
them and when speaking we asked that patients state their name to ensure that their 
comments could be differentiated from each other on the recording. We gave the 
participants the opportunity to ask any questions prior to the focus group starting and 
also informed them that the researchers would be available immediately after the 
focus group had finished to speak with if needed. We re-iterated that full ethical and 
research and development approval had been sought and secured.  
Ethics 
As we were conducting a focus group with IBD patient participation we were 
required to obtain full ethical and local NHS Health Board research and development 
approval. We applied and received this prior to the invitation of participants to the 
focus group. The IRAS application was submitted in December 2009 and we were 
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notified that we had been granted full ethical approval on 5th March 2010 (see 
appendix 12).  
The focus group conduct and study monitoring was overseen regularly by the 
trial manager and by monthly meetings of the research management team.   
Data collection 
I prepared questions for the focus group in three main topics: IBD 
information and education, care planning and communication with health 
professionals. I informed the participants that we would not be covering subject 
areas specifically about their condition or their current symptoms, but would rather 
be listening to them talk about their views on the ways they had sought IBD 
information and used this to self care and impart and transmit information with their 
IBD care provider.  
The prepared questions were:  
 Education and information: 
1. What information about your condition have you had and has 
it met your needs or expectations? 
2. What information would help you to manage your problems?  
3. How do you perceive your individual needs?  
 Care planning: 
1. What would you find most beneficial to know? What would 
be most useful to be contained in any information?  
2. Which areas do you think you need most help and support in, 
and are there things we have left out in your care information?  
 Communication:  
1. How would you want to contact us when you need help and 
why? 
2. How helpful is it to come and see a Dr or nurse or could 
seeing or holding your own IBD information give you answers 
to your queries?  
3. How comfortable would you be looking at the clinical IBD 
letters we send from outpatients to your GP?  
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Following the refreshment break we reconvened and we asked the 
participants to consider critiquing a prototype demonstration of our designed 
intervention. We asked the participants to:  
 Consider whether the title was more appropriate as “Your history” or “My 
history”.  
 Think about whether they would use the kind of IBD report we proposed. 
 Identify if they felt it could be helpful in them knowing more about their 
disease and care. 
 Judge whether it could save patients time.  
 Contemplate whether it could alleviate concerns.  
We used audio recording of the focus group to capture the data and the 
lecturer researcher made field notes during the discussions. The one hour and forty 
minutes of recordings were transcribed shortly after the focus group.  
Summative analysis 
The focus group was held to provide us with patient views of their IBD 
information, care planning and communication with healthcare providers, and for us 
to gather opinions on our potential intervention ELIJAH.  
We employed a summative analysis methodology (Rapport 2010) to sort and 
explore the data. We chose this methodology to exploit the very good multi-
professional research team working we had already established within the ELIJAH 
team. We were drawn to the methodology by the opportunity for 
 “an egalitarian approach: (where) everyone’s view matters; (and) all members 
are included”  
                                                 Rapport 2010 (p272) 
and the potential to identify the more nuanced themes and topics discussed by the 
participants.  
We wanted to ensure that we had analysis of the focus group text from the 
many different points of view of members of the research team, and we aspired to 
work through the summative analysis method and achieve a consensus of the key 
components of the focus group feedback.   
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We consulted with Professor Rapport, author of the summative analysis 
technique and drew on her experience and knowledge while following the basis of 
the summative analysis methodology.  
We first gave each of the six research team members the full transcript of the 
focus group and asked each of them to write a short and concise paragraph of each of 
the focus group question topics i.e.: education and information, care planning, 
communication and the prototype intervention. We asked that the group reflected 
within their paragraphs their understanding of the core elements of the transcript. I 
then gathered these short reports together and reviewed them, and identified 
similarities, differences and unexpected instances between the reports.  
We then met as a team to discuss our summary reports and to debate 
pertinent points. During the afternoon session we also reviewed the items I had 
identified in the collation of the individual reports. After debate and discussion of the 
overall themes and topics of the text and identification of supporting evidence for 
our consensus, we agreed the results of the focus group.  
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3.3 Results  
Ten, randomly selected people with a confirmed diagnosis of IBD and under 
the care of the gastroenterology team at Neath Port Talbot Hospital attended the 
focus group. Three researchers attended alongside the participants.  
The focus group met to discuss the information provided for patients with 
IBD, and how patients’ use this information to self-manage and communicate with 
health professionals, particularly at time of increased symptoms. The adequacy and 
provision of information and accessibility was discussed, and a potential intervention 
to deliver individualised educationally enriched IBD information was critiqued by 
the participants following their review of a mock-up of the intervention.   
Patients’ ability to gather useful information dominated the first part of the 
focus group conversation. Patients’ were keen to describe the lack in the consistency 
in information provision:  
“Information  ... should be uniform right through the NHS, every place should 
have exactly the same information wherever you go”  
                                                          (participant number 019).  
Many patients reported they had not been given any IBD information by their 
healthcare providers, and consequently had sought and acquired information 
themselves that suited their individual needs. Some had gained information via 
buying books or searched the internet. There was consensus that the information 
received from the major U.K. IBD charity – National Association of Crohn’s and 
Colitis was very applicable and reliable and some patients relied largely on the IBD 
telephone helpline for general and specific information. 
Patients reported that some of the information gathered from the sources 
outside the healthcare setting could “frighten you” (participant number 023) and that 
some felt the information could be overwhelming in amount and content. But the 
group acknowledged that insightful IBD information could help support patients in 
understanding and self-managing their disease, however the wide variety and sources 
of information that they could access could be confusing or frustrating.  
The focus group reported that information from GPs or GPs surgeries varied 
in quality and availability and some agreed that they would bypass this facility and 
be “better off coming straight direct to the hospital” (participant 021) for any advice 
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or help. Members of the group felt that GPs should be able to have access to more 
information about IBD and then impart this to patients more readily, but they 
understood that GPs breadth of expertise meant that this may not always be 
achievable; “they do need to have a little bit of information particularly if they know 
they have got a patient on their books” (participant number 021). The GPs lack of 
knowledge about IBD left patients feeling unable to comprehend their care and they 
felt unable to access help from the GP to help them understand their disease process, 
investigations or treatment options.  
When participants were asked about the kind of information they would like 
to help them manage their condition better, they replied that they wanted to know 
how they could help limit the chances of increased symptoms “things you could do 
to prevent things changing” (participant number 005). They wanted to know if IBD 
was hereditary, and “triggers” (participant number 023) that could exacerbate 
symptoms were discussed at length.  
Patients wanted to know what may arise in their disease process and wanted 
to be clear on what may happen to them; “it is worrying when you don’t know what 
it is” (participant number 023). This lack of knowledge was identified as a cause of 
worry and concern for patients and imagining of a wide variety of scenarios.  
Participant number 021 wanted to be able to “get in touch immediately when 
your symptoms are arising”, and stated that there had been conflicting advice 
received from different departments that meant that knowing what to do if symptoms 
arose was confusing. They continued to state that the information and knowledge 
they could hold if informed, could reduce their reliance on secondary care contacts 
and reduce the time they spent on trying to access help. The participants described 
sometimes as if they were a bother to their healthcare providers if they did make 
contact: “you’re afraid of making a fuss” (participant number 022).  
Patients described using personal experience of their disease and personal 
wisdom as important in providing a sense of autonomy over their disease process.  
There was broad agreement from the participants that any advice or 
information should be clear, concise and should avoid abbreviations, complex 
sentences and in particular jargon. Participants reported they had asked for further 
explanation especially when clinicians had discussions with other clinician: “I don’t 
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understand can you repeat that. Can you put it in layman’s terms please?” 
(participant number 019). This participant further stated:  
“There is a lot of jargon unless you hear them speaking about it all the time  ... 
you do get used to what they say, it’s just now and again they throw in a word 
and you think what on earth!” 
The participants thought that newly diagnosed patients could need more 
information than those who had their diagnosis for a long time.  
Patients discussed the items they thought could be most beneficial to know. 
They reported that more guidance on diet, medications and who and how to contact a 
specialist at time of need was needed.  
When questioned more closely on how participants would want to have 
contact with their clinicians most considered varied options that relied more upon 
information technology than more traditional methods of contact through outpatient 
clinics. Ringing and speaking to a clinician was considered important especially for 
reassurance, but also text and particularly e-health methods such as email. 
Participants considered how they accessed other services in their lives and thought 
that these methods could be applied to their health needs; “the world is on-line. It 
would be good to send a question and get a reply” (participant number 015). There 
was an appreciation of the security requirements of using I.T. methods of contact “I 
would want to make sure that it is secure as well” (participant number 021).  
Participants concentrated on defining the things that could improve their 
well-being: a speedy response to queries, the ability of health care providers to 
support them when they were stressed or anxious and they wanted systems that 
included both their primary and secondary care health providers working in 
collaboration with access to all of their IBD information. Participant number 021 
suggested a new way of health professionals working that could quicken processes 
and enable speedier access to treatment. They suggested that at time of need patients 
could email secondary care, have a quick response with a treatment plan and this 
reply could be forwarded to the GP by email and a prescription for medication 
dispensed immediately. Other participants supported this idea and endorsed a more 
joined up care system between primary and secondary care, and they were emphatic 
that they should be fully included in their care team “it would be a three way thing” 
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(participant number 019), “between yourselves, us and  ... (the) GP” (participant 
number 023). 
The focus group participants discussed the possibility of seeing and retaining 
their medical records, so that they could know more about their care and feel more in 
control of their IBD through greater understanding of their disease. Some 
participants thought they would like to hold their own medical records because they 
saw that organisation and care of their medical records by secondary care was 
sometimes lacking;  
“I would be able to sort my own notes out properly … and be able to control 
them and take them wherever I went and know what was happening”                                                           
(participant number 019). 
Participants reported how they had experience of their notes being unread by 
the health professional they saw, and how they were asked to repeat information they 
had already given, some had notes lost by hospital and had been seen in clinic 
without their full notes. Other participants thought there might be issues with them 
holding their own medical records. One thought they may lose them, others worried 
about the security of them at home and some wanted the information electronically 
rather than the physical file as they thought this could be easier to keep safe. One 
participant worried that if a patient had not been explicit with their partner or family 
about their illness, then their privacy could be compromised, one worried that the 
information could be stolen.  
Overall, having better access to their IBD health information was seen as a 
positive move forward as it could improve patients’ ability to keep abreast of their 
illness, tracing its patterns and ensuring better preparedness for future flares.  
When asked how they would use the information if they held their own IBD 
information, participants reported a range of ways they would actively use the data. 
Some would update the notes and use it as a diary of their symptoms, some would 
use it as an aide memoire during appointments to remember pertinent dates in their 
disease such as diagnosis or surgeries.  
“If you have a flare up … you can look back through and see what happened 
to make you improve instead of calling someone else and you could try and 
improve your condition yourself and control it more”  
                                                            (participant number 023). 
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Many participants agreed with this form of self-management and gave 
examples of how they already self-cared during flares, they reported that they largely 
drew upon previous experience to manage symptoms.  
One participant stated they did not think that patients should be enabled to 
“change your notes” (participant number 021), and they drew on their own 
experience of working in a confidential environment to support their assertion.  
During the second section of the focus group we asked the participants to 
spend ten minutes reviewing a prototype of our idea for an intervention that could 
deliver access to individualised educationally enhanced IBD reports.  
The prototype was developed by reviewing two IBD patient self-care 
management plans, one sourced from a NHS Trust (Luton and Dunstable Hospital 
2010), and one from NACC. Both examples were brief, paper based and generic. 
Within each patient management plan there was space provided for clinicians to 
manually write and relay information to patients. Advice was given regarding the 
recognition of a flare in symptoms and how and who to contact regarding this. No 
individualised patient education was given within the leaflets. We used and adapted 
the broad patient information topics included in both leaflets i.e.: diagnosis, current 
medication and how to recognise a flare, and expanded upon it to create a more 
complete patient history and care plan.  
Both examples were formatted on an A4 sized, hand-written leaflet.  We 
produced a more detailed proto-type product using publisher software. The prototype 
looked similar to a newsletter of individualised patient information with attached 
educationally enriched paragraphs. We called the three prototypes “Your History”, 
“Your Plan” and “Your Follow-up” and included baseline specifications such as 
patient demographics, details of the care team, previous medical history, medication, 
investigations, how to access help when needed, what to do in the event of a flare 
and any recent changes to planned care. We provided a set of the completed 
prototypes with details of an invented patient history.  
Participants fed back that they wanted the name of the reports to be changed 
from “Your History” to “My History” to increase a sense of ownership over the 
reports; “My, because if its “your” it is someone telling you what to do” (participant 
number 023).  
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The group very much welcomed the inclusion of sections of education 
alongside their information and reasoned that this improved the clarity and ability to 
understand the clinical terms contained. The participants stressed that jargon and 
abbreviations should not be used. They endorsed the inclusion of epidemiological 
information about IBD, such as incidence, because this was felt too be reassuring 
that there were many others with the same condition.  
Patients required detailed personal information that was easy to understand, 
without jargon but providing reliable, practical information of how they can help 
themselves and when and where to seek expert advice. 
The research group report 
Six members of the research group were given the full transcript of the focus 
group and asked to write a short synopsis of the major themes they elicited from 
their reading of the text. Each of the six researchers completed the task and I 
reviewed them to identify similarities, differences and anomalies between them.  
There was broad agreement regarding the major emerging themes of the 
focus group. We heard there was a lack of uniformity in the provision and quality of 
information across primary and secondary care, patients’ ability to self care 
developed over time and patients wanted more information about their care and a 
more collaborative team working approach with their primary and secondary care 
clinicians working with patients to provide care. 
All of the research group picked up on themes of the use of jargon by health 
professionals and patients dislike of jargon as they felt it could lead to confusion and 
misunderstanding of information. The ways that patients sourced IBD information 
varied and different hospitals provided different information. The information 
received from an IBD charity was found to be most useful, whilst some information 
gleaned from television or the internet was found to be inconsistent and could cause 
anxiety.  
Patients wanted to know more about diet, triggers for flares and treatments. 
Some patients were happy to self-care and others required more guidance and 
intensive help from their IBD care providers. Self-medication at time of flare was 
initiated by some patients, but others felt unsure about how to do this, and were not 
confident without clear guidance and the permission to do this. Patients’ experiences 
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of their disease process were idiosyncratic and differed greatly between the 
participants. All members of the research group felt that patients wanted appropriate, 
timely and effective care at time of need.  
The research team keenly picked up that patients wanted closer working 
between their primary and secondary providers and patients wanted to be more 
included within decision making and communication. All the researchers felt the 
participants voiced that they wanted more information about their care and some 
would like to hold their medical records. 
There were dissimilarities between the researchers reading of the focus group 
transcription. Some researchers felt that participants stressed the importance of 
secondary led IBD care and stated that the search for IBD information had taken a 
lot of time. Some researchers picked up that patients mostly wanted tailor-made 
dietary advice, and whilst some participants would want IBD reports electronically, 
some wanted paper copies.  
The researchers were asked if there were any aspects of the focus group 
discussion that was unexpected. The researchers concurred that there was surprise at 
how many of the participants used their own experiences and wisdom rather than 
prescribed plans to cope with episodes of increased symptoms. The revelation that 
some participants may not want to hold their records because they had not divulged 
their health information to their family, was also unanticipated. The way that 
participants had described the loneliness and helplessness of coping with their 
symptoms was acutely noted by the researchers.  
The researchers felt there was broad endorsement of the idea for the ELIJAH 
intervention, but there were important modifications and requirements that would 
have to be considered and included. These were: naming the products “My” instead 
of “Your” to increase patient ownership of the product and content, the exclusion of 
jargon and abbreviations from the text. Clear individualised information supported 
by explanatory text, presented in a uncluttered way and delivered via electronic or 
paper means according to patient preferences.  
We met as a research team and discussed the focus group transcription, our 
summary reflections of the transcription and my analysis of researchers’ texts. We 
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spent an afternoon debating the differences picked up by each researcher and 
democratically reached consensus on the main outcomes:  
 That patients want more IBD information and this should be individualised 
and include their IBD disease history.  
 Patients want to better self care under guidance.  
 The information should be jargon and abbreviation free.  
 There should be educational supplement to each section of information. 
 The same information should be shared with the patient, and primary and 
secondary care providers.  
 Patients need a variety of methods of contact especially at time of need, 
including email.  
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2.4 Discussion 
We gained a rich yield of patient feedback from the focus group about how 
patients gather information about IBD, how they use this to self-care, and how they 
communicate with their primary and secondary care providers.  We also gained 
approval for a modified development of an intervention that could enable patients to 
have individualised IBD reports supported by interwoven educational paragraphs.  
Strengths and weaknesses 
The patient engagement has been very rewarding, with good recruitment and 
participation in the focus group which clarified patients views and opinions of their 
requirements of IBD information. Recruitment and consent of the participants 
worked well, as did the randomisation of the participants. The focus group included 
a range of ages and IBD disease types, but male participants were unrepresented on 
the focus group and the sample was drawn from one secondary care settings.  
I conducted the focus group, and some of the participants were patients under 
my care, this may have skewed their openness in sharing their views and opinions of 
the information they had received.  
The research group individually worked thoroughly to analyse the 
transcription of the focus group and progressed through the summative analysis 
phases well.  The research team together maintained a democratic focus and all the 
researchers were encouraged to contribute to discussions. There were differences in 
the researchers reading of the transcription and in their subsequent reporting. Perhaps 
this was because the group was multi-professional and there was a high degree of 
diversity between the members. However, these differentiations were viewed by the 
group as a positive, particularly in discussions of dissimilarities in the text, and were 
used to explore nuances and gain deeper understanding of the text.  
The use of summative analysis methodology to explore the findings of the 
focus group proved to be very useful as it ensured that many disparate views of the 
text were heard, and consensus of the richer meaning of the text was gained through 
open, honest and focused discussion. Had we had only one or two researchers 
analysing the text we could have missed the opportunity to elicit some of the more 
surprising or subtly aspects of the participant feedback. The debate of the text 
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between the researchers allowed different meanings of the text to be explored, 
defended, challenged and collectively defined.  
A limitation of using the summative analysis methodology was that we did 
not carry out a formal thematic analysis of the transcription. As a result of this, we 
could have missed the opportunity to identify underlying emerging themes. It is 
possible the use of an alternative methodology could have yielded more useful 
insight from the data set to inform the development of the intervention. We may 
have, as a research group, negated to appreciate some of the more subtle ideas or 
assumptions revealed by the transcript.    
As with all qualitative research methodology the results of this focus group 
cannot be generalised to whole populations.  
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2.5 Conclusion 
As a result of the focus group we understood that we needed to extend the 
scope of our electronic health record system to enable the production of 
individualised and personalised IBD reports, and add email to our existing repertoire 
of methods of contact. We needed to share these IBD reports with patients and GPs 
in order to enhance our communication methods and ensure parity of information 
and understanding of the content of the reports. 
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Chapter three: The intervention:  
Electronic Linkage for Inflammatory bowel disease to deliver Joint 
Access to Health reports (ELIJAH) 
So far, I have conveyed how we noted a rising demand for outpatient IBD 
services that outstripped our capacity and, how we were unable to gain additional 
funding to expand the number of clinical personnel to accommodate this upsurge in 
referrals. As a result of these two interdependent factors we were led to consider 
innovative ways to provide patients with opportunities to better self-manage whilst 
maintaining the balance of the financial cost of the service and preserving the patient 
safety profile. We decided to extend the functionality of our existing electronic 
patient record (EPR) GeneCIS, and use it to provide more detailed information to 
patients and their GPs. We hypothesised that we could produce individualised and 
educationally enriched IBD patient reports that could be used by patients and their 
GPs and these would better guide care, and empower patients to self-manage within 
agreed IBD care pathways.  
In the previous chapter (Chapter two: the focus group), I reported the 
findings of our IBD patient focus group. The patients were asked questions about 
their views on their hospital based records, whether they had sufficient IBD 
information and how they gained help from their IBD care providers when needed. 
The valuable feedback relayed how patients felt frustrated having to repeat their IBD 
history, medication or care plan at appointments in primary and secondary care. 
They reported how they felt an individualised summary of their past medical history 
and future care plans would be useful, particularly if this was held by themselves, 
their GP and secondary care provider. Some voiced concern over the poor 
presentation of their notes and incomplete or disordered clinical information. They 
were supportive of the development of an intervention that would provide 
individualised IBD information supported by educational supplementation that could 
circumnavigate patients’ reliance upon generic patient information that often did not 
have relevance to their disease process.  
In this chapter, I will describe how we developed the ELIJAH intervention by 
pragmatically extending the functionality of our EPR.  
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The methods used in this explanation of the intervention follow the TIDieR 
(Template for Intervention Description and Replication) 2014 checklist and guide 
(Hoffman et al 2014) (see appendix 2).  
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3.1 Background  
Why  
Patients’ access to their health information and records has been a long-
standing policy priority supported by professional bodies (Royal College of 
Physicians 2017), government legislators (Ross 2003, Cruikshank et al 2012) and 
IBD patients (Politi et al 2008, Winkleman et al 2005) and other patient groups 
(Honeyman et al 2005).   
There is evidence to suggest that better access to health information can 
improve patients’ knowledge (Cimino et al 2002) and understanding of their health 
condition (Cimino et al 2001, Ferreira et al 2007), and that this can lead to better 
self-management of care and enhance the patient/ clinician relationship (Bhavnani et 
al 2010, Fisher et al 2009). Cimino et al (2000) acknowledge these patient benefits, 
and found that the safety profile of traditionally run clinical services do not 
deteriorate by increasing patient access to their health information.  
In 2010, at the time of building the intervention, we found there to be a 
paucity of high quality literature describing how EHR systems could be built to 
enable patients to gain greater access their health information (Ross et al 2003). We 
found only two papers that could influence our development process. Masys et al 
(2002) described how their team had created a security system to protect on-line 
communication between patients and their physicians. They tested the system in 
detail to identify and potential security breaches. They found that PCASSO (Patient-
Centered Access to Secure Systems Online p. 181) met each security challenge 
without infringement of the security processes, but overall the system was had low 
ratings  for usability by physicians because of the complex log-in process. Patients, 
however, liked the system and found it easy to use. Di Marco et al, four years later in 
2006, explained how a developmental system intended to deliver tailored educational 
information to pre-surgical patients could supplement the traditional outpatient 
appointment and verbal explanation of surgery and giving of a generic patient leaflet. 
The article concentrates on the development of “National Language Generation” to 
support the production of the output of the system, but there was no evidence that the 
system was implemented or tested.   
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When we were undertaking the feasibility trial, pre 2010, we found a limited 
number of published rigorous trials testing an intervention to deliver increased 
patient information using an EHR, and of those identified very few showed 
statistically significant results or positive impact of the intervention. In 2001 
Williams et al assessed the effectiveness of producing a patient held record for 
cancer patients. The randomised controlled trial found “no significant impact on the 
quality of life for patients or NHS resource use” (p. 159), but some younger patients, 
and those with multi-professional input did find the intervention advantageous. In 
2006, another U.K. based research team published the randomised control trial 
results of a patient-held guideline for hypertension. McKinstry et al in a large study, 
again found “no clinically significant perceived benefit” (p. 842). Garcia-Lizana 
(2007), in a systematic review, concurred with the two trial findings of Williams et al 
(2001) and McKinstry et al (2006) and did not find evidence of a link between the 
use of advanced IT communication interventions and an improvement in clinical 
outcomes. We were unable to locate evidence of a trial that included IBD patients, 
and neither intervention provided patients with the individualisation of the record 
and the supplemental education component that we proposed developing from our 
EHR.  
Since 1990 our department of Gastroenterology within Neath Port Talbot 
Hospital was supported clinically and administratively by an electronic system: 
GeneCIS (Generic Clinical Information System). At the time of building the 
intervention, the vast repository housed 20 years of information and data in 
structured coded form (Clinical Terms Version 3) and free text, and detailed all 
patient contacts with the department. Each patient endoscopy reports, outpatient 
letters to GPs, telephone calls to the IBD helpline and free text were stored and 
organised to create a longitudinal record about each patient. The patient record was 
used by all staff within the department for administrative and clinical functions. 
Outputs included the generation of endoscopy reports by the completion of clinical 
questionnaires and the production of formatted letters to GPs. Audit and research 
functions including analysis of activity were facilitated by the clinical and clerical 
coding of information. Within my routine clinical function I used the electronic 
patient record to support all my clinical, research and educational activity.  
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As GeneCIS had been designed to facilitate customisation to specific 
contexts we discussed a pragmatic use of the existing software and extension of the 
programme concept applications.  We considered whether we could allow direct 
patient access, through the NHS firewall, to enable patients to view their longitudinal 
record. But, after consultation with NHS IT security we found this to be a complex, 
costly and timely adjustment to facilitate within our constraints and one that did not 
meet the focus group patient feedback requirement of a summary of patient history 
or care plans for more directed self-management.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
3.2 Methods 
What   
Drawing on our experience of using GeneCIS we were supported by Jayne 
Morgan (Information scientist, and original developer of GeneCIS, based at Swansea 
University) and Hayley Dickinson (GeneCIS technical manager) who customised the 
system to meet the functionality needed to produce individualised educationally 
enriched IBD reports from clinical questionnaires. During this developmental period 
the customisation of GeneCIS to support the data collation and production of 
personalised reports was undertaken, piloted and refined.   
The prototype, that was developed and discussed by patients in the focus 
group (detailed in chapter two), was produced using Publisher software. The final 
intervention products to be used in the feasibility trial, were planned to be produced 
using a different software programme; GeneCIS. We utilised GeneCIS’ existing 
facility to transfer clinical questionnaire data into a WORD document and utilised 
this facility for the production of the intervention. Therefore, we anticipated and 
understood there would be significant differences between the prototype and the 
finalised intervention product in terms of appearance, but we aimed to maintain the 
broad content themes and included the modifications identified by the focus group.  
The hierarchical questionnaires we designed had questions and corresponding 
answers for each section of information which we wished to relay, e.g. for IBD 
diagnosis the high-level answers were Ulcerative Colitis, Crohn’s disease, 
Indeterminate Colitis and Microscopic Colitis. The answer to any question had 
multi-levels of potentially different answers written in so that we could carefully and 
precisely detail the clinical information e.g. if a person were diagnosed with 
Ulcerative Colitis, the next level of questioning sought information on the extent of 
the known disease (see appendix 5 example of ELIJAH report).   
The speedy production of individualised IBD reports was aided by access to 
the existing clinical data that were held in paper and electronic form in secondary 
care. However, much of the data needed were already held within GeneCIS in the 
existing patient electronic healthcare record. We did not include an IBD disease 
symptom index calculated score within the intervention as we did not find evidence 
of routine use of such a tool within the patients’ notes in either primary or secondary 
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care. Supplementary evidence about other health conditions and interventions were 
obtained from the hospital medical paper based notes. Investigation results were 
obtained from the electronic results system (INDIGO), and the hospital patient 
administration system (PIMS) provided information about appointments and 
admissions. The information was inputted by a clinician, and used to populate the 
questionnaires. Patient educational components were also included in this structure.   
Each answer in the questionnaire was linked to a specific paragraph or 
picture of educational content, this was automatically included in the output of the 
report e.g. for a patient diagnosed with distal ulcerative colitis a picture describing 
the extent of the disease was attached (see figure 3. ELIJAH colon diagram for self 
management plan; distal ulcerative colitis).  
Figure 3. ELIJAH colon diagram for self management plan; distal ulcerative colitis.  
 
 
 
 
 
 
 
 
We involved the National Association for Colitis and Crohn’s (NACC now 
known as Crohn’s Colitis UK), the charity supportive of people with IBD, to enable 
the educational element of the intervention to be obtained from existing, evidence 
based and peer reviewed information. We validated the educational content and we 
involved the President of NACC at that time; Richard Driscoll and gained 
permission to use and dissect the patient information as required. We analysed 
NACC’s generic patient information for useable content, directly took sections that 
were applicable and applied them to the ELIJAH levels and descriptors. We were 
careful to use unambiguous phraseology in the reports and adhered to the Plain 
English (www.plainenglish.co.uk) directives.  
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A user friendly and comprehensive structure for the reports was devised. The 
ELIJAH report was to be in three parts, and formed a “My folder” of information for 
the patient, secondary care and GP. 
 
 The first section called “My History” gave information and education about 
the patients’ diagnosis, previous investigations and surgery, medication, diet, 
co-morbidities and social history. This enabled patients and clinicians to gain 
a greater understanding of the past IBD medical history.  
 The second section: “My plan” informed patients and GP’s of how to make 
contact with secondary care services to gain advice when needed and how to 
initiate treatment modifications. The information contained within “My plan” 
detailed current medication, planned changes to treatment, investigations to 
be carried out, planned surgery, medication monitoring, and general health 
guidance, follow up arrangements and referrals and a communication plan 
and feedback opportunity.  
 The final element of “My folder”: “My update” was a documentation of any 
contact with the gastroenterology department either by clinic appointment, 
telephone call or email. It detailed the symptoms, medication, investigation 
results and the GP correspondence.  
Intervention patients choose to receive this information via email or in paper 
form. As part of the intervention, facilities to provide feedback and update secondary 
care about any clinical changes was available to patients and GPs via a secure NHS 
email Elijah.gastro@wales.nhs.uk . This provided the patients and the GP practices 
participating in ELIJAH use of email to answer queries and receive advice or triage.  
Each report was saved automatically in GeneCIS as an ELIJAH report in the 
patient longitudinal record.  
Who  
Our multi-disciplinary research team included my participation as an 
Advanced Nurse Practitioner and researcher, and a Consultant Gastroenterologist, 
Computer Scientist, local GP, Trial Manager, Health Economist, Research 
Methodologist and Nurse Academic.  
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I undertook the collation of the patient data, input into the questionnaires, 
production of the reports and dissemination of the elements of “My Folder” to the 
intervention patients, GPs and secondary care clinicians. I was a band 8A Advanced 
Nurse Practitioner (ANP) with experience as an IBD Specialist Nurse and had co-
created the GeneCIS ELIJAH extension. No specific education or training was 
therefore given for these tasks.  I had experience of reading and deciphering the 
hospital paper and electronic notes and navigating the other patient information 
systems.  
We did not provide additional training in secondary care to members of the 
multi-disciplinary team involved in the care of the intervention patients i.e. 
Consultant Gastroenterologists and Colorectal surgeons, Registrars, Junior Doctors, 
Specialist Nurses, Ward and outpatient Nurses, Dieticians and Pharmacists as the 
information provided was a summary and explanation of care, and was a new format, 
rather than additional information. The inclusion of educational information 
alongside the clinical information was thought sufficient to inform secondary care 
clinicians if they were unfamiliar with the IBD terminology.  
In primary care, patient GPs had agreed to be part of the trial implementing 
the intervention, and so they had information on the structure and format of the 
reports. GP interest and support for the project was crucial. We involved a GP within 
our research team to ensure GP’s and their practice views were taken into account 
when designing the intervention. The information we gleaned about systems of 
working in primary care was used to ensure that the ELIJAH intervention dovetailed 
with their existing processes rather than added bureaucracy or duplication.   Other 
members of the primary care team e.g. District and Practice Nurses, Health care 
support workers and Pharmacists may have come into contact with the reports, but 
this was less likely than the patient GP, and we presumed that the educational 
content would suffice to render the reports understandable.  
How  
The customised ELIJAH report outputs; “My Folder” were shared with the 
patient and their GP, either electronically or in paper form.  
Intervention patients decided to receive the reports by post or via email or 
both, and GP’s received the intervention by post. I sent all of the correspondence in 
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paper form with an accompanying letter or in electronic form attached to a formatted 
email.  
The ELIJAH reports were stored within GeneCIS under each individual 
patient record automatically and were available to be viewed by clinicians accessing 
GeneCIS. A print out of the reports was also filed into the hospital paper record.  
Where  
 
Participants for the trial were recruited from one Gastroenterology 
Department located within Neath Port Talbot Hospital, a District General Hospital 
operating within the Local Health Board scenario of NHS Wales. All patients had a 
confirmed diagnosis of inflammatory bowel disease and were under the specialised 
out-patient secondary care of two local Gastroenterologists. The patients were also 
registered to the practice of six local GPs who had agreed to participation in the trial.  
 
When & how much  
The intervention was delivered four times over a six month intervention 
period. The first intervention episode was at the trial commencement, and then bi-
monthly.  
The first time the intervention was delivered “My History” and “My Update” 
was sent to patients and GPs. At the subsequent intervention periods these elements 
of “My Folder” were re-sent, and were updated if changes had occurred that 
influenced the information they contained during the two months since the last 
intervention was delivered. If the patient had a secondary care appointment e.g. 
outpatient clinic, endoscopy, blood results, then “My Update” was sent additionally 
to give information and results of the test or appointment. If no changes had occurred 
during the two month gap between sending the intervention, the intervention was 
still sent.  
Tailoring  
The intervention was tailored and personalised for each patient according to 
their medical history and care plan. The ELIJAH IBD reports contained 
individualised information retrieved and collated from the patients’ paper and 
electronic notes. Therefore, no two interventions were identical, but each 
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intervention followed the same structure and format as the same questionnaires were 
answered to formulate the intervention.  
Patients chose to receive the intervention in paper or electronic form 
according to their preference.   
Modifications  
The intervention was modified following the original ethics application. 
Initially we requested permission to enable patients to view their IBD record within 
GeneCIS by direct access through the NHS firewall and security. When we explored 
this further we found that the time needed to develop the technology to enable this, 
and the financial costs required proved impracticable. We had been awarded a 
research grant for the trial, but the strict stipulations stated we had only one year to 
complete the study and only £75,000 as the budget and we recognised that we could 
not carry out the planned intervention within the time period or budget. We therefore 
applied for an amendment to our application to reflect a more pragmatic and 
achievable intervention. We were successful in our application to produce “My 
Folder” as the intervention.  
Initially we enrolled four GP surgeries to yield 61 participants with a 2:1 
ratio in favour of the intervention. Due to a less than anticipated recruitment rate we 
extended the number of GP practices to six. This action delivered the required 
number of participants.   
The intervention was piloted before implementation in July and August 2010 
and revised in light of the patient feedback gathered. The intervention was deemed 
usable, efficient and effective and the few minor layout and content adjustments 
were made.  
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3.3 Findings 
How well  
The ELIJAH intervention; “My Folder”, and the three sections contained 
within the folder: “My history”, “My Plan” and “My update” were designed and 
created as planned (see figure 4. ELIJAH research project timeline). Elements 
crucial to the development of the intervention i.e. the agreement of the clinical and 
IT specifics of the intervention, customisation, piloting and sourcing of the linked 
education component are highlighted in figure 4.  
 Figure 4. ELIJAH research project timeline. 
Summary of timeline 
TASK ACTION FINISH 
ETHICS.R&D APPLICATION 24.12.09 
 INTERVIEW 22.01.10 
 PT LEAFLET & CONSENT 05.02.10 
 NHS R&D 05.02.10 
SHINE FUNDING APPLICATION 02.11.09 
 INTERVIEW 09.12.09 
 MEET SPRINGFIELD CONSULTANCY 08.01.10 
 HEALTH CHECK 04.02.10 
 CONTRACT 03.02.10 
 APPOINT PROJECT MANAGER 0.4 01.02.10 
 CONFERENCE AWARD 25.02.10 
 DASHBOARD 01.02.11 
OUTCOMES PT SATISFACTION QUESTIONNAIRE 26.03.10 
 TESTING Q 12.03.10 
 ADVERSE EVENTS 15.04.10 
 COST 09.02.10 
 TIMELINESS 19.03.10 
 EQUITY 19.03.10 
INTERVENTION AGREE SPECIFICS & CUSTOMISE 25.06.10 
 REVISE INTERVENTION & PILOT 07.07.10 
RECRUITMENT IBD PT LIST GENECIS 17.12.09 
 IBD PT LIST BY GP 20.12.09 
 GP RECRUITMENT 12.02.10 
 GP INFORMATION LETTER 06.02.10 
FOCUS GROUP ADVICE FROM PROF F RAPPORT 10.02.10 
 PATIENT RECRUITMENT 11.03.10 
 HOLD FOCUS GROUP 26.05.10 
 FULL TRANSCRIPTION                            10.11.10                
 ANALYSES 13.02.11   
 REPORT 12.04.11   
PATIENT EDUCATION SOURCE EDUCATION PACKAGES 28.02.10   
 NACC VISIT TO NPTH 29.01.10   
 
REVIEW EDUCATIONAL 
PACKAGES 12.03.10 
  
PATIENT 
RECRUITMENT SEND LETTERS 02.06.10 
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PATIENT RANDOMISATION 30.06.10   
TRIAL START 
 
01.12.10   
EXTRACT GP NOTES 22.02.11   
FINAL FOLLOW UP 31.03.11   
FULL ANALYSIS & REPORT 31.08.11 
 
 
 
PUBLICATIONS  
31.08.11  
 
  
 
We worked well in collaboration with the IT Scientist, and together created a 
clinically accurate and administratively usable extension of our electronic health 
record to create the ELIJAH reports. The questionnaires were functional and worked 
to capture and store the inputted information.  
Piloting of the intervention, by two patients not eligible for inclusion in the 
main train, prior to roll out, enabled fine tuning of the layout and content of the 
intervention and ensured patient participation in the assessment of the quality of the 
intervention.  
We accessed all patient information from the paper and electronic record in 
secondary care to populate the ELIJAH questionnaires and were able to send the 
reports to patients and GPs, and store the reports in the secondary care notes and 
within the GeneCIS system. We recorded the time each step took to produce the 
reports and logged this as a direct cost of the intervention.   
All processes of the development of the intervention were reported monthly 
to the trial research team, and the trial manager ensured the intervention adhered to 
the development and implementation quality assurance process.   
Actual  
Fidelity of the intervention was high and we delivered the ELIJAH “My 
Folder” components as planned to the 41 intervention group participants. All 
participants and their GPs received the intervention four times over the six month 
trial period.  The ELIJAH reports were stored within the individual patient 
longitudinal health record on GeneCIS and were accessible to secondary care 
clinicians via GeneCIS and via the paper-based hospital notes. No patients or GPs 
reported not receiving the reports.  
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3.4 Discussion 
We created the three part electronic folder containing the clinical history 
(“My History”); management plan (“My Plan”); and an update after planned and 
unplanned appointments and contacts (“My Update”) by pragmatically extending our 
existing electronic health record and creating electronic questionnaires. We used the 
existing facility of GeneCIS to produce endoscopy reports via the completion of 
questionnaires, and wrote original questionnaires for IBD and linked educational 
content. We used the existing capability of GeneCIS to convert questionnaire 
information into WORD format and store information in a longitudinal electronic 
patient record.  
The content for the questionnaires was derived from data already held on our 
electronic system and supplemented by data extracted from paper records and other 
departmental systems. We presented the IBD reports in a user-friendly and 
comprehensive format and supplemented the clinical information by automatically 
linking portions of relevant peer reviewed educational material.  
Strengths and limitations 
The development of the ELIJAH intervention “My folder” and its constituent 
parts was designed, revised, developed and implemented into a finalised useable 
product within the allocated budget and on time. The ELIJAH research team and 
especially the trial manager helped ensure that deadlines were met and progress was 
feedback regularly, however, the intervention was resource-intensive to develop in 
terms of cost and time.  
We were helped to develop the intervention by primary and secondary care 
clinical and organisational support for the intervention, and the collaborative team 
working with Jane Morgan and Hayley Dickinson. It was helpful that the Principal 
Investigator of the project and I, had both used GeneCIS extensively over a long 
period of time to support our clinical practice and so were very familiar with the 
existing functionality of the system and the opportunities the programme presented.  
We used the existing structures within GeneCIS pragmatically to build the 
intervention. Other systems potentially could have constructed a similar product but 
we did not explore this. We built new layered clinical questionnaires using IBD 
content and educational attachments to produce “My Folder”.  This process was 
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largely dictated by the constraints of the software system we used i.e. GeneCIS, but 
the content of the questionnaires and the addition of structured educational content 
was novel. We understood that GeneCIS, as a generic EHR, already supported other 
specialties other than endoscopy i.e. urology services, and so surmised that the 
adaption to provide IBD reports would be feasible.  
A limitation of our building of the intervention within GeneCIS is that we did 
not build the intervention according to national guidance or IT standards available in 
2010 and this could have influenced the design, content or format. We relied on the 
IT developers to ensure the system complied with the most recent guidance 
available. As a result we may have missed an important quality recommendation that 
could have enhanced the intervention.  
The inclusion of the patient voice throughout the development and evaluation 
period brought a rich and very valuable contribution to the intervention. During 
initial discussions and planning of the intervention we relied heavily on the patient 
feedback gained during the IBD focus group (see chapter two). In the sourcing of the 
IBD peer reviewed educational content we worked in partnership with the largest 
IBD charity in the UK and were very fortunate to have personal interest in the 
project from their Chairman. This allowed us to use reliable portions of existing IBD 
education to link to the individualised clinical data presented in the reports. In the 
testing and refinement of the intervention useful feedback was gained by the piloting 
of the intervention by two patients, but we did not formally evaluate the pilot 
intervention. 
The intervention, whilst IBD specific, could if adapted be readily 
transferrable to other chronic disease patient groups e.g. diabetes and asthma. The 
principles of delivering individualised patient information in a three-part folder of 
“My History”, “My Plan” and “My Update” with adjoining sections of educationally 
enriched information would be applicable to most long-term health conditions, 
particularly those that relapse or remit, and as such require an enhanced degree of 
patient information and understanding to help improve patient self-care.   
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3.5 Conclusion 
Within this chapter I have relayed how we designed the ELIJAH intervention 
and produced a tri-part folder of individualised and educationally enriched IBD 
information. We have demonstrated how the intervention was piloted by patients and 
refinements to the intervention made. We have acknowledged that there was little 
evidence, in 2010, of the testing of interventions in this field, and so we recognised 
there was need for rigorous testing of the intervention.   
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Chapter four: ELIJAH: a pragmatic randomised controlled 
feasibility trial 
In the previous chapter I discussed the evolution of the intervention from 
concept to product. In this chapter, I will discuss the application and initial testing of 
the intervention in a pragmatic randomised controlled feasibility trial.  
Patients with inflammatory bowel disease (IBD) are routinely given generic 
information leaflets about their condition. The IBD Standards Update 2013, standard 
D: Patient Education and Support, emphatically advocates the distribution of 
educational literature to patients, stating that:   
“All patients should be offered appropriate information about their care and 
treatment options at all stages of their illness” P20.  
The introduction (chapter one) showed that these standard IBD educational 
publications often offer a background and overview of the relevant condition and are 
distributed to aid self-management of symptoms, but can however only give limited 
usable information to guide individualised patient care.  This was further confirmed 
through patient feedback from our focus group work (which is reported in chapter 
two). This identified that patients’ want more individualised information and 
knowledge about their condition, and detailed usable guides at time of need (such as 
during a flare-up of their condition) to take greater responsibility for their health 
care.  
In the light of this, with the help of colleagues, I developed a method to 
provide personalised information to each patient, tailored to their own condition 
(described in chapter three). I then tested the effectiveness of this approach. In this 
chapter I will discuss the initial evaluation of this personalised information (the 
intervention), in a randomised controlled feasibility trial. I will further go on to 
evaluate my findings with regards to designing a fully powered definitive trial.  
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4.1 Background & objectives 
To date there has been limited research to explore the usefulness of 
interventions which provide tailored patient information. Wright Oliver et al (2001) 
explored pain management for cancer patients and found that an individualised 
coaching and education package proved beneficial in reducing pain. Chi et al (2012) 
individualised the recommendations of types of lifestyle interventions to reduce 
cardiovascular risk and offered an IT system to predict the most likely effective 
educational package. Neither of these studies looked at a gastro-intestinal patient 
population, and to date there is a paucity of evidence about the development, use and 
outcomes of using individualised information in gastroenterology.  
Having developed an approach to generate personalised educational 
information, the main study aim was to learn lessons from the trial processes, 
acceptability of the intervention and costs that would inform and determine the 
feasibility of running a fully powered randomised controlled trial of this intervention 
in patients with inflammatory bowel disease.  
From discussions with IBD patients in clinic and their GPs, we identified that 
patients regularly requested additional information about IBD i.e.: detailed 
information of diagnosis and treatments, the disease process and what to action to 
take if a flare occurred. Whilst this detailed useful clinical information is often held 
within the patient paper based notes, there can be problems accessing the relevant 
pertinent information e.g. because of the volume of notes, disordered filing in terms 
of chronology and specialty grouping, missing information and time available to 
search. Information within the notes can be illegible or poorly structured with 
undefined standardisation and this can lead to further issues accessing information 
when needed. An example of hospital paper-based notes can be seen in figure 5.  
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Fig. 5 Example of paper-based hospital notes 
 
 
Electronic Health Records can overcome some of these issues (Litvin 2007), 
but many are based on an electronic replication of the paper record and so have 
many of the same inherent problems. There are few paper or electronic systems that 
provide a summary of disease history and prescribed programmes of action to be 
taken in the event of an increase in symptoms. 
ELIJAH was developed to overcome these issues for clinicians whether in 
the primary or secondary care setting. It was aimed at providing individualised IBD 
summaries of disease history, plans for flares in symptoms and follow ups. The 
information was designed to be shared in the same format with patients so that 
patients, primary and secondary care clinical staff all had access to the same 
information.  
We hypothesised that the implementation of the ELIJAH intervention could 
have possible benefits for participants, including:   
 Increased empowerment arising from raised knowledge about their 
individualised care, gained from access to personalised reports about their 
health and care. 
 Improved education and information about their condition. 
 Improved education and knowledge about managing disease symptoms.  
 Speedier access to services and advice at time of need. 
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 Increased responsibility and empowerment for care decisions based upon 
evidence. 
 More effective communication with health care professionals. 
 More effective communication between primary & secondary care 
professionals and patients. 
 Better managed care. 
 More patient centred services.  
We tested these anticipated participant benefits by assessing the feasibility of 
the intervention, study processes and of data collection of the following outcomes: 
cost, patient satisfaction, safety, timeliness and equity to inform the development of 
a larger scale phase III trial.  
The feasibility of a larger trial was tested according to the framework 
described by Lancaster (2015), defined by the National Institute for Health Research 
(2017) to answer the question “Can this study be done” (NIHR 2017 p. 2) and 
reported in line with the CONSORT 2010 checklist with extension for pilot or 
feasibility trials (2016) (see appendix 13).  
Lancaster et al (2004) proposed that feasibility studies are a preparation for a 
fully powered phase III randomised controlled trial as demonstrated in the MRC 
Complex Intervention analysis (2010), see Fig 6. The pre-clinical phase, explained 
by the MRC in Fig 2, is described in chapter six – the literature review within this 
thesis, and phase I modelling within chapter two the qualitative focus group and 
chapter three the intervention.  It is recognised that a feasibility is not the same as a 
phase II trial (described in Fig. 6 taken from Arain et al 2010), as a feasibility trial 
lacks adequate power to establish statistical significance. However, the feasibility 
study can help the likely success of a larger trial by testing the processes within the 
trial, intervention, data collection and outcome measures.  
In a later publication (2015) Lancaster summarised the findings of the 2004 
literature review into seven central potential outcomes of feasibility trials:  
 to test the integrity of the study protocol  
 to gain initial estimates for sample size calculation  
 to test data collection forms or questionnaires 
 to test randomisation procedure(s)  
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 to estimate rates of recruitment and consent 
 to determine the acceptability of the intervention  
 to select the most appropriate primary outcome measure(s) 
                                                            
We assessed the feasibility of our study by testing the development of the 
intervention and its acceptability by patients. We tested the feasibility of completion 
of the patient questionnaire and researcher data collection forms, and assessed rates 
of recruitment, consent and drop-out. We also assessed each outcome measure to 
identify the most appropriate primary outcome measure for the main trial and to 
determine if any outcomes were inappropriate to extend to a larger trial.    
Fig. 6 MRC Complex Intervention Analysis  
 
(MRC, Taken from reference Arain et al 2010 ) 
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4.2 Methods 
We designed this study in order to establish the feasibility of a fully powered 
randomised controlled trial to evaluate the clinical effectiveness and cost of the 
ELIJAH intervention.  
Participants 
Patients from Neath Port Talbot Hospital, Abertawe Bro-Morgannwg 
University Health Board (ABMUHB) were invited to participate in this feasibility 
trial. Recruitment began in July 2010 with the study final follow up finishing in 
January 2011.  
Of the 77 GP practices in ABMUHB 24 are in the Neath Port Talbot area. 
These GP practices were judged more likely to have patients who had attended 
Neath Port Talbot Hospital for their IBD care as they had a direct referral pathway to 
gastroenterology services at Neath Port Talbot Hospital. Primary care engagement 
and involvement was crucial to the project, and advice and support was sought from 
the outset via the involvement of a GP within the research team. The GP advised of 
GP practices most likely to respond favourably to an invitation for their patients to 
participate in the study. We did not approach GP practices whose patients with IBD 
had been participants in the ELIJAH focus group to reduce the risk of bias (see 
chapter 2). Four GP practices were initially contacted and sent an invitation letter 
and the ELIJAH protocol and participant information sheet. These four practices 
agreed to participate in the study, but the yield of participants was low and so two 
additional practices were included.  
The eligibility criteria for inclusion for patients in the ELIJAH feasibility 
trial, were:  
 aged between eighteen – ninety years 
 a confirmed diagnosis of IBD (specifically Ulcerative Colitis, Crohn’s 
disease or proctitis), diagnosed via endoscopic assessment and / or 
radiological investigation plus histological evidence;   
 on-going and recent follow up (within 18 months of the start of the trial) for 
IBD care at Neath Port Talbot Hospital (either via out-patient clinic, 
telephone review or postal review);- 
 65 
 
 under the care of one of six participating GP’s practices within the Neath 
Port Talbot area.   
 
Eligible patients were identified from the searchable coded patient database 
available at Neath Port Talbot Hospital (GeneCIS). The patients’ electronic record in 
GeneCIS was then cross-checked against their diagnoses and histological reports in 
both their paper based medical records, and the histology electronic database 
INDIGO 4 Review.  
Patients’ records were also checked to ensure that they were still under the 
care of NPTH. This was done by checking on GeneCIS the date of the last recorded 
clinical contact with the gastroenterology department.  Those patients who had been 
seen in a gastroenterology out-patient clinic or had postal or telephone consultations 
since December 2008 at Neath Port Talbot Hospital were included for potential 
randomisation and formed the potential sample patient list.  
The six GP participating practices were: Briton Ferry Health Centre, Castle 
surgery, Dyfed Road Surgery, Riverside Surgery, Skewen Medical Centre and Vale 
of Neath Practice (see Figure 7).   
Fig. 7. Location of participating GP practices, demonstrating the location of 
Neath Port Talbot area in Wales, and the location of ELIJAH participating GP 
surgeries within Neath Port Talbot.  
 
Vale of Neath Practice 
Dyfed Road Surgery 
Castle Surgery 
Skewen Medical Centre 
Briton Ferry Health Centre 
Riverside Surgery 
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Patients deemed ineligible for participation in the feasibility trial were: those 
that did not meet the eligibility criteria in terms of age, diagnosis, follow up care, or 
GP practice; and those that could not comprehend the study.  
Eligible patients were invited to participate by letter containing the ELIJAH 
participant information sheet (see appendix 3) and consent form (see appendix 4). 
The GPs of eligible patients were simultaneously sent a GP information letter and 
summarised protocol.    
We sought consent from all eligible patients prior to their participation in the 
study. Consent was obtained at a face to face appointment at Neath Port Talbot 
Hospital gastroenterology department (the patients usual care centre for IBD). As the 
appointment was supplementary to their normal clinical appointments a nominal 
one-off payment of £20.00 was made to patients to cover their travel costs. At this 
appointment, we provided further clarification of the participant information sheet if 
required and answered any questions posed prior to informed consent being taken, 
including verbal re-iteration of the participant conditions of withdrawal from the 
study. We clarified that identifiable data already collected with consent would be 
retained and used in the study, but no further data would be collected or any other 
research procedures carried out on or in relation to the participant following 
withdrawal. 
Randomisation: sequence generation 
 
Following written consent, eligible participants were randomly assigned to 
receive either the control or the intervention. We used a web-based remote 
randomisation service run by Bangor University which allocated the patients 
between the groups. To ensure that the groups were balanced in terms of 
demographics we also stratified the groups by GP practice, gender and under or over 
retirement age (65). We randomised the patients in real time following consent.  
We chose to randomise participants to a 2:1 ratio interval in favour of the 
intervention. This was to reduce the potential effect of any participant drop-out from 
the intervention group as the study had small numbers, and we wished to give the 
intervention to as many participants as possible, within our limited financial budget, 
to gain sufficient information and understanding of the intervention. Dumville et al 
(2006) reviewed 65 trials with an unequal randomisation ratio and found that where 
 67 
 
justified, other studies had an unequal ratio for similar reasoning, and moreover they 
recommended that more studies consider an unequal ratio to benefit the study 
assessment.  
Remote randomisation protects against bias in the allocation of patients 
between groups. To protect against bias occurring before randomisation the patient 
participant sheet we gave stressed the equality in distribution (see participant 
information sheet and consent form appendix 3 and 4). Clinical staff sought and took 
consent, in accordance with Good Clinical Practice (GCP) guidelines and verbally 
reinforced the randomisation equipoise.  To limit bias in the analysis and reporting of 
the trial, the trial statistician remained blind to patient allocations throughout 
analysis.  
The control 
The control group received care as usual for IBD follow up. In Neath Port 
Talbot Hospital gastroenterology department and many secondary care services 
across the U.K. this includes pre-scheduled follow-up outpatient clinic appointments 
and / or postal review, access to the telephone triage service and investigations and 
in-patient admissions as necessary. In primary care, care as usual included pre-
scheduled or emergency appointments with GPs at the practice, home visits, 
appointments with the wider multi-disciplinary health team and investigations.  
The intervention 
The intervention group received care as usual plus the intervention. The 
intervention consists of an individualised inflammatory bowel report; “My Folder”, 
made up of three parts; “My History”, “My Plan” and “My Update”. “My History” 
detailed participant’s disease history and progress, “My Plan” offered guidance on 
actions for self-management during an increase in symptoms, and “My Update” 
provided a report of any follow up. There was also email access established for 
intervention patients and GPs used for helpline advice (appendix 5, 6 and 7).  
The intervention was implemented across primary and secondary care. 
Patients, GPs and secondary care multi-disciplinary teams received the same 
personalised, educationally enriched patient reports.  The membership of a GP 
within the research team enabled careful identification of the clinical information 
needs for GPs for IBD patients.  
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The intervention group received ‘care as usual’ plus the intervention. We sent 
reports containing information about the patients’ condition including educational 
material which offered explanation of clinical terminology, advice on health and 
lifestyle matters. We compiled the reports using the existing standardised patient 
clinical information which was gathered from the paper and electronically held 
hospital notes, and we loaded the information in the ELIJAH questionnaire and 
generated a WORD report that automatically joined the clinical information with 
relevant educational material. We generated the reports electronically from the 
patients’ individual clinical record held within GeneCIS. More detailed information 
regarding the development and implementation of the intervention is described 
within chapter three.  
The ELIJAH intervention patient report was produced in three parts, and 
collated to form a product; “My folder”, of information for use by the patient, GP 
and secondary care team: 
 The first section “My History” (example in Appendix 5) gave detailed 
information and education about diagnosis, previous investigations and 
surgery, medication, diet, co-morbidities and social history. This enabled 
patients, GPs and the secondary care team to gain a greater understanding of 
the past inflammatory bowel disease medical history.  
 The second section “My Plan” (example in Appendix 6) informed patients, 
GP’s and the secondary care team how and when to contact secondary care 
services to gain advice when needed and how to initiate treatment 
modifications. The information contained within “My Plan” detailed current 
medication, planned changes to treatment, investigations to be carried out, 
planned surgery, medication monitoring, and general health guidance, follow 
up arrangements and communication plan and an opportunity for feedback.  
 The third section “My Update” (example in Appendix 7) provided an 
electronic report of any contact with the gastroenterology department, 
whether it be a consultation, telephone call or email. It detailed the 
symptoms, medication, investigation results and the GP correspondence.  
 
At the start of the trial, intervention patients, their GPs and secondary care 
providers were sent the ELIJAH first two sections: “My History” and “My Plan”. At 
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their subsequent three follow up correspondence (at two, four and at six months) we 
reviewed the patients’ paper and electronic notes to identify if there had been any 
change or review of their care and produced and then sent the additional final 
element of “My Folder” – “My Update” if appropriate.  
Patients were given the choice to receive “My folder” and its components via 
email and /or in paper form sent through the post. In an accompanying cover letter 
sent with the intervention to the participants we detailed the elements that “My 
folder” included and requested that participants contact us should there be any 
inaccuracies of information provided.  
In addition to the intervention, facilities to provide feedback and update 
secondary care about any changes were made available to patients and GPs via a 
secure NHS email Elijah.gastro@wales.nhs.uk. This provided intervention patients 
and the six GP practices participating in ELIJAH use of email to ask questions, have 
queries answered and receive advice or triage to secondary care services. Update of 
condition symptoms or contact with health professionals were also reported via the 
secure email.  
The adherence to and the fidelity of the intervention was tested and reported 
upon using the TIDIER checklist (see chapter three). 
 
Data collection 
 
We collected data using three specifically designed forms; the “ELIJAH Data 
Abstraction Form DAF” (see appendix 8), the “ELIJAH Adverse Events Form” (see 
appendix 9) and the “Inflammatory bowel disease Service Satisfaction Questionnaire 
(ISSQ)” (see appendix 10).  
The “ELIJAH Data Abstraction Form DAF” collected information on the 
patient demographics and GP details, any contact with or visits to primary or 
secondary care services, medications prescribed and the time spent in preparing the 
ELIJAH “My folder” during the study. We used this combined data to test the 
feasibility of collecting total NHS cost used by the participants in the study period 
and timeliness to receiving care.  
In primary care we noted visits to GPs, out of hours services and 
appointments with other members of the multi-disciplinary team.  
 70 
 
In secondary care we amassed information on services accessed i.e. open 
access services (via telephone or email helplines or unscheduled drop in), outpatient 
clinics, multi-disciplinary team appointments (e.g. physiotherapy, dietician), 
emergency admissions to accident and emergency or minor injuries units, 
investigations and in-patient episodes.  
For all primary and secondary care contacts or visits we determined from the 
patients records the time and duration of when the patient recognised the increased 
or new symptom that caused them to seek help, when the symptom was reported and 
the time taken for primary or secondary care services to respond to the request. 
We completed this data form at the end of the study and populated it by 
accessing primary and secondary care paper-based and electronic health records.  
The “ELIJAH Adverse Events form” detailed any symptoms or problems 
reported by the patient and assessed seriousness of the issue and established if there 
was causality arising from the intervention. This information formed the safety 
assessment of the intervention.  These data were collected on-going during the study 
by accessing the GeneCIS electronic patient record and the Patients Information 
Management system (PIMS) record 2 weekly to assess any report of symptoms or 
secondary care services accessed.  
The “Inflammatory bowel disease Service Satisfaction Questionnaire” 
included the EQ5D (EuroQol five dimensions questionnaire https://euroqol.org/ ). 
This form was completed by all participants and their answers were scrutinised to 
assess the feasibility of collecting satisfaction regarding the IBD services accessed 
and the intervention.  
We enquired as to whether patients knew their diagnosis and when they were 
diagnosed and assessed whether they had enough good quality usable information on 
their condition, accessing services at time of need, communication skills of health 
professionals, the quality of care received and their health-related quality of life.   
We sent a paper based questionnaire which included the ISSQ (Inflammatory 
bowel disease Service Satisfaction Questionnaire and the EQ5D to the participants 
one week after they had received the intervention: “My folder”. A stamped 
addressed envelope for return was included with the ISSQ. We collected information 
via the ISSQ on all participants at four time points – baseline and at two and four 
months and at the end of the trial (at six months from commencement), see Figure 8.  
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Figure 8. ELIJAH flowchart which illustrates the number of patients identified 
and included in the study.  
ELIJAH flowchart. 
Patients identified and screened  
Inclusion criteria: Diagnosis of ulcerative colitis, Crohn’s disease or proctitis; 
Aged 18 to 90 years; 
Under current care at NPT Hospital; Registered with collaborating practice. 
Informed consent obtained  
Baseline data collection (ISSQ and EQ5D) at initial visit 
Remote randomisation stratified by: 
GP practice, gender, over / under retirement age 
Control group                                     Intervention group  
Care as usual                                          Care as usual and 
                                                               3 educationally enhanced 
                                                               IBD reports: “My History”, 
                                                              “My Plan”, “My Update” 
                                                               Reports via post or email 
                                                               Communication via email 
                                                               GP receive reports 
First follow up – 2 months after baseline using ISSQ and EQ5D 
 
Second follow up – 4 months after baseline via ISSQ and EQ5D                                        
Third follow up – 6 months after baseline via ISSQ and EQ5D 
                                                                         
 
 
 
 
 
 
 
 
 72 
 
Missing data 
We adopted a consistent approach and made efforts to keep missing data to a 
minimum.  
We scoured the hospital paper and electronic patient records, and GP 
electronic patient records to find care episodes in the study period. We cross matched 
the information found to ensure a robust data set. We used these data to populate the 
ELIJAH Adverse Event form and Data Abstraction Form.  
The ISSQ and EQ5D tools were patient reported. To minimise missing data 
we waited two weeks after sending the questionnaire to receive a reply, we then sent 
a two week reminder to patients who had not returned their questionnaire (see table 2 
ELIJAH study Chronology). The patient questionnaires not returned two weeks after 
the reminder were treated as missing data. We employed three methods to impute 
missing data on a per question basis:  
1. Last carried forward 
2. When there was no initial score, but other scores existed for the participant, 
last carried back 
3. When there was no score for a question for a participant, other similar 
questions were examined for a trend.  
 
There were no exclusions from the analyses.  
Outcomes 
ELIJAH was run primarily as a highly pragmatic feasibility trial: assessing 
the practicality of running a trial of the intervention, using the methodology of the 
RCT within the allocated budget and timeframe, and applicability within the 
secondary care environment with the participating health settings, health 
professionals and patient group. We hypothesised that there may be many effects 
seen as a result of receiving the intervention and as such in this feasibility study we 
used questionnaires and methods to collect information on the outcomes of interest, 
not for definitive analysis but rather to determine the feasibility and practicality of 
collecting information for a full trial.   
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The areas of feasibility for the main trial we looked at were:  
 Whether we were able to recruit GPs and patients into the study 
 If consent and randomisation could be carried out as proposed 
 If there were any drop-outs from the study and if so why 
 If we could collect data on the outcomes 
 If the intervention assessment forms were completed fully and if not the 
amount of missing data 
 The time and cost taken to produce the intervention 
 Whether we could identify the most appropriate primary outcome, and as a 
result formulate a sample size needed for a fully powered phase III trial 
 
These feasibility outcomes are in-line with the potential list of feasibility 
parameters stated by the NIHR “Guidance on Applying for Feasibility Studies” 
(2017).  
Based on the hypothesised effects of the intervention we wanted to test the 
feasibility of collecting data on the following outcomes (see below). Because this 
was a feasibility study we did not identify a primary outcome measure but used our 
findings to try to identify one for the larger trial through our analyses of this study.  
1. Cost – we looked at the cost of NHS resources used by participants in 
primary and secondary care, to identify whether the intervention reduced 
total NHS costs. We collected data from the patients electronic and paper 
based records in primary and secondary care for the six-month trial period, 
and documented any use of primary or secondary care including inpatient and 
outpatient episodes across all specialities, not just for IBD care, and added 
the cost of any medication prescribed. We added these joint costs to the cost 
of the nursing time taken to collate and prepare the ELIJAH reports. We used 
two national UK references to identify the precise costs: the PSSRU Unit 
Costs of Health and Social Care 2011, and the Department of Health National 
Schedule of reference costs 2010-2011. These individual costs were 
documented in the ELIJAH Data Abstraction Form (DAF) (see appendix 8). 
We collated and assessed the costs at two and four months and at the end of 
the trial.  
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To calculate the costs, the direct cost of the intervention and time 
taken by the clinician to formulate the elements of “My folder” were 
analysed and were added to the indirect total NHS costs of the intervention 
which it brings about through altered patient use of other NHS services.    
 
All direct and indirect costs were documented on-going on the 
ELIJAH Data Abstraction form (see appendix 8), and recorded participant 
details, hospital based services use, community based services use, 
medication, time to prepare the “My Folder” initially and subsequently.  
 
Direct costs 
A costing exercise was undertaken which quantified and valued the 
resources used in implementing the innovation.  It was surmised that the most 
likely clinicians to formulate the interventions within trials would be the 
Gastrointestinal Specialist Nurse (most likely salary Band seven pay-scale). 
These members of the multi-disciplinary team would have prior, on-going 
knowledge of the patients, could produce the individualised ELIJAH reports 
within their clinical activities and crucially be accurate in their assessment of 
the medical records.  
The activities below which were carried out by a Gastrointestinal 
Specialist Nurse to formulate the ELIJAH intervention were cost assessed;  
 preparation of a request for patient notes  
 retrieval of patient notes 
 reading of patient notes 
 accessing GeneCIS 
 data entry of the ELIJAH questionnaire on to GeneCIS 
 printing and sending out ELIJAH notes to patients and GPs.   
 
Indirect costs 
The indirect patient costs collected were inpatient stays, operations, 
outpatient clinics, GP appointments, investigations, open access service use 
and medication use. Data were collated from primary and secondary patient 
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electronic and paper based records and were documented via the ELIJAH 
Data Abstraction Form. 
 
2. Safety – we identified the number of adverse events (AE) leading to a 
hospital admission or that otherwise threatened the health and well-being of 
participating patients and that were reported to a health professional, to 
identify whether the causality or seriousness of an event was related to being 
in the intervention group. These data were collected by analysing the primary 
and secondary care records at two and four months from the trial 
commencement and at the end of the trial, and recorded upon the ELIJAH 
Adverse Event form (see appendix 9).   
We used data from GP and hospital electronic and paper based 
records to obtain information relating to primary and secondary care 
attendances, including acute admissions to hospital. We were able to view all 
scheduled and unscheduled hospital and outpatient appointments. We used 
the ELIJAH Adverse Events form to record the adverse event description, 
categorisation and assessment of causality and seriousness of the event.  
No stopping rules were included in the AE form; however it was 
assumed that due to the benign intervention nature an unexpected event with 
direct causality and seriousness would unlikely be due to the distribution to 
the patient of individualised health reports. However in the event of a 
suspected, unexpected serious adverse event, we agreed to report it to the trial 
research and development department within twenty four hours of the trial 
team becoming aware of the event.  
 
3. Patient-centeredness – we assessed the satisfaction of participants with the 
IBD care they received at baseline, and then at two and four months and at 
the end of the trial.  Each time point was one week after sending the 
intervention “My Folder” to the intervention patients. We wanted to know if 
it was feasible to collect information regarding patient satisfaction during the 
trial period and wanted to assess what patients felt about their sense of well 
being and their care.   
We developed and piloted a questionnaire containing questions 
relating to satisfaction using the ISSQ, and quality of life using the EQ5D. 
 76 
 
Prior to implementation in ELIJAH we piloted the ISSQ in patients with 
inflammatory bowel disease who were not eligible to be participants of the 
trial because of GP practice exclusion. Patient comments and 
recommendations were incorporated into the final version.   
We sent patients the ISSQ and the EQ5D at each of the time points 
(see appendix 10).The (ISSQ) contained twenty five questions in four 
sections. The four ISSQ sections of the questionnaire were: Your condition; 
Getting care when you need it; Quality of care you received recently; and 
General quality of the care you received. In addition five quality of life 
indicators were collected from the EQ-5D. Two open patient feedback boxes 
were also included to provide participants space to add any other information 
relating to their condition, treatment or experience which they deemed 
relevant (see appendix 10).   
The ISSQ was derived from the Gastro-intestinal Endoscopy 
Satisfaction Questionnaire (GESQ) developed for, and validated in, the 
MINuET study (Cheung et al 2015).  
 
4. Timeliness – we explored the feasibility of reviewing retrospectively, the 
average elapsed time between the onset of a new IBD-related issue needing 
health care for the participant and the start of that care. This was to determine 
whether we could assess if patients could better self-manage their care with 
the aid of the intervention in a large scale trial. We assessed the feasibility of 
collecting data on the time elapsed between patients recognising symptoms, 
reporting symptoms and receiving care for their symptoms. We recorded this 
information on the ELIJAH Data Abstraction Form (see appendix 8).  
Data were collected on the speed of response to a patient reporting 
symptom, and were monitored via time differences between patients noting 
symptoms, duration of symptoms, patient reporting of symptoms and health 
professional reaction to the report of symptoms.  We called this patient 
sequence of events the 3 R’s: Recognition, Reporting and Response.  Data 
were thus collected on the recognition of patient noting problems or 
increased symptoms, the time of reporting of symptoms and response time 
of health professionals to respond.  
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The timeliness was captured within the ELIJAH Data Abstraction 
Form (used also for outcome 1 – cost).  
 
5. Equity – we assessed the feasibility of collecting information regarding the 
social status of participants through documentation of their postcode against 
the Welsh Index of Multiple Deprivation 2011 for the Neath Port Talbot area 
(see appendix 11).  
Postcodes of participants was split into 2 groups via a deprivation 
score.   
 
Sample size 
As the study was designed as a feasibility trial and not a definitive fully 
powered trial, we did not carry out a formal sample size calculation based on 
detecting a difference in the primary outcome measure (as we did not identify a 
primary outcome measure). The purpose of the feasibility study was to test processes 
for a larger phase III trial; to ensure the feasibility of undertaking a full-scale trial 
(i.e. ability to recruit patients, patient retention, data collection and processes of the 
study). From the literature written about feasibility studies Thabane et al (2010), 
offers clear guidance on how to conduct feasibility studies and states that a sample 
size calculation is not required for a study like this one, but rather the study 
participant groups should be;  
“representative of the target study population … (and) large enough to 
provide useful information about the aspects that are being assessed for 
feasibility”. (p5) 
and Lancaster et al (2002) suggests a number of “30 patients or greater to estimate a 
parameter” (p308), Tickle-Degnen (2013) supports this assertion and states that a 
small sample size is acceptable for feasibility studies.  
On this basis we aimed to recruit at least 50 patients to the feasibility trial 
(out of an IBD population at Neath Port Talbot Hospital Gastroenterology 
department of 439), randomised in a 2:1 ratio in favour of the intervention.  
Ethics 
ELIJAH, as a feasibility randomised controlled trial with patient participation 
was classified as a research study. Full ethical and NHS Local Health Board research 
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and development approvals were therefore sought and obtained before 
commencement of the study.  The Integrated Research Application System (IRAS) 
application (reference number 09/WMW02/61) was submitted on December 23rd 
2009, and ELIJAH research team representatives (Phedra Dodds and Professor I. 
Russell) attended the South West Wales Research Ethics Committee (REC) meeting. 
The study was granted a full favourable ethical opinion on 5th March 2010 (see 
appendix 12),   following minor amendments to the patient information sheet and 
consent form (see appendix 3 and 4).  
Following ethics approval, we submitted local Research and Development 
(R&D) approvals. NHS R&D office permission at ABMUHB was also granted. A 
further amendment to the protocol was submitted to REC and R&D on 19/04/10.  
This amendment involved a change in the intervention. The original intervention was 
planned to allow patients’ and their GPs access to their patient records directly into 
GeneCIS electronic patient system through the NHS firewall. However, feedback 
from the ELIJAH focus group (see chapter 2) reported that patients preferred being 
provided with patient educationally enhanced reports, which was developed as the 
ELIJAH intervention.   
We ensured that care providers were adhering to the study by monitoring at 
regular intervals. The study was overseen on a day-to-day basis by the trial manager 
and monthly by the ELIJAH research management team. The study sponsor 
(ABMUHB) also provided governance oversight. Regular update reports were 
provided to The Health Foundation who funded the feasibility trial through their 
“Shine” programme.   
Study management 
Trial oversight and quality assurance of the trial was carried out by regular 
review in accordance with WWORTH (West Wales Organisation for Rigorous Trials 
in Health) approved standard operating procedures (SOPs). Because the duration of 
ELIJAH was only one year and was low risk, it was decided that WWORTH review 
would be more pragmatic and effective than setting up a data monitoring committee.  
Independent scientific external review for ELIJAH was carried out via the 
funder of the trial: The Health Foundation as part of the competitive funding 
application to the SHINE Award programme.  
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Progression rules and stopping guidance 
 
The following criteria was explored to determine whether the ELIJAH 
feasibility study could be progressed to be designed as a fully powered phase III trial 
(see Table 1 ELIJAH progression criteria). The blue highlighted area within table 1 
denote the ELIJAH feasibility criteria, the remaining criteria are clinical outcomes.  
Table 1: ELIJAH progression criteria highlighting the ELIJAH feasibility 
criteria 
Criteria Derivation 
50% or more of individual clinicians 
approached agree to take part in the 
study 
Determined from site records 
50% or more of patients eligible to take 
part in the study are consented  
Calculated from patient screening data 
75% or more of patients are consented 
and randomised in real time at the same 
appointment  
Calculated from patient screening data 
Less than 20% of patients drop out from 
the study 
Calculated from patient screening data 
Data are collected on all outcome 
measures for over 80% of patients 
Calculated from ISSQ and EQ5D, 
ELIJAH Adverse Events form and Data 
Abstraction form 
75% or more of patient data for direct 
and indirect costs (cost) can be collected 
over primary and secondary care   
Calculated from the Data Abstraction 
form 
Adverse events show no Suspected 
Unexpected Serious Adverse Reactions 
(SUSARs) resulting from the 
intervention 
Calculated from the ELIJAH Adverse 
Events form 
Less than 20% difference between the 
intervention and control group for 
adverse events, including Serious 
Adverse Events (SAE) with causality 
related to the ELIJAH intervention.  
Calculated from the ELIJAH Adverse 
Events form 
Patient reported data (ISSQ and EQ5D) 
can be collected for more than 75% of 
participants across the control and 
intervention groups 
Calculated from the amount of missing 
data within the Data Abstraction Form 
Less than 20% difference between the 
intervention and control group for 
timeliness in recognition of symptoms, 
reporting of symptoms and receiving 
care 
Calculated from the Data Abstraction 
Form  
Feasibility study findings indicate that at 
least 3 out of 4 outcome measures were 
feasible to collect in the intervention 
Calculated from the ISSQ and EQ5D, 
ELIJAH Adverse Events form and Data 
Abstraction Form 
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group and the control group. 
Identification of potential primary 
outcome.  
(The outcome measures are cost, safety, 
patient centeredness, timeliness) 
 
The criteria for judging the ELIJAH feasibility study a success is based on 
the analysis of the study feasibility outcomes (highlighted in blue) and the clinical 
outcome measures (without highlight) included in the table above. These criteria 
provide the basis for the analysis of the study and decision whether the advance to a 
fully powered phase III randomised controlled trial. Thabane et al (2010) suggest 
four feasibility study outcomes, which we have adopted as the decision model for 
progression to a phase III ELIJAH trial; 
 Stop –do not advance to main trial 
 Continue, but modify protocol  
 Continue without modifications, but monitor closely  
 Continue without modifications 
 
Descriptive statistical analysis 
The primary outcomes of ELIJAH are feasibility outcomes that will 
contribute toward the decision to plan for a fully powered, definitive phase III trial: 
cost, safety, patient centeredness, timeliness and equity.  
As this study is based upon feasibility; with a small cohort size in both arms, 
and is not powered for the production of definitive statistically significant results, we 
did not include any comparative sub-group analysis in the results. Rather, we 
provided a brief descriptive analysis in numbers and percentages, and where 
applicable mean, standard deviation and range, of the study population based on the 
feasibility outcomes and clinical outcome measures. 
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4.3 Results 
Patient recruitment and retention 
708 patients with a documented confirmed diagnosis for inflammatory bowel 
disease were screened against the eligibility criteria for inclusion in the study. 431 
were excluded because they did not have their care managed in primary care by one 
of the participating GP practices. Of the remaining 277 patients:  
 3 (1%) were excluded because they did not meet the inclusion criteria: 1 
(0.4%) because they could not comprehend the study, 2 (0.8%) because they 
did not have documented IBD (one had a colectomy for reasons other then 
IBD, 1 had microscopic colitis),  
 37 (13%) were excluded because they declined to take part in the study,  
 120 (43%) were excluded because they had not attended Neath-Port Talbot 
Hospital in the previous 18 months for an IBD outpatient appointment and so 
were not current patients,  
 47 (17%) did not answer the invitation letter.  
 
Invitations for participants to attend for consent were sent between the 21st of 
May 2010 and the 11th June 2010. GPs were informed of which participants who 
were their patients and who had agreed to attend for the consent appointment 
between the 2nd June 2010, and the 22nd June 2010. Consent was held between 7th 
June 2010 and the 27th July 2010, (see Table 2: ELIJAH study chronology). 
70 patients agreed to attend for consent, of these 61 attended, were consented 
and randomised in a 2:1 ratio in favour of the intervention, (see fig. 9 ELIJAH 
CONSORT diagram). 
Participants commenced the trial between 20th July 2010 and the 22nd August 
2010.  
There were differences between the dates for patient recruitment, sending of 
GP information, participant consent and study commencement, because we needed 
to include 2 additional GP practices to the original 4, because of lower than expected 
recruitment rates.  
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Table 2: ELIJAH study chronology 
Activity  Date/s 
Invitations for consent sent to eligible 
patients 
21/5/2010 – 11/6/2010 
GPs informed of their patients who had 
agreed to take part in ELIJAH 
2/6/2010 – 22/6/2010 
Patients consented and randomised at 
Neath Port Talbot Hospital 
7/6/2010 – 27/7/2010 
ELIJAH study commenced 20/7/2010 – 22/08/2010 
1st follow up: 2 months from 
commencement of study  
 ELIJAH folder sent to 
participants and GPs 
 ISSQ and EQ5D sent to 
participants 
 ISSQ and EQ5D reminder sent to 
participants who had not 
responded and returned the 
questionnaire  
 
 
1/10/2010 – 5/10/2010 
 
25/10/2010 
9/11/2010  
2nd follow up: 4 months from 
commencement of study  
 ELIJAH folder sent to 
participants and GPs 
 ISSQ and EQ5D sent to 
participants 
 ISSQ and EQ5D reminder sent to 
participants who had not 
responded and returned the 
questionnaire  
 
 
2/12/2010 
 
6/12/2010 
6/1/2011 
3rd follow up: 6 months from 
commencement of study  
 ELIJAH folder sent to 
participants and GPs 
 ISSQ and EQ5D sent to 
participants 
 ISSQ and EQ5D reminder sent to 
participants who had not 
responded and returned the 
questionnaire  
 
 
28/1/2011 – 1/2/2011 
 
3/2/2011 
21/2/2011 
Completion of baseline and follow-up questionnaires was achieved and all 
intervention patients received “My Folder” on schedule.  The study was run for the 
full 6 months planned and was not ended prematurely, nor was stopped. Each 
feasibility objective and clinical objective was reviewed using data from 40 sets of 
data from the control group and 21 sets from the intervention group (see fig. 9 
ELIJAH CONSORT diagram).  
  
Fig. 9. ELIJAH CONSORT diagram, adapted from Eldridge et al (2016) 
CONSORT 2010 
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Enrolment 
Screened prior to eligibility 
assessment (n=708) 
Excluded(n=431) 
   Did not have primary care managed 
by a participating GP (n= 431 ) 
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There was no negative feedback regarding the content of the intervention and 
no patient drop-out from the trial.   
Baseline data 
Details of the baseline demographics of the patients included in the study within the 
intervention and control groups are illustrated in Table 3. We collected data on the 
gender, age, diagnosis and deprivation score to determine the general characteristics 
of the ELIJAH patient group and looked at whether the findings would be 
generalisable compared to epidemiological data on IBD. 
Table 3: ELIJAH participant demographics 
 Intervention  
n:40 
Control 
n:21 
Gender 
Male (n:29, 47.54%) 
 
Female (n:32, 52.46% ) 
 
n:18 
45.00% 
n:22 
55.00% 
 
n:11 
52.38% 
n:10 
47.62% 
Age 
< 65 (n:36, 59.02%) 
 
>65 (n:25, 40.98%) 
 
(Range 18-88 years) 
 
n:26 
65.00% 
n:14 
35.00% 
 
n:11 
52.38% 
n:10 
47.62% 
Diagnosis 
Ulcerative colitis (n:32, 
52.46%) 
 
Crohn’s Disease (n:21, 
34.43%) 
 
Proctitis (n:8, 13.11%) 
 
n:21 
52.50% 
n:14 
35.00% 
n:5 
12.50% 
 
n:11 
52.38% 
n:7 
33.33% 
n:3 
14.29% 
Equity determined from 
Deprivation category 
(WIMD) 
1 Least deprived (n: 16, 
26.23%) 
 
2 (n:7, 11.48%) 
 
3 (n:7, 11.48%) 
 
4 (n:15, 22.59%) 
 
5 Most deprived (n:16, 
26.23%) 
 
 
 
n:8 
20.00% 
n:5 
12.50% 
n:7 
17.50% 
n:9 
22.50% 
n:11 
27.50% 
 
 
 
n:8 
38.10% 
n:2 
9.52% 
n:0 
0% 
n:6 
28.57% 
n:5 
23.81% 
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Table 4: ELIJAH participants by GP practice 
GP Practice Intervention  
n:40 
Control  
n:21 
Briton Ferry Health 
Centre  
(n:9, 14.75%) 
Riverside Surgery  
(n:5, 8.2%) 
Castle Surgery  
(n:15, 24.59%) 
Skewen Medical Centre  
(n:13, 21.31%) 
Vale of Neath Practice  
(n:7, 11.48%) 
Dyfed Road Practice  
(n:12, 19.67%) 
n:6 
15.00% 
n:4 
10.00% 
n:8 
20.00% 
n:9 
22.50% 
n:4 
10.00% 
n:9 
22.50% 
n:3 
14.29% 
n:1 
4.76% 
n:7 
33.33% 
n:4 
19.05% 
n:3 
14.29% 
n:3 
14.29% 
 
Participants chose how to receive the intervention “My folder” and its 
component parts: in electronic form via email, in paper form via post or both.  
Table 5: ELIJAH participants by choice of contact method 
Choice of contact 
method 
Intervention  
n:40 
Control  
n:21 
Email 
(n: 23, 37.70%) 
Post  
(n: 32, 52.46%) 
Email and post  
(n:6, 9.84%) 
n:15 
37.50% 
n:21 
52.50% 
n:4 
10.00% 
n:8 
38.10% 
n:11 
52.38% 
n:2 
9.52% 
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Outcomes and estimation 
Feasibility outcomes 
Feasibility outcomes are reported as numbers and percentages of the study 
clinicians and screened, eligible and consented patients (see Table 6: Results of 
ELIJAH feasibility outcomes).  
Table 6: Results of ELIJAH feasibility outcomes 
Criteria Findings Result 
50% or more of individual 
clinicians approached agree 
to take part in the study 
n:6  
100% 
Yes 
50% or more of patients 
eligible to take part in the 
study are consented  
n:70 eligible patients  
n: 61 consented 
87.14% 
Yes 
75% or more of patients are 
consented and randomised 
in real time at the same 
appointment  
n:61 
100% 
Yes 
Less than 20% of patients 
drop out from the study 
n:0 
0% 
Yes 
Some data are collected on 
all outcome measures for 
over 80% of patients 
n:61 
100%  
Yes 
 
Clinical outcomes 
Clinical outcomes were analysed and reported individually for each outcome 
measure. As this was a feasibility study, each outcome was reported in numbers, 
percentages by randomised group.  
1. Cost data 
We collected information and amassed data on all participants (the 
intervention and control groups) and analysed these to identify the feasibility of 
collecting data of the total cost of NHS resources used by participants in primary and 
secondary care.  We collated the cost in local currency (U.K. sterling) and have 
noted these in each cost table. We did not formally analyse, or provide statistical 
analysis on the costs as the trial was based on exploring feasibility. We have 
included the cost data to provide a more complete data set. 
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We used the current existing patient data from primary and secondary care 
held within the patient records.  
In primary care we accessed information held in the GP electronic record. 
This record covered all GP treatments, visits and communications with the patient 
across all specialties and all NHS locations (UK wide). The records contained letters 
from secondary care services regarding admissions, outpatient visits and secondary 
care treatments. All the patient records were accessed. There were no missing 
records.   
In secondary care we used the patient paper records to access treatment, 
investigation and inpatient and outpatient episodes covering all specialities. We also 
accessed the GeneCIS electronic patient record to extract specific data about the 
patients’ IBD care including outpatient and in-patient episodes, medication and 
endoscopy investigations. All paper based and GeneCIS records were accessed. 
There were no missing records.  
We verified the secondary care data against the gathered primary care data to 
ensure there were no missing data.  
We recorded all the costs and documented these on the Data Abstraction 
Form (see appendix 8). Each form was completed for the identified direct and 
indirect NHS costs, and at each study time point (at 2, 4 months and at the end of the 
trial). We assessed the health economic impact of the direct and indirect costs using 
PSSRU Unit costs (Curtis, L. (2011) and the National Schedule of reference costs 2010 – 
2011 for NHS Trusts and PCT’s combined (Department of Health 2011).  
To assess the direct costs of the study, we looked at the times taken to 
produce the intervention: the 3 elements of “My folder”. We collected data for the 
intervention group (as the control group had care as usual), and looked at the four 
stages in production of the intervention – the request of the secondary care medical 
record, reading and analysis of the notes for pertinent information, the access of the 
electronic patient record (GeneCIS) which held the gastroenterology (IBD) and 
endoscopy information, the time taken to complete the ELIJAH questionnaire to 
produce the ELIJAH report, and the time taken to print and send the report to the 
patient and GP (see appendix 17 Time taken to produce the ELIJAH intervention). We 
 88 
 
calculated the cost of producing the intervention using the cost of a Gastro Intestinal 
Nurse Practitioner (Band 7) carrying out the required activities. All timing data were 
recorded (see table 7. Timings of ELIJAH production).  
Table 7. Timings of ELIJAH production 
 Time taken in 
minutes  
Min - max 
Missing data Total time in 
minutes for all 40 
intervention patients 
Requesting of notes 1 – 30 minutes 
 
nmiss:0 
0% 
126 mins 
Total: £94.50 
m: £2.36 (SD 4.33) 
Reading notes 2 – 24 minutes 
 
 
nmiss:0 
0% 
398 mins 
Total: £298.50 
m: £7.46 (SD 4.77) 
Accessing GeneCIS 
information 
1 – 17 minutes 
 
nmiss:0 
0% 
114 mins 
Total: £85.50 
m: £2.14 (SD 2.26) 
Completing 
ELIJAH 
questionnaire 
2 – 45 minutes 
 
nmiss:0 
0% 
410 mins 
Total: £307.50 
m: £7.69 (SD 5.91) 
Printing and 
sending reports 
1 – 13 minutes 
 
nmiss:0 
0% 
146 mins 
Total: £109.50 
m: £2.74 (SD 1.91) 
Total   1194 mins 
Total: £895.00 
m: £22.39 (SD 10.11) 
m: mean, SD: standard deviation 
There were no missing data. The 2 stages of production of the ELIJAH 
intervention that required the most time, and therefore cost, were the reading of the 
paper based hospital records and the completion of the ELIJAH questionnaire. The 
total cost of the production of the ELIJAH intervention was £895.50 based on a band 
7 Nurse Practitioner completing each task, if a more junior Nurse were completing 
the activities i.e. band 5, the costing’s would be reduced to £513.42.  
We collected indirect cost data on all participants (across the control and 
intervention groups) across primary and secondary care. We identified primary and 
secondary care appointments, treatments and investigations and medications.  
In primary care there were 342 accessed appointments, 194 were provided by 
a GP, 140 by a Nurse and 8 by a Health Care Support Worker (see appendix 15 
Primary and secondary care appointments and frequency). A range of appointment 
methods were used: 292 face to face visits at the GP surgery, 43 remotely accessed 
appointment via telephone and 7 home or out of hour visits.  
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Out of a cohort of 61 patients, 52 accessed primary care appointments at least 
once in the 6 month study period (see Table 8 primary care appointments).  
Table 8. Primary care appointments.  
 Total 
n:342 
Intervention 
n:209 
Control 
n:133 
Missing 
data 
GP appointment, 
minor surgery, out 
of hours (£53.00) 
n:154 
45.03% 
n:104 
49.76% 
Total:£3850.00 
m: 96.25  
(SD 88.53) 
n:50 
37.59% 
Total: £1656.00 
m: £78.86 
(SD 77.73) 
nmiss:0 
0% 
 
Telephone call with 
GP (£22.00) 
n:33 
9.65% 
n:27 
12.92% 
Total: £594.00 
m: £14.85 
(SD 37.08) 
n:6 
4.51% 
Total: £132.00 
m: £6.29 
(SD 12.33) 
nmiss:0 
0% 
 
Home visit from GP 
(£120) 
n:7 
2.05% 
n:7 
3.35% 
Total: £840.00 
m: £21.00 
(SD 114.93) 
n:0 
0% 
Total: £0.00 
m: £00.00 
(SD 0.00) 
nmiss:0 
0% 
 
Nurse appointment 
(£22.00) 
n:130 
38.01% 
n:58 
27.75% 
Total: £696.00 
m: £17.40 
(SD 18.22) 
n:72 
54.14% 
Total: £874.00 
m: £41.62 
(SD 55.52) 
nmiss:0 
0% 
Telephone call with 
Nurse 
(£6.00) 
n:10 
2.92% 
n:5 
2.39% 
Total: £30.00 
m: £0.75 
(SD 2.43) 
n:5 
3.76% 
Total: £30.00 
m: £1.43 
(SD 3.23) 
nmiss:0 
0% 
 
Appointment with 
HCSW 
(£8.00) 
n:8 
2.34% 
n:8 
3.83% 
Total: £64.00 
m: £1.60 
(SD 5.49) 
n:0 
0% 
Total: £0.00 
m: £0.00 
(SD 0.00) 
nmiss:0 
0% 
 
Primary care 
appointment costs 
£8766.00 
Mean (£):  
280.04 
 
£6074.00 
Mean (£): 
151.85 
54.22% 
Min (£): 0.00 
Max (£): 
1317.00 
(SD 212.69) 
£2692.00 
Mean (£): 
128.19 
45.78% 
Min (£): 0.00 
Max (£): 382.00 
(SD 108.51) 
nmiss:0 
0% 
m: mean, SD: standard deviation 
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We found it was feasible to cost the primary care appointments for all 
participants, there were no missing data. The interventions provided by Nurses were 
lower in cost than those provided by GPs.  
In secondary care there were 84 gastroenterology appointments for IBD 
accessed by patients from across the control and intervention groups. 43 were 
provided by a Medical Consultant and 41 by a Nurse Practitioner (see appendix 15 
Primary and secondary care appointments and frequency). A range of appointment 
methods were used: 60 face to face visits at the hospital and 24 remotely accessed 
appointment via telephone, postal review and email.  
Across the 61 participants, 32 accessed secondary care appointments (see 
table 9 secondary care appointments).  
Table 9. Secondary care appointments.  
 Total 
n:84 
Intervention 
n:63 
Control 
n:21 
Missing 
data 
Outpatient 
appointment with 
Medical Consultant 
(£106.00) 
n:43 
51.19% 
n:33 
52.38% 
Total: £3498.00 
m: £87.45 
(SD 223.75) 
 
n:10 
47.62% 
Total: 
£1060.00 
m: £50.48 
(SD 103.96) 
nmiss:0 
0% 
 
Outpatient 
appointment with 
Nurse Practitioner 
(£52.00) 
n:17 
20.24% 
n:12 
19.05% 
Total: £624.00 
m: £15.60 
(SD 29.32) 
n:5 
23.81% 
Total: 
£260.00 
m: £12.38 
(SD 22.69) 
nmiss:0 
0% 
 
Telephone call with 
Nurse Practitioner 
(£17.00) 
n:20 
23.81% 
n:14 
22.22% 
Total: £594.00 
m: £14.85 
(SD 37.08) 
n:6 
28.57% 
Total: 
£102.00 
m: £4.86 
(SD 15.34) 
nmiss:0 
0% 
 
Postal review 
(£17.00) 
n:2 
2.38% 
n:2 
3.17% 
Total: £22.00 
m: £0.55 
(SD 2.43) 
n:0 
0% 
Total: £0.00 
m: £0.00 
(SD 0.00) 
nmiss:0 
0% 
Email with Nurse 
Practitioner 
(£11.00) 
n:2 
2.38% 
n:2 
3.17% 
Total: £22.00 
m: £0.55 
(SD 2.43) 
n:0 
0% 
Total: £0.00 
m: £0.00 
(SD 0.00) 
nmiss:0 
0% 
 
Secondary care 
appointment costs 
£5838.00 £4416.00 £1422.00 nmiss:0 
0% 
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Mean 
(£):  
178.11 
Mean (£): 
110.40 
61.98% 
Min (£): 0.00 
Max (£): 
1218.00 
(SD 232.82) 
Mean (£): 
67.71 
38.16% 
Min (£): 
0.00 
Max (£): 
424.00 
(SD 108.10) 
 
m: mean, SD: standard deviation 
It was feasible to cost the secondary care appointments for all participants 
and there were no missing data.  
The number of treatments and investigations patients attended and whether 
they were likely due to have been caused by, or as an effect of IBD was investigated. 
Overall 51 patients out of a total cohort of 61 patients, access treatments or 
investigations during the study period, 10 did not. There were 265 treatments or 
investigations identified from the primary and secondary care notes. Of these, 218 
were likely due to be linked to the patients IBD care, (please see appendix 14 List of 
treatments and investigations, frequency and likely linked to IBD). The highest 
frequency of investigation / treatment was for patients blood tests at 176 during the 
study period (see table 10 treatments and investigations).  
 
Table 10. Treatments and Investigations.  
 Total 
 
Intervention 
 
Control 
 
Missing 
data 
Number of patients 
accessing treatments 
and investigations 
n:51 n:32 
80.00% 
n:19 
90.48% 
nmiss:0 
0% 
Number of 
treatments and 
investigations 
n:265 
 
n:198 
74.72% 
 
n:67 
25.28% 
 
nmiss:0 
0% 
 
Range of  treatments 
and investigations/ 
patient 
0-55 min:0 
max:55 
min:0 
max:10 
nmiss:0 
0% 
Likely linked to IBD n:218 n:162 
74.31% 
n:52 
23.85% 
nmiss:0 
0% 
 
Treatment and 
intervention costs 
£24920.00 
Mean (£): 
798.21 
£17174.00 
Mean (£): 
429.35 
53.79% 
Min (£): 0.00 
£7746.00 
Mean (£): 
368.86 
46.21% 
Min (£): 0.00 
nmiss:0 
0% 
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Max (£): 
12272.00 
(SD 1941.57) 
Max (£): 
5861.00 
(SD 1275.80) 
SD: standard deviation 
The intervention group had higher rates of patients accessing greater numbers 
of treatments and investigations and these were more likely to be linked to IBD. 
There were no missing data and it was feasible to collect the data.  
We collected data on the medication the patients were prescribed (see 
appendix 16 List of medications). Data were collected on the drug title, strength, 
dose, frequency and duration.  We accessed each patients’ primary and secondary 
records to identify the date, there were no missing data. We noted if there were 
missing data within the prescription details e.g. the frequency was missing or dose. 
We judged whether the medication was used to treat the patients IBD or wider 
effects of IBD e.g. anaemia, osteoporosis prevention. (See table 11, Medications).  
We identified 117 different medications the patients were collectively taking. 
Of these, 23 were medications used to treat IBD. 12 patients were not taking any 
medication.  
Table 11. Medications 
 
 Total 
 
Intervention 
n:40 
 
Control 
n:21 
 
Missing 
data 
Number of patients 
prescribed 
medication 
n:51 n:32 
80.00% 
n:19 
90.48% 
nmiss:0 
0% 
Number of patients 
prescribed IBD 
medications  
n:23 n:31 
96.88% 
n:17 
89.47% 
nmiss:0 
0% 
Missing information 
on IBD prescription 
n:61 n:31 
50.82% 
 
n:30 
49.18% 
nmiss:61 
44.85% 
 
 
Medication costs £24070.00 
Mean (£): 
719.22 
 
£18879.00 
Mean (£): 
471.99 
65.63% 
Min (£): 0.00 
Max (£): 
5481.89 
(SD 874.98) 
£5191.00 
Mean (£): 
247.23 
34.37% 
Min (£): 0.00 
Max (£): 
618.49 
(SD 179.80) 
nmiss:0 
0% 
SD: standard deviation 
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There were 136 discrepancies in the prescription of IBD medication due to 
missing data. The highest frequency of data missing within the prescription was 
frequency of medication (see appendix 16 List of medications).   
There were no missing data of number of patients taking medication and the 
information and data were feasible to collect.   
 
2.  Safety data 
We gained information, and collated data on all ELIJAH participants (within 
the control and intervention groups) and analysed these for Serious Adverse Events. 
There were no expected adverse events or Serious Adverse Events arising from the 
ELIJAH intervention. All adverse events and the number of participants affected 
were reported.  
In total, 197 adverse events were reported, or identified from the primary and 
secondary care notes. Of these 33 were likely related to IBD, (see appendix 18 list of 
adverse events). Out of a cohort of 61 participants, 47 reported or had at least 1 
event. The cohort range was 0-21 events. See Table 12: ELIJAH adverse events. 
There were no missing Adverse Event data. 
Table 12: ELIJAH adverse events 
Outcome Total Intervention  Control  < 20% 
difference 
between 
intervention 
and control 
group 
ELIJAH 
Participants 
n:61 n:40 n:21  
ELIJAH 
participants having 
Adverse events 
n: 47 
77.05% 
n:31 
77.5% 
n:16 
76.19% 
Yes 
Adverse events n: 197  n: 134  
mean: 4.32 AE 
/ participant 
n:63  
mean: 3.94 
AE / 
participant 
Yes 
Criteria of Adverse 
event: 
1. Known 
undesirable 
effect of IBD 
 
 
n:26 
13.20% 
 
n: 8 
 
 
n:17 
12.69% 
 
n:7 
 
 
n:9 
14.29% 
 
n:1 
 
 
Yes 
 
 
Yes 
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2. Exacerbation 
of known IBD 
3. Stable 
symptom of 
other pre-
existing 
condition 
4. Medical / 
Surgical 
procedure 
5. Other 
4.06% 
n:23 
11.68% 
 
 
n:36 
18.27% 
 
n:104 
52.79% 
 5.22% 
n:19 
14.18% 
 
 
n: 24 
17.91% 
 
n:67 
50.0% 
1.6% 
n:4 
6.35% 
 
 
n:12 
19.05% 
 
n:37 
58.73% 
 
Yes 
 
 
 
Yes 
 
 
Yes 
Timing in ELIJAH 
trimesters 
1 (0-2 months) 
 
2 (2-4 months) 
 
3 (4-6 months) 
 
 
n:61 
30.96% 
n:72 
36.55% 
n:64 
32.49% 
 
 
n: 40 
29.85% 
n: 50 
37.31% 
n: 44 
32.84% 
 
 
n: 21 
33.33% 
n: 22 
34.92% 
n: 20 
31.75% 
 
 
Yes 
 
Yes 
 
Yes 
 
There was a less than 20% difference in number of participants across the 
control and intervention group having adverse events and each criteria of the adverse 
events. Each trimester of the study showed no significant difference in number of 
adverse events, nor between the control and intervention groups.  
The number of Serious Adverse Events was recorded and causality to the 
ELIJAH intervention was assessed. No deaths were recorded within the study period 
of the ELIJAH participants (see Table 13, ELIJAH Serious Adverse Events). 
Table 13: ELIJAH Serious Adverse Events 
Serious adverse event Total 
serious 
adverse 
events 
n: 92  
Intervention  
Adverse events 
n: 74 
Control  
Adverse 
events 
n: 18 
< 20% 
difference 
between 
intervention 
and control 
group 
Serious adverse 
events: 
1. Not serious 
 
2. Required 
hospitalisation 
3. Resulted in 
incapacity 
4. Was life 
threatening 
 
 
n: 78 
84.78% 
n: 11 
11.96% 
n: 2 
2.17% 
 
n: 1 
 
 
n: 61 
82.43% 
n: 10 
13.51% 
n: 2 
2.70% 
 
n: 1 
 
 
n: 17 
94.44% 
n: 1 
5.56% 
n: 0 
0% 
 
n: 0 
 
 
Yes 
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1.09% 
 
1.35% 0% 
Causality  
1. Related to 
intervention 
2. Not related to 
intervention 
 
 
n: 0  
0% 
n: 92 
100% 
 
 
n: 0 
0% 
n: 74 
100% 
 
 
n: 0 
0% 
n: 18 
100% 
 
 
Yes 
 
Yes 
 
The number of unexpected events was recorded and causality to the ELIJAH 
intervention was assessed.  (See Table 14: ELIJAH Unexpected Adverse Events).  
Table 14: ELIJAH Unexpected Adverse Events 
Unexpected adverse 
event 
Total 
n: 105 
 
Intervention  
n: 78 
 
Control  
n: 27 
 
< 20% 
difference 
between 
intervention 
and control 
group 
Unexpected adverse 
events: 
1. Not serious 
 
2. Required 
hospitalisation 
5. Resulted in 
incapacity 
6. Was life 
threatening 
 
 
n: 99 
94.29% 
n: 5 
4.76% 
 
n: 1 
0.95% 
n:0 
0% 
 
 
n: 73 
93.59% 
n: 4 
5.13% 
 
n: 1 
1.28% 
n:0 
0% 
 
 
n: 26 
96.30% 
n: 1 
3.70% 
 
n: 0 
0% 
n:0 
0% 
 
 
Yes 
Causality  
1. Related to 
intervention 
2. Not related to 
intervention 
 
n: 0 
0% 
n:105 
100% 
 
n: 0 
0% 
n: 78 
100% 
 
n: 0 
0% 
n: 27 
100% 
 
Yes 
 
No Suspected Unexpected Serious Adverse Reactions (SUSARs) were 
recorded. We did not find any increased risks to patients from having their own 
electronic, individualised educationally enhanced IBD health reports. No patients 
found access to their reports emotionally burdensome, this was evaluated by patients 
recording this as an adverse event.  
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3. Patient centeredness 
We gained patient reported information from the Inflammatory Bowel 
Disease Service Satisfaction Questionnaire (ISSQ), and collated data on all ELIJAH 
participants (within the control and intervention groups). The ISSQ was given to 
patients at baseline (i.e. at consent and randomisation), and sent by post to all 
participants (2 weeks after the intervention patients had received their “My Folder”) 
at the study follow up intervals: 2, 4 and 6 months. If the ISSQ was not received 
back within 2 weeks of the sending date, a reminder letter with the ISSQ was sent. 
All patients completed the baseline ISSQ. In total 64 ISSQ reminders were sent (see 
table 15, ISSQ reminders and non-responders), and 15 participants did not respond 
and send back the completed ISSQ after the reminder. Overall more reminders (as a 
percentage total), were sent to the intervention group than the control group. 
Throughout the ELIJAH trimester follow up periods the number of reminders sent 
remained similar.  
Table 15: ISSQ reminders and non-responders 
 Intervention 
n:40 
Control 
n:21 
Total patient reminders 
sent 
n:64 
n:44 
68.75% 
n:20 
31.25% 
Study trimester 
1 
n:22, 34.38% 
2 
n:20, 31.25% 
3 
n:22, 34.38% 
 
n:15 
34.09% 
n:14 
31.82% 
n:14 
31.82% 
 
n:7 
35.00% 
n:6 
30.00% 
n:8 
40.00% 
Total non-responders 
after reminder. 
nmiss:15 
Min 1, max 3/ patient 
nmiss:10 
66.67% 
Min 1, max 3/ patient 
nmiss:5 
33.33% 
Min 1, max 3/ patient 
Study trimester 
1 
nmiss:22, 34.38% 
2 
nmiss:20, 31.25% 
3 
nmiss:22, 34.38% 
 
nmiss:5 
50.00% 
nmiss:2 
20.00% 
nmiss:3 
30.00% 
 
nmiss:1 
20.00% 
nmiss:2 
40.00% 
nmiss:2 
40.00% 
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More participants in the intervention group did not respond to the reminder 
and return the questionnaire. 2 participants, 1 from the intervention group, 1 from the 
control group completed the baseline ISSQ, but did not complete any subsequent 
follow up ISSQ.  
The ISSQ was analysed by section: ISSQ introductory answers, satisfaction 
questionnaire and EQ5D.  
The ISSQ introductory answers (see Table 16. ISSQ introductory answers) 
looked at whether patients knew, with accuracy, their diagnosis and date of 
diagnosis, these data were verified against their medical record.  
Table 16.  ISSQ introductory answers 
 
 
Total 
incorrect 
answers 
 
Total 
correct 
answers 
 
Correct 
answers 
Intervention 
 
 
Correct 
answers 
control 
 
 
Missing 
data 
 
Data 
collected 
for more 
than 75% 
of 
participants 
Total 
n:244 
n:21 
8.61% 
n:198 
81.15% 
n:131 
 
n:67 
 
nmiss:25 
10.24% 
Yes 
Study 
trimester 
Baseline 
 
1 
 
2 
 
3 
 
 
n:10 
47.62% 
n:3 
14.29% 
n:4 
19.05% 
n:4 
19.05% 
 
 
n:49 
24.75% 
n:48 
24.24% 
n:52 
26.26% 
n:49 
24.75% 
 
 
n:31 
23.66% 
n:33 
25.19% 
n:34 
25.95% 
n:33 
25.19% 
 
 
n:18 
26.87% 
n:15 
22.39% 
n:18 
26.87% 
n:16 
23.88% 
 
 
nmiss:2 
8.00% 
nmiss:10 
40.00% 
nmiss:5 
20.00% 
nmiss:8 
32.00% 
Yes 
 
Of the completed answers most (over 80%) were correct. Of the incorrect 
answers (8%), more were noted at baseline than in subsequent follow-ups. There was 
little difference between the intervention and control group in amount of correct 
answers.  
Over 10% of participants did not answer these introductory questions (see 
table 17. ISSQ introductory answers: missing data). 
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Table 17.  ISSQ introductory answers: missing data 
 Intervention  
missing data 
Control 
missing data 
Total 
nmiss:25, 10.24% 
 
nmiss:18 
11.25% 
nmiss:7 
8.33% 
Study trimester 
Baseline 
nmiss:4, 16.00% 
1 
nmiss:10, 40.00% 
2 
nmiss:5, 20.00% 
3 
nmiss:8, 32.00% 
 
nmiss:2 
11.11% 
nmiss:6 
33.33% 
nmiss:4 
22.22% 
nmiss:6 
33.33% 
 
nmiss:0 
0% 
nmiss:4 
19.04% 
nmiss:1 
4.76% 
nmiss:2 
9.52% 
 
There were more missing data for both the intervention and control groups in 
the first trimester than in subsequent trimesters.  
The ISSQ questions were split into 4 sections: Your condition, Getting care 
when you need it, Quality of the care you received recently, and General quality of 
the care you receive. 23 questions were distributed across these 4 sections (see table 
18. ISSQ answers).  
We looked at the amount of incomplete and missing answer data across both 
groups and at each time point. The total complete data set, if all patients answered all 
questions (61 patients X 4 time points) would be 244 answers per question. 
Questions 4 and 5 did not need to be answered if the patient had not received any 
information about their IBD since diagnosis.  
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Table 18.  ISSQ answers 
Question sections, 
number and question 
description 
Potential n: 244 
Total 
Missing 
data 
Intervention 
Missing data 
Potential 
n:160 
Control 
Missing 
data 
Potential 
n:84 
Data 
collected for 
more than 
75% of 
participants 
Your condition 
1. Amount of 
information 
2. Ease of 
understanding 
3. Usefulness 
 
4. Opportunity to 
ask questions 
 
 
nmiss:16 
6.56% 
nmiss:26 
10.66% 
nmiss:23 
9.43% 
nmiss:14 
5.74% 
 
nmiss:11 
6.88% 
nmiss:16 
10% 
nmiss:15 
9.38% 
nmiss:10 
6.25% 
 
nmiss:5 
5.95% 
nmiss:10 
11.90% 
nmiss:8 
9.52% 
nmiss:4 
4.76% 
Yes 
Getting care when you 
need it 
5. Explanation 
about getting 
care 
6. Ease of 
Understanding 
7. Usefulness 
 
8. Communication 
skills of person 
9. Difficulty in 
accessing care 
Free text 
 
 
nmiss:14 
5.74% 
 
nmiss:18 
7.38% 
nmiss:17 
6.97% 
nmiss:16 
6.56% 
nmiss:30 
12.30% 
 
 
nmiss:10 
6.25% 
 
nmiss:11 
6.88% 
nmiss:11 
6.88% 
nmiss:9 
5.63% 
nmiss:15 
9.38% 
 
 
nmiss:4 
4.76% 
 
nmiss:7 
8.33% 
nmiss:6 
7.14% 
nmiss:7 
8.33% 
nmiss:15 
17.86% 
Yes 
Quality of the care 
you received recently 
10. Quality 
 
11. Communication 
skills of person 
12. Discomfort 
noted 
13. Pain noted 
 
14. Discomfort in 
week following 
symptoms 
15. Pain in week 
following 
symptoms 
16. Opportunity to 
ask questions 
17. Explanation 
 
 
nmiss:18 
7.38% 
nmiss:18 
7.38% 
nmiss:28 
11.48% 
nmiss:21 
8.61% 
nmiss:25 
10.25% 
 
nmiss:25 
10.25% 
 
nmiss:26 
10.66% 
nmiss:26 
 
 
nmiss:10 
6.25% 
nmiss:10 
6.25% 
nmiss:13 
8.13% 
nmiss:9 
5.63% 
nmiss:13 
8.13% 
 
nmiss:13 
8.13% 
 
nmiss:13 
8.13% 
nmiss:13 
 
 
nmiss:8 
9.52% 
nmiss:8 
9.52% 
nmiss:15 
17.86% 
nmiss:12 
14.29% 
nmiss:12 
14.29% 
 
nmiss:12 
14.29% 
 
nmiss:13 
15.48% 
nmiss:13 
Yes 
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18. Understanding 
of 
understanding 
19. Usefulness 
10.66% 
nmiss:28 
11.48% 
 
nmiss:29 
11.89% 
8.13% 
nmiss:15 
9.38% 
 
nmiss:15 
9.38% 
15.48% 
nmiss:13 
15.48% 
 
nmiss:14 
16.67% 
General quality of the 
care you receive 
20. Availability of 
care 
21. Satisfaction 
 
22. Happy to repeat 
care 
23. Quality of IBD 
care 
 
 
nmiss:21 
8.61% 
nmiss:23 
9.43% 
nmiss:24 
9.84% 
nmiss:20 
8.20% 
 
 
 
nmiss:12 
7.50% 
nmiss:12 
7.50% 
nmiss:12 
7.50% 
nmiss:12 
7.50% 
 
 
nmiss:9 
10.71% 
nmiss:11 
13.10% 
nmiss:12 
14.29% 
nmiss:8 
9.52% 
Yes 
 
We collected data on each question from over 75% of all participants, and 
within the intervention and control group. Mostly, there were more missing data per 
question in the control than intervention group. The section with most missing data 
was that asking questions of the IBD care most recently received.  
We looked at the ISSQ questionnaire missing data across the baseline 
collection of data and the 3 trimester data collection points: at month 2, 4 and 6 (see 
table 19). 
Table 19. ISSQ missing data across ELIJAH trimesters 
Questions and section,  
 
Total 
Missing data 
Number  
potential n: 244 
Baseline Trimester 1 Trimester 2 Trimester 3 
Your condition 
3  
 
4  
 
5 
 
6 
 
nmiss:16 
6.56% 
nmiss:26 
10.66% 
nmiss:23 
9.43% 
nmiss:14 
5.74% 
 
nmiss:0 
0% 
nmiss:4 
6.56% 
nmiss:3 
4.92% 
nmiss:0 
0% 
 
nmiss:6 
9.83% 
nmiss:9 
14.75% 
nmiss: 10 
16.39% 
nmiss:6 
9.83% 
 
nmiss:5 
8.20% 
nmiss:6 
9.83% 
nmiss:5 
8.20% 
nmiss:4 
6.56% 
 
nmiss:5 
8.20% 
nmiss:7 
11.48% 
nmiss:5 
8.20% 
nmiss:4 
6.56% 
Data collected for more than 
75% of participants 
Yes Yes Yes Yes Yes 
Getting care when you need 
it 
7 
 
8 
 
 
 
nmiss:14 
5.74% 
nmiss:18 
7.38% 
 
 
nmiss:0 
0% 
nmiss:0 
0% 
 
 
nmiss:6 
9.83% 
nmiss:8 
13.11% 
 
 
nmiss:4 
6.56% 
nmiss:5 
8.20% 
 
 
nmiss:4 
6.56% 
nmiss:5 
8.20% 
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9 
 
10 
 
11  
nmiss:17 
6.97% 
nmiss:16 
6.56% 
nmiss:30 
12.30% 
nmiss:0 
0% 
nmiss:0 
0% 
nmiss:3 
4.92% 
nmiss:8 
13.11% 
nmiss:6 
9.83% 
nmiss:11 
18.03% 
nmiss:5 
8.20% 
nmiss:5 
8.20% 
nmiss:8 
13.11% 
nmiss:4 
6.56% 
nmiss:5 
8.20% 
nmiss:8 
13.11% 
Data collected for more than 
75% of participants 
Yes Yes Yes Yes Yes 
Quality of the care you 
received recently 
12 
 
13  
 
14 
 
15 
 
16 
 
17 
 
18  
 
19 
 
20 
 
21 
 
 
nmiss:18 
7.38% 
nmiss:18 
7.38% 
nmiss:28 
11.48% 
nmiss:21 
8.61% 
nmiss:25 
10.25% 
nmiss:25 
10.25% 
nmiss:26 
10.66% 
nmiss:26 
10.66% 
nmiss:28 
11.48% 
nmiss:29 
11.89% 
 
 
nmiss:0 
0% 
nmiss:0 
0% 
nmiss:2 
3.28% 
nmiss:2 
3.28% 
nmiss:2 
3.28% 
nmiss:2 
3.28% 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
 
 
nmiss:7 
11.48% 
nmiss:7 
11.48% 
nmiss:10 
16.39% 
nmiss:7 
11.48% 
nmiss:9 
14.75% 
nmiss:10 
16.39% 
nmiss:10 
16.39% 
nmiss:10 
16.39% 
nmiss:10 
16.39% 
nmiss:11 
18.03% 
 
 
nmiss:6 
9.83% 
nmiss:6 
9.83% 
nmiss:8 
13.11% 
nmiss:6 
9.83% 
nmiss:7 
11.48% 
nmiss:6 
9.83% 
nmiss:7 
11.48% 
nmiss:7 
11.48% 
nmiss:8 
13.11% 
nmiss:8 
13.11% 
 
 
nmiss:5 
8.20% 
nmiss:5 
8.20% 
nmiss:8 
13.11% 
nmiss:6 
9.83% 
nmiss:7 
11.48% 
nmiss:7 
11.48% 
nmiss:8 
13.11% 
nmiss:8 
13.11% 
nmiss:9 
14.75% 
nmiss:9 
14.75% 
Data collected for more than 
75% of participants 
Yes Yes Yes Yes Yes 
General quality of the care 
you receive 
22 
 
23 
 
24 
 
25 
 
 
nmiss:21 
8.61% 
nmiss:23 
9.43% 
nmiss:24 
9.84% 
nmiss:20 
8.20% 
 
 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
nmiss:1 
1.64% 
 
 
nmiss:7 
11.48% 
nmiss:8 
13.11% 
nmiss:8 
13.11% 
nmiss:7 
11.48% 
 
 
nmiss:5 
8.20% 
nmiss:6 
9.83% 
nmiss:7 
11.48% 
nmiss:6 
9.83% 
 
 
nmiss:8 
13.11% 
nmiss:8 
13.11% 
nmiss:8 
13.11% 
nmiss:6 
9.83% 
Data collected for more than 
75% of participants 
Yes Yes Yes Yes Yes 
Total data collected for more 
than 75% of participants 
Yes Yes Yes Yes Yes 
 
We collected data on each section and each question from over 75% of all 
participants. Each section, and each question had some missing data across the 4 
timeline periods.   
We collected patient free text comments in two questionnaire boxes; one 
after question 11 and one at the end of the questionnaire (see appendix 10 ISSQ, see 
appendix 19 for patient free text comments). We looked at the number of participants 
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adding comments, the number of comments, when they occurred within the study 
trimesters, and whether the comments were positive or negative (see table 20).  
Table 20. Patient free text comments 
 Total Intervention 
n:40 
Control 
n:21 
Number 
participants 
filling in the free 
text comments 
n:34 
55.74% 
n:22 
55% 
n:12 
57.14% 
Number of 
comments 
n:75 n:44 
58.67% 
n:31 
41.33% 
Range 1 - 4 1 – 4 1 - 4 
Study trimester 
Baseline 
 
1 
 
2 
 
3 
 
n:16 
21.33% 
n:19 
25.33% 
n:19 
25.33% 
n:21 
28% 
 
n:9 
20.45% 
n:10 
22.73% 
n:12 
27.27% 
n:13 
29.55% 
 
n:7 
22.58% 
n:9 
29.03% 
n:7 
22.58% 
n:8 
25.81% 
Type of comment 
Positive 
 
Negative 
 
n:55 
73.33% 
n:20 
26.67% 
 
n:32 
72.73% 
n:12 
27.27% 
 
n:23 
74.19% 
n:8 
25.80% 
 
We found that approximately half of all participants wrote free text 
comments. Both the intervention and control group patients provide free comments 
in much the same frequency. The range (1-4 comments) was the same in both 
groups. Comments were provided by both groups in each trimester. There were far 
more positive than negative comments written by participants in both groups.    
We collected descriptive data of the ISSQ scores as we wanted to explore 
more fully the amassed information from the trial. We did not seek to test statistical 
significance of the data via a comparison as the trial was based on feasibility. We 
collected summary statistics (mean, standard deviation, range) for the intervention 
and control groups for each of the four time points of the trial and collectively (see 
table 21).  
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Table 21. ISSQ summary statistics 
Question sections Intervention 
n: 40 
Control 
n: 21 
Your condition 
Baseline 
 
2 months 
 
4 months 
 
6 months 
 
 
Total 
 
m: 15.38 (SD 3.00) 
r: 8-20 
m: 15.58 (SD 2.13) 
r:11-20 
m: 16.65 (SD 1.94) 
r: 13-20 
m: 16.68 (SD 1.79) 
r: 12-20 
 
m: 16.07 (SD 0.69) 
 
m: 16.19 (SD 3.50) 
r: 5-20 
m: 16.00 (SD 2.92) 
r: 7-20 
m: 15.90 (SD 3.10) 
r: 6-20 
m: 16.24 (SD 3.13) 
r: 6-20 
 
m: 16.08 (SD 0.16) 
Getting Care when you need it 
Baseline 
 
2 months 
 
4 months 
 
6 months 
 
 
Total 
 
m: 22.6 (SD 2.18 ) 
r: 15-25 
m: 22.43 (SD 2.07) 
r: 17-25 
m: 22.10 (SD 2.23) 
r: 16-25 
m: 22.43 (SD 2.10) 
r: 16-25 
 
m: 22.39 (SD 0.21) 
 
m: 22.19 (SD 2.19 ) 
r: 12-25 
m: 21.95 (SD 3.43) 
r: 10-25 
m: 21.62 (SD 3.99) 
r: 9-25 
m: 21.86 (SD 2.76 ) 
r: 12-25 
 
m: 21.91 (SD 0.24) 
Quality of the care you received 
recently 
Baseline 
 
2 months 
 
4 months 
 
6 months 
 
 
Total 
 
 
m: 40.10 (SD 5.46) 
r: 23-48 
m: 39.92 (SD 4.62) 
r: 31-50 
m: 39.54 (SD 4.89) 
r: 28-46 
m: 40.10 (SD 4.25) 
r: 32-47 
 
m: 39.92 (SD 0.26) 
 
 
m: 38.76  (SD  4.88) 
r: 23-46 
m: 39.29  (SD 6.56 ) 
r: 21-49 
m: 39.52  (SD  5.97) 
r: 21-49 
m: 40.48  (SD  5.63) 
r: 24-49 
 
m: 39.51 (SD 0.72) 
General quality of the care you 
received 
Baseline 
 
2 months 
 
4 months 
 
6 months 
 
 
Total 
 
 
m: 18.00 (SD 2.47) 
r: 11-20 
m: 17.58 (SD 2.17) 
r: 12-20 
m: 17.35 (SD 2.36) 
r: 9-20 
m: 17.73 (SD 2.12) 
r: 13-20 
 
m: 17.67 (SD 0.27) 
 
 
m: 17.45 (SD 3.70) 
r: 8-20 
m: 17.05 (SD 3.14) 
r: 8-20 
m: 16.90 (SD 2.88) 
r: 8-20 
m: 17.62 (SD 2.82) 
r: 8-20 
 
m: 17.26 (SD 0.34) 
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m: mean, SD: standard deviation, r: range.  
A lower mean score indicates worse patient satisfaction. Baseline satisfaction was 
moderately high in all four sections. We found that overall mean scores were similar 
for the intervention and control groups in each of the four ISSQ question sections. 
Within each question section there was small variability noted between the 
intervention and control groups. The overall standard deviation scores would 
indicate that data results are close to the expected value for the population. But we 
did not explore the statistical significance of this data set.   
We collected health related quality of life data using the EQ5D to assess 
participants’ general well-being. We positioned the EQ5D questions at the end of the 
ISSQ questionnaire and before a comment box (see appendix 10 ISSQ).   We utilised 
the EQ5D five quality of life questions, but not the thermometer. We looked at the 
amount of missing data across the intervention and control group (see Table 212).  
Table 22. EQ5D missing data  
EQ5D Question  Total 
Missing 
data 
Potential 
n:244 
Intervention 
Missing data 
Potential 
n:160 
Control 
Missing 
data 
Potential 
n:84 
Data collected 
for more than 
75% of 
participants 
1. Mobility nmiss:19 
7.79% 
nmiss:14 
8.75% 
nmiss:5 
5.95% 
Yes 
2. Self-care nmiss:21 
8.61% 
nmiss:16 
10% 
nmiss:5 
5.95% 
Yes 
3. Usual 
activities 
nmiss:19 
7.79% 
nmiss:14 
8.75% 
nmiss:5 
5.95% 
Yes 
4. Pain or 
discomfort  
nmiss:18 
7.38% 
nmiss:13  
8.13% 
nmiss:5 
5.95% 
Yes 
5. Anxiety / 
depression 
nmiss:19 
7.79% 
nmiss:14 
8.75% 
nmiss:5 
5.95% 
Yes 
 
We collected data on each question from over 75% of all participants, from 
across the intervention and control group. Mostly, there were more missing data per 
question in the intervention than control group.  
We looked at EQ5D data completion across the 4 timelines; at baseline, at 
month 2, 4 and 6 at completion of the study (see table 23).  
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Table 23. EQ5D missing data across ELIJAH trimesters 
EQ5D Question 
 
Total 
Missing data 
Number  
potential n: 244 
Baseline Trimester 
1 
Trimester 
2 
Trimester 
3 
1. Mobility 
 
nmiss:19 
7.79% 
nmiss:0 
0% 
nmiss:6 
9.84% 
nmiss:6 
9.84% 
nmiss:7 
11.48% 
2. Self-care nmiss:21 
8.61% 
nmiss:0 
0% 
nmiss:6 
9.84% 
nmiss:7 
11.48% 
nmiss:8 
13.11% 
3. Usual 
activities 
nmiss:19 
7.79% 
nmiss:0 
0% 
nmiss:6 
9.84% 
nmiss:6 
9.84% 
nmiss:7 
11.48% 
4. Pain or 
discomfort 
nmiss:18 
7.38% 
nmiss:0 
0% 
nmiss:6 
9.84% 
nmiss:6 
9.84% 
nmiss:6 
9.84% 
5. Anxiety / 
depression 
nmiss:19 
7.79% 
nmiss:0 
0% 
nmiss:6 
9.84% 
nmiss:6 
9.84% 
nmiss:7 
11.48% 
Data collected for 
more than 75% of 
participants 
Yes Yes Yes Yes Yes 
 
We collected data each question from over 75% of all participants across the 
four timeline points. . Each question had some missing data.    
We gathered summary statistics for the EQ5D scores at baseline and each of 
the two monthly timelines during the trial period. We did not formally statistically 
analyse the data as the trial was designed to test feasibility (see table 24). 
Table 24. EQ5D summary statistics 
 Intervention 
n: 40 
Control 
n: 21 
Baseline 0.86 0.76 
2 months 0.81 0.77 
4 months 0.80 0.76 
6 months 0.80 0.77 
 
We found there were little differences between the two groups in EQ5D scores at 
each time period during the trial. The intervention group had slightly higher scores at 
each time period. The intervention and control group scores remained largely 
unchanged for the trial periods.  
4. Timeliness 
We gained information from primary and secondary care patient records, and 
collected data on all ELIJAH participants (within the control and intervention 
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groups) for timeliness of action from reporting of symptoms to response. We based 
this timeliness analysis upon the ELIJAH adverse events (see appendix 18. List of 
ELIJAH Adverse Events). In many cases the timings were missing in the records. 
The range was 1 to 120 days. We split the timings identified into time periods (see 
Table 25: ELIJAH timeliness). 
Table 25: ELIJAH Timeliness 
Time period from 
recognising symptoms 
to reporting and 
response to symptoms 
Total 
n:197 
Intervention 
n:134 
Control 
n:63 
< 20% 
difference 
between 
intervention 
and control 
group 
Not Known nmiss: 91 
46.19% 
nmiss: 54 
40.30% 
nmiss: 37 
58.73% 
Yes 
1 day n: 85 
43.15% 
n: 64 
47.76% 
n: 21 
33.33% 
Yes 
2-7 days n: 10 
5.08% 
n: 8 
5.97% 
n: 2 
3.17% 
Yes 
8-14 days n: 4 
2.03% 
n: 4 
2.99% 
n: 0 
0% 
Yes 
15-21 days n: 2 
1.02% 
n: 2 
1.49% 
n: 0 
0% 
Yes 
22-28 days n: 0 
0% 
n: 0 
0% 
n: 0 
0% 
Yes 
Over 28 days n: 5 
2.54% 
n: 2 
1.49% 
n: 3 
4.76% 
Yes 
 
There was a less than 20% difference in number of participants across the 
control and intervention group in the timeliness of recognising, reporting and 
response for symptoms. However, there were a substantial amount of missing data 
that could not be found across the primary and secondary paper and electronic 
patient records (46.19%). Clinicians, in nearly half of all entries into the patient 
record, documented symptoms but not the start of symptoms, or the duration.  
Missing data  
Overall there were more missing data in the patient reported clinical outcome 
(patient centeredness) than in clinical outcome information derived from the patient 
records (cost, safety) but in one outcome (timeliness) there was significant missing 
data.  
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The most easily obtainable and complete data sets were in cost and safety.   
Clinical outcomes summary 
A summary of the clinical outcomes data, amount of missing data, and the 
relation to the progression criteria is displayed below (Table 26 Summary of 
ELIJAH results).  
Table 26:  Summary ELIJAH results; clinical outcomes, missing data and 
attainment of progression criteria 
Clinical outcome Target criteria  Total 
number 
patients 
Intervention 
group 
Control 
group 
Missing 
data 
Progression 
criteria met 
1. Cost  75% or more of 
patient data for 
direct and 
indirect costs 
can be collected 
over primary 
and secondary 
care   
n:61 
100% 
n: 40 
100% 
 
n:21 
100% 
None Yes 
2. Safety Adverse events 
show no 
Suspected 
Unexpected 
Serious Adverse 
Reactions 
(SUSARs)result
ing from the 
intervention 
n:0 
0% 
n:0 
0% 
n:0 
0% 
None Yes 
3. Patient 
centeredness 
Patient reported 
data (ISSQ and 
EQ5D) can be 
collected for 
more than 75% 
of patients 
across the 
control and 
intervention 
groups 
n: 61 n:40 
ISSQ 
missing data: 
5.63%- 
10.00% 
EQ5D 
missing data: 
8.75%-
10.00% 
n:21 
ISSQ 
missing 
data: 
4.76%- 
17.86% 
EQ5D 
missing 
data: 
5.95% 
Yes 
variable  
Yes 
4. Timeliness 75% or more of 
patient data for 
timeliness can 
be collected 
over primary 
and secondary 
care 
n:61 
100% 
 
n:54 
40.43% 
n:37 
58.73% 
46.19% No 
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This concludes that it was feasible to collect data on each outcome for the 
intervention and control group. Cost data was easily accessible, ELIJAH participant 
adverse events were collected without any data missing, patient satisfaction was 
collected across the two study groups, and only in the timeliness outcome measure 
was there a proportion of missing data within the primary and secondary care 
records.  
Overall the data collected from the intervention and control group were found 
to be much the same (within 20% of each other) for the safety, patient centeredness 
and timeliness clinical outcomes.  
Feasibility study findings indicate that three out of four clinical outcomes 
were met for progression: cost (based on resource use), safety and patient 
centeredness. Timeliness did not meet the progression criteria because of the amount 
of missing data. The most complete data sets were cost and safety.   
Cost and safety could each be considered as the potential primary outcome 
for a fully powered phase III trial because of the completeness of data, and 
attainment of the progression criteria. Cost and safety data proved easy to collect 
from the primary and secondary care patient records, and did not require patient 
reported outcomes.  
There were no expected, or identified SUSARs resulting from the 
intervention, and the intervention was not found to be emotionally burdensome upon 
the patient.  
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4.4 Discussion 
Summary of main findings 
The ELIJAH study was able to meet the majority of the clinical outcomes 
feasibility criteria. We had less than 25% missing data for both the intervention and 
control group for 2 out of 3 clinical outcomes judged by these criteria (cost, and 
patient centeredness). In addition the feasibility outcome for safety was also met, as 
analysis of the patients’ adverse events within the trial period show there were no 
Suspected Unexpected Serious Adverse Reactions (SUSARs) resulting from the 
intervention.  
We were unable to meet the progression criteria for only 1 clinical outcome 
measure; timeliness, as there were less than 75% of data collected. There were a 
large proportion of data missing across the 3 R’s (see appendix 8. Data Abstraction 
Form and table 23. ELIJAH timeliness). We judged a complete data set for the 3R’s 
(recognition, reporting, response to symptoms) as having information in all 3 areas. 
Often 1 or 2 areas had incomplete data.   
Each of the study feasibility outcome criteria were met: all clinicians 
approached agreed to participate in the study and there were no clinician drop outs. 
Over 50% of patients approached to take part in the study were consented, there 
were no formal patient drop outs from the study, although there were missing 
questionnaire data in the patient reported outcome of patient centeredness. The 
consent and randomisation processes were effective and all patients received a 
combined consent and randomisation appointment that was not delayed. Some data 
were collected on all patients on all outcome measures. There were no whole missing 
data sets for any patient.  
Context of findings with existing literature 
The ELIJAH study did aim to compare to the real world in terms of reflecting 
the national IBD patient population demographic, disease distribution and care 
services and were mindful of the need for the study design to be representative of the 
typical IBD patient in terms of patient background, care delivery and health care 
experience.   
Nationally IBD is a major cause of mortality and morbidity for men and 
women equally and affects and wide age range – from early teens to old age (BSG 
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2005 p.2).There are about 150,000 cases in the UK with more patients with 
Ulcerative Colitis than Crohn’s disease. The patients may have debilitating 
symptoms from the disease and treatments and may make frequent demands on 
health services from their GP’s and secondary care providers (Williams et al 2007 p 
1) as patients often require close communication with long-term specialist follow up 
and seek and require significant involvement with their health-care providers. We 
found that the ELIJAH study population was generally equally balanced for gender 
and disease type, but for age there was a difference; there was a higher number of 
participants aged over 65 in the control group. We found the participants did access 
both primary and secondary care and required a range of interventions, medications, 
treatments and investigations. Most IBD care in the UK is delivered by hospital 
based secondary care, and integrated multi-disciplinary and multi-professional teams 
and this national experience was reflected and evidenced within the participant 
cohort. Neath Port Talbot Hospital, the setting for the study is a District General 
Hospital operating within the Local Health Board scenario of NHS Wales and the 
study participating GP practices have a care pathway to the gastroenterology services 
at the Hospital. Neath Port Talbot Hospital refers patients to larger tertiary centres 
for specialised care. This pattern of care delivery is replicated throughout the UK. 
The GP practices and study participants location were spread amongst semi-rural and 
urban districts and covered more deprived and less deprived areas, this again is 
replicable among the UK.   
There is a paucity of existing literature regarding feasibility randomised 
controlled trials of the type of intervention explored.  
Strengths and limitations 
The clinician engagement in ELIJAH was good with no clinician within the 
trial across primary and secondary care withdrawing from the study or withdrawing 
their patients. We found no clinical resistance to the intervention or lack of clinical 
engagement.  Evidence from work of the Royal College of Physicians (2016) is that 
colleagues are very keen to collect and use analysable data about their patients and 
increasingly supportive of the concept of the patient focused record. The 
involvement of a primary care clinician (a local participating GP), and participating 
secondary care clinicians (a Consultant Gastroenterologist and Nurse Practitioner) 
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may have contributed to this success as there was local available knowledge of 
patient and clinical communities willing to participate in the research.  
The ELIJAH study team was a multi-disciplinary and multi-professional 
team with core members spanning academia and clinical care. Many within the team 
had collaborated in high quality research projects (using mainly pragmatic 
randomised controlled methodology) over the previous two decades and had a can-
do philosophy underpinned by experience of running trials. We worked together as a 
team to collate the application for the study and completed the qualitative ELIJAH 
focus group. The team had clear demarcation of role and responsibility and was 
democratic and pragmatic in the approach to decision making and delegation. We 
met regularly (monthly), and were available for discussion at short notice should this 
be needed. Therefore rapid alteration and amendment where needed was carried out 
without affecting the set timescales. This proved very effective when the protocol 
amendment was required to be passed by the ethics committee (see appendix 12. 
Letter of confirmation of full ethical approval). The nature of our team working 
contributed to the completion of the research, Shneiderman (2016) concurs that 
successful research teams have many of the characteristics that our team displayed;  
“previous successful collaborations… mixtures of senior and junior 
members… (with a) shared vision… (and) schedule… regular and open 
discussion… (and) good communication… (all guided by) trained experienced 
leadership”.  
We maintained a tight timescale of a 6 month intervention period and a 6 
month planning and reporting period. We delivered the randomised feasibility trial 
and intervention within a tight budget that equated to approximately £1200 per 
patient (61 patients, trial budget of £75,000) (see appendix 20. ELIJAH budget). We 
did not request an extension of trial period or budget.  
 However, because of the tight financial and time constraints of the study 
funding, many of the trial team generously worked more than could be funded, and 
many worked more hours than accounted for.  
Conducting a small scale pragmatic randomised controlled trial feasibility 
trial was of academic interest to the trial team, as many of their previous projects had 
been on RCT studies many times larger than ELIJAH. Yet, the interest lay in the trial 
methodology as well as the intervention. We discussed as a study team whether 
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carrying out the study was feasible, whether we could provide a valid trial for such 
limited funding, whether the intervention could be developed and implemented in 
such a short time period, and whether the trial team could work effectively to deliver 
a small RCT on a much reduced budget and time frame than they were used to. 
Whilst a fully powered RCT would have provided a more rigorous evaluation of 
effectiveness of the intervention it would have also necessitated more intensive 
resources in terms of time, money and participant numbers.  
For ELIJAH we decided to run a pragmatic feasibility randomised trial to 
ensure we could remain within the budgetary and timing limitations, scrutinise the 
feasibility of study processes, and learn from the experience for the development of a 
larger trial. We keenly understood that rigorous statistical significance could not be 
obtained reliably from such small study numbers and the trial lacked the power to do 
this. However we were mindful that decisions regarding the feasibility of progression 
to a full trial could be gleaned from this feasibility study.  
Patient recruitment was from 6 local participating GP surgeries within the 
same Health Board. In our planning we had originally anticipated higher recruitment 
rates, with the expectation that four surgeries would suffice to recruit the stipulated 
patient cohort. This was not the case but with the help of our GP we were quickly 
able to identify two further GP surgeries that were willing to participate and whose 
patients were willing to be consented into the feasibility trial. Consent was 
completed for all patients without issues. Even though all patients approached to take 
part in the study were under the care of the clinicians within the study team there 
were some reluctance of some patients to participate, perhaps because they felt the 
study too onerous in terms of completion of questionnaires, but we did not 
investigate this.  
We decided to randomise patients to provide comparison data of the 
feasibility of data collection and implementation of the intervention. The remote 
randomisation process worked well and in real-time. Many feasibility studies do not 
randomise patients to two arms. Arain et al (2010) found that in 2007-8, out of the 
54 pilot and feasibility studies critically examined in their review, just over half did 
randomise participants within feasibility studies. However, as this study was to 
inform a larger RCT we felt it important to test the feasibility of the RCT 
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methodology to be used in the scaled up study that would be powered to elicit and 
demonstrate effectiveness of the intervention. We randomised the intervention in a 
2:1 ratio in favour of the intervention to ensure a higher number of patients receive 
the intervention. We aimed, from the ELIJAH outcomes (feasibility and clinical), to 
ensure that we could present supporting data for a full trial protocol development and 
acknowledge this would likely involve multiple centres to ensure the numbers 
needed to ensure a fully powered trial.   
The development of the intervention (see chapter 3) was pragmatic. We 
designed the ELIJAH folder and outputs in conjunction with patients and the 
intervention concept ideas were supported by the focus group (see chapter 2). The 
content of the folder used existing individual patient clinical data and the 
accompanying educationally enhanced paragraphs were taken and adapted, with 
permission from existing IBD patient literature from the National Association of 
Crohn’s and Colitis (NACC). This ensured that we could provide detailed 
individualised personalised IBD information and education in a reliable, accepted 
way.  
The production of the elements of My Folder: My History, My Plan and My 
Update were achieved with ease, but My Update proved more difficult to produce in 
a timely way following each visit of the patient for IBD care. The three parts of My 
Folder proved easier to complete from the electronic patient record than from the 
paper record as this took more time, and therefore more cost to produce. 
 It proved difficult to keep track of the 40 intervention patients IBD care 
pathway as there were no automatic notification system of a patient seeking help, 
attending an appointment, receiving an investigation or being admitted for their IBD 
care. Whilst it is was worthy to create a longitudinal patient record of their IBD care, 
perhaps in a wider trial “My History” and “My Plan” should be evaluated without 
“My Update” in order to pragmatically and feasibly provide clinicians and patients 
with summarised educationally enhanced IBD information, but potentially reduce 
time and cost load.  
We did anticipate problems in participant compliance with the intervention 
and potential barriers and challenges. We thought that a larger number of patients 
would choose to receive the ELIJAH folder in electronic form rather than on paper, 
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but this did not prove so (see table 5. Choice of method of contact). This could be 
because of lower levels of patient acceptance of IT delivery methods of patient 
information, rates of IT literacy or issues of security and confidentiality. Leahy 
(2009)17 stated that 75% of all American adults have access to the internet, and with 
the age range of IBD patients known to range from teenagers to the elderly (and 
reflected within the patient demographic see Table 3. Patient demographic) it was 
anticipated that access to internet services will be viable for at least half the patients. 
However, the study area of Neath Port Talbot had a mix of areas of deprivation, the 
participants had mostly moderate to high levels of deprivation and so may not have 
had access to IT services at home.  No patients reported difficulties or queries 
regarding the security of their health information as displayed within the ELIJAH 
folder.  
The clinical outcome data proved easy to obtain across primary and 
secondary care by generous access to the electronic patient records (EPR) and paper 
based notes. During the study period I worked within the unit from which we 
recruited patients, and I was used to using the GeneCIS EPR that held the IBD 
information, INDIGO that held pathology and histology results and PAS (Patient 
Administration System) that stored information on appointments and investigations, 
and therefore the hospital data were able to be accessed efficiently. Although I did 
not work in primary care, because I was employed within the Health Board the GPs 
were very generous in allowing me to access their EPRs without hindrance. The 
secondary care data were verified against the primary care data to ensure validity of 
the information.  
The Data Abstraction Form and Adverse Events form (appendix 8 and 9), 
both worked well as data collection recording tools across primary and secondary 
care. However improvements could be made by moving from paper-based forms to 
electronic versions, perhaps automatically populated by existing electronic patient 
records e.g. the upload of medication from primary care databases. 
The DAF was used to collect two clinical outcomes – cost and timeliness and 
this proved successful as it meant one fewer form to complete and core location of 
data ready for analysis.   
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Timeliness was recorded on the DAF but proved difficult to identify and 
record across primary and secondary care. The recording of when patients noted 
increased symptoms was particularly hard to ascertain. In many cases there were 
reporting of symptoms, but not when they were noted. The response to symptoms 
was more regularly recorded i.e.: adjustment or prescription of medication, initiation 
of investigations or referral from primary to secondary care, but there was regularly 
missing data.  
The patient reported data collected on the ISSQ (see appendix 10), was 
documented well by participants and there were no adverse comments made by 
participants about the form within the free text comment boxes. We did meet the 
clinical outcome criteria of over 75% collected data for the ISSQ, but improvements 
to the questionnaire in terms of length of questionnaire, delivery method and 
frequency of questionnaire sent to participants could be made for a full trial.  
The ISSQ is seven pages in length, and this could be reduced by adjustment 
of the layout or reduction in the number of the questions whilst maintain the four key 
question areas. The EQ5D was completed by over 75% participants and was 
positioned on the last page of the ISSQ. We did not include the EQ5D thermometer 
but in an adapted and shortened ISSQ this could be included for more insightful 
patient data.  
The ISSQ was paper based and in a main trial could be completed on-line or 
via email which would enable easier collation of data and identification of non-
responders and missing data. The ISSQ was sent to participants three times over a 
six month period and they were required to complete the questionnaire at baseline 
after consent and randomisation. This may prove too frequent in a main trial for 
researchers and patients, however, if the study period is elongated to e.g. a year, the 
frequency could be maintained but the interval between questionnaires lengthened. 
We sent completion reminders two weeks after sending the questionnaire if we had 
not received a reply, this proved effective in maximising the data yield.  
The clinical outcomes were based on feasibility rather than as comparators of 
effectiveness of the intervention, as the study was not powered in terms of patient 
numbers, funding or time to make statistically significant conclusions.  
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We identified that two clinical outcome measures could serve as the primary 
outcome measures in a larger trial (cost or safety). There were no SUSARs arising 
from the intervention and no adverse events, and this is in keeping with the low risk 
intervention design. However as was demonstrated in the focus group analysis the 
sharing of patient information with patients can result in raised anxiety or stress (see 
chapter two).  
 This feasibility study did not look at comparative cost data of the 
intervention, nor did it look at whether the cost of production of the intervention 
would be off set by a patient reduction in total NHS costs. For the intervention to be 
adopted widely a careful cost – benefit assessment would need to be calculated, 
especially in a National Health Service in times of austerity.  
Future recommendations 
The ELIJAH study has met the feasibility criteria, three out of four of the 
clinical outcomes. There are strengths and weaknesses of the study methodology, 
and for the study to be replicated or progressed to a fully powered trial, learning and 
adaptations to the trial protocol would be required.   
Our research team integrated approach was central to the planning and 
development of the study. A future research team should consider a multi-
professional structure of academics and health care professionals including 
participation of primary and secondary care clinicians (doctors and nurses) who can 
give local knowledge of healthcare settings and patient populations. However, a 
more realistic accounting of the cost of required personnel and expertise would be 
required to ensure professional costs are covered.    
Whilst our team consulted with patient representative groups and piloted the 
intervention with patients, we did not have a patient representative within the 
research team, this would be a recommendation for future teams to ensure high-
levels of patient engagement and participation throughout the research trial.  
I worked within the research team as a researcher-practitioner. I was 
employed as a Nurse Practitioner (Band 7 on the Agenda for Change pay-scale) 
delivering IBD care to the patient population included within this study. The 
advantages were that I had experience or working with the patient population and 
Health Board structures and could plan and implement the intervention using local 
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knowledge. However, if replicated, the practitioner implementing the intervention 
would not need to be a researcher, and trial teams may assign the collation of 
information and production of the intervention to a band 6 nurse, perhaps most 
appropriately a nurse specialist in IBD.  This would ensure the nurse has a 
subspecialised knowledge of IBD and the local population and structures, be used to 
using the medical notes and EPR for pertinent data, and be able to act autonomously, 
whilst being cost effective. A general band 5 nurse may not have the skill set to 
deliver the intervention, a band 7 nurse may be too un-necessarily expensive and 
skew the cost analysis.  
We did not explore the feedback of health professionals about their opinions 
of the ELIJAH intervention, nor their use of it. Collection and analysis of this would 
be a key recommendation for future research to ensure joint care givers and patient 
satisfaction is correlated.  
This study provided feasibility data about the intervention but not rigorous 
evaluation of the intervention effectiveness. In order to obtain this information a 
fully powered RCT would need to be undertaken. This would require more resources 
in terms of time, money and sites and participant numbers. A fully powered RCT 
would be required to obtain statistical significance of the intervention and some of 
the methodology, intervention product design and delivery methods be altered.  
A control and intervention group would be required again but a 1:1 ratio 
would be adequate to obtain comparison between the two groups of participants. 
The ease of production of the elements of “My folder” were variable. “My 
History” and “My Plan” information proved relatively easy to glean from the patient 
notes and EPR but “My Update” proved more difficult as there were no automatic 
notification of when the patient had attended primary or secondary care. In a larger 
trial, an electronic notification system would be needed or if not possible, the “My 
Update” component be dropped from the intervention. “My Plan” could be updated 
as changes occurred without the need to complete the third part of the intervention to 
pragmatically and feasibly provide clinicians and patients with summarised 
educationally enhanced IBD information, but potentially reduce time and cost load.   
Patient notes proved feasible to obtain and analyse, but more time consuming 
than accessing the primary and secondary care EPR. A future recommendation 
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would be for data to be obtained from the primary and secondary care EPR. The 
intervention was offered to participants as a paper and/ or electronic version a future 
recommendation would be to offer the intervention in electronic version only as an 
email attachment to participants and clinicians.  
Cost, safety and patient centeredness clinical outcomes were met by the study 
but timeliness was not. Timeliness was recorded on the DAF but proved difficult to 
identify from the primary and secondary care records, especially the time between 
recognition of symptoms and reporting of symptoms. In a larger trial this clinical 
outcome measure should not be included. 
The Data Abstraction Form and Adverse Events form (appendix 8 and 9), 
both worked well but again were paper based, in a full multi-centre trial it would be 
prudent to move to electronic versions, some of which could be automatically 
completed by links to the EPR.  
The ISSQ was paper based too, and in a main trial could be completed by 
participants on-line or via email. It was completed by participants immediately after 
consent and randomisation and this should be replicated in a larger trial as it enables 
a baseline to be established. It was then sent to patients three times – at two, four 
months from baseline and at the end of the trial at 6 months. This close interval may 
prove too frequent in a main trial for researchers and patients, the study period 
should be elongated to one year, and the frequency of ISSQ completion be 
maintained but the interval between questionnaires lengthened. Sending reminders to 
patients after two weeks if the ISSQ had not been returned proved effective and 
should be followed in a larger trial.  
The ISSQ was seven pages long with the EQ5D at the end of the 
questionnaire. The questionnaire should be shortened with less questions but 
maintaining the four sections. We did not include the EQ5D thermometer but in an 
adapted and shortened ISSQ this could be included for more insightful patient data.  
The study methodology, intervention and data collection was feasible but 
more research would be needed to establish whether the intervention is effective.  
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4.5 Conclusion  
The study has shown that the ELIJAH intervention has met all of the 
feasibility criteria, that: 
 50% or more of individual clinicians approached agree to take part in the 
study 
 50% or more of patients eligible to take part in the study are consented 
 75% or more of patients are consented and randomised in real time at the 
same appointment 
 Less than 20% of patients drop out from the study 
 Data are collected on all outcome measures for over 80% of patients 
And feasibility study findings indicate that at least 3 out of 4 outcome 
measures were feasible to collect in the intervention group and the control group.  
 75% or more of patient data for direct and indirect costs (cost) can be 
collected over primary and secondary care   
 Adverse events show no Suspected Unexpected Serious Adverse Reactions 
(SUSARs) resulting from the intervention and there is less than 20% 
difference between the intervention and control group for adverse events, 
including Serious Adverse Events (SAE) with causality related to the 
ELIJAH intervention. 
 Patient reported data (ISSQ and EQ5D) can be collected for more than 75% 
of participants across the control and intervention groups.  
One clinical outcome was not met; timeliness. Recommendations within the 
discussion have concluded that due to difficulty in data collection, this outcome 
measure should not be replicated in future studies or included in a larger fully 
powered trial.  
We have identified a potential primary outcome for a fully powered trial; cost 
and it has been shown feasible to collect data on this outcome measure.  
The progression criteria to advance this study from a feasibility study to a 
fully powered phase III randomised controlled trial have been achieved but the trial 
protocol and methodology would require modifications:  
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 The cost per participant would need to be increased. 
 The timing of the trial should be increased to one year.  
 The trial should be multi-centre in order to include the number of participants 
required to ensure the trial is fully powered.  
 A band 6 IBD nurse specialist should formulate the intervention.  
 The trial should explore the satisfaction of participants and health 
professionals.  
 A 1:1 ratio of intervention to control of the intervention should be used.  
 “My Update” should not be included as a part of “My folder”, instead 
changes should be made to “My Plan”.  
 The intervention should be populated by information from the primary and 
secondary care EPR.  
 The intervention should be offered via IT only.  
 Timeliness should not be included as an outcome measure.  
 The DAF, AE form and ISSQ should be used for data collection but in 
electronic form and linked to the EPR and automatically populated from it 
where possible.  
 The ISSQ should be shortened and include the EQ5D plus thermometer.  
 
This chapter has demonstrated how we conducted a feasibility trial using the 
ELIJAH intervention. We have demonstrated that the study feasibility and clinical 
outcomes of the intervention were largely met and that the study is feasible. I have 
also explored how the study should be adjusted and modified to enable progression 
to a phase III randomised controlled trial. There is a need for more study in this area 
and protocol development. We have contributed to the body of evidence in an area 
that has previously been little explored. 
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Chapter 5: A reflection on my research as a nurse practitioner.   
In the previous chapter I discussed the ELIJAH pragmatic randomised 
controlled feasibility trial. I described the methodology used to carry out the trial, 
examined the results obtained and considered issues arising from the within the 
discussion. One of the points made within the previous chapters’ discussion was 
regarding the perceived effective nature in which the research team worked together. 
In this chapter, I will explore my experience of working within the research team 
whilst we conducted a feasibility trial of ELIJAH using a randomised controlled trial 
methodology.   
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5.1 Background 
With the success of a research application to The Health Foundation, our 
multi-professional research team was awarded £75,000 to carry out a pragmatic 
randomised controlled feasibility trial (ELIJAH, discussed in chapter 4). We initially 
built our research team from applicants on the research award (Chief Investigator 
(Consultant Gastroenterologist), Principle Investigator, Computer Scientist, 
Methodologist and Health Economist). We enlisted further professionals from other 
disciplines to provide additional support, advice and expertise (local G.P., Trial 
Manager, a Professor specialising in Qualitative research). We also sought the 
expertise of a Nurse Academic within the trial team as the intervention was to be 
produced and distributed by a clinical nurse and we wanted to be mindful of any 
nursing issues that could affect the running of the trial.  
As a team we considered various ways to explore the intervention. The 
research team gave me insights into the potential methodologies we could employ, 
and after careful consideration we chose the randomised controlled trial. I acted 
within the team as the Principle Investigator while continuing to work within the 
NHS setting as an Advanced Nurse Practitioner in Gastroenterology. Patients for the 
study were taken from the IBD population within my workplace; some, but not all 
were under my care.  
The enlarged and empowered research team planned the qualitative and 
quantitative elements of the trial together (focus group and randomised controlled 
feasibility trial).  There however was a marked difference, and less enthusiasm from 
the Nurse Academic noted whilst I was undertaking the quantitative part of the 
research. During the qualitative focus group development, there was a high level of 
partnership working and engagement. In the planning and execution of the RCT 
feasibility trial I felt from discussion with the Nurse Academic, that our choice of 
RCT methodology seemed to struggle to fit in traditional nursing research. The 
reasons for this were explored by the student but still remain largely unclear. The 
Nurse did state she had a lack of experience within the research field of RCTs and 
was unused to working in research teams but also that the methodology did not fit in 
nursing research. I was interested in why this may be the case and so have reflected 
on the experience, with specific focus on whether the methodology can or is used by 
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nurses more widely, and whether there is a reasoned disparity between nursing and 
the RCT.  
I have used a reflective tool (Rolfe et al 2001) to explore these questions as 
this is a widely accepted nursing line of enquiry.  
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5.2 Reflection 
Nurses have been encouraged to use and adhere to reflective methodology to 
enquire about their practice (e.g. Johns 2009, Pierson 1998, Taylor 2006, Bradbury-
Jones et al 2009) and use the reflection to implement change in practice.  
In the hierarchy of methodology, reflection would be classed as “expert 
opinion” (Dieppe 2004), because it is a subjective method whereby personal thinking 
and feeling is analysed and used to amend or support future action. The RCT would 
be classed as the gold standard of research methods in terms of rigour, replicability 
and minimised bias (Bench et al 2013).  
Reflection can, perhaps, be viewed as the antithesis to the scientific trial 
method of enquiry, and especially: the randomised controlled trial (RCT). The 
fluidity and realism of reflection and the rigidity and artificialness of the RCT do 
seem to be diametrically opposed.  
This reflection of an RCT can therefore, seem to be unusual and unorthodox 
because of the mix of two such different methodologies. However, Mantzoukas 
(2006), states that the two methodologies hold “very similar definitions, aims and 
procedures” for eliciting evidence for practice, and reflection in and on practice. The 
embodiment of reflection within, and upon practice, and the opportunity for truly 
“reflective practitioners” (Schön 1983) encourages reflection while practising all 
elements of a role, including conducting research.  
In the nursing literature personal reflection upon carrying out or taking part in 
RCTs is rare; I identified only one article addressing this. Newall et al (2009) 
describes the discussions of a focus group of Australian nurses who had carried out 
an RCT. The use of a formalised reflective model for reflection of carrying out an 
RCT is absent. 
The reflective model I chose (Rolfe et al, 2001), “addresses both the macro 
and micro levels of reflection” and includes “descriptive… theory and knowledge 
building (and is) … action orientated”.  Elements within the tool build to a detailed, 
easy to apply list of questions. The framework is levelled at nurses and in particular 
Advanced Nurses due to its simple practicality and depth of insight within 3 simple 
questions “What …So what…Now what” (Rolfe et al 2001).  
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What….. 
My role as Principle Investigator was designated and defined by the research 
team and defined within the “Responsibilities of Sponsor” (Russell 2010) within a 
Standard Operating Procedure of the trials unit overseeing the trial.  
 We followed The Medical Research Council two seminal documents: A 
framework for development and evaluation of RCTs for complex interventions to 
improve health (2000) and update:  Developing and evaluating complex 
interventions: new guidance (2007) and developed a mixed methods approach with a 
focus group and pragmatic randomised feasibility trial that contained a blend of 
feasibility outcome measures.  
Full ethical and NHS Trust research and development approval was sought 
and obtained before the intervention commenced. 
To summarise: I held a focus group to inform the intervention and clarify 
patient’s preferences. Full analyses of the transcription from the discussion group 
was carried out using summative analysis (Rapport 2010).  All members of the 
ELIJAH team contributed to the discussion and this was an example of the research 
team working very well, quickly and efficiently together with an enthusiastic ‘can 
do’ attitude.   
We then worked together to develop the intervention and research methods. 
We implemented this with 61 participants recruited from six local GP surgeries. 
During this phase of the research process we noted that one member of the research 
team (the Nurse Academic) was uncomfortable with the research methodology of the 
RCT.  
Randomised controlled trial methodology and nursing 
The randomised controlled trial (RCT), also known as the true experiment or 
classic experiment, has as its main feature a comparison of the outcomes of two or 
more groups of participants who receive either an intervention (known as the 
intervention group) or placebo or treatment as usual (control group). The aim of the 
RCT is to maximise the elimination of bias from the study by randomising 
participants into comparable groups that are as similar as possible and blinding the 
investigators and / or participants as to what group allocation they have received 
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(Bowling 2004). In comparing outcomes, the classic RCT is powered to elicit and 
demonstrate effectiveness of the intervention. Therefore, because of its rigor, 
straightforwardness of methodology for use, and ability to demonstrate unbiased 
effectiveness of intervention, the RCT sits at the zenith of the hierarchy of research 
methodologies. Robson (2002) states that the power of the RCT has led to it being 
recognised as the “gold standard... in the many fields of applied research”, and 
furthermore represents the “method of choice if you seek to do quality research” 
(Robson 2002). Dieppe (2004) acknowledges the RCT position, and states that it 
attains the: 
         “premier position of ‘top dog’ in the production of high   quality      
evidence for systematic reviews and meta-analyses” 
                                                             (Dieppe 2004).  
The ability of RCTs to combine to form powerful longitudinal collective 
evidence has constituted the bulk of the Cochrane library. Cutting, (2008 p. 216) 
recognises that the Cochrane library content is the basis upon which decisions in 
healthcare and academia are made, as they “rank evidence according to its perceived 
value in clinical care”.  
The RCT has been adopted by medicine enthusiastically and constitutes the 
“heartland of medical research” (Robson 2002 p. 116) with RCTs forming the 
substantive majority of evidence. Nursing, though, has not endorsed RCT 
methodology with such emphasis. Fridlund et al (2014), found a paucity of Cochrane 
reviews of RCTs led by nurses, and Seers, (1997) stated that only 1% of reviews 
within the Cochrane library were conducted by nurses or concerned nursing 
interventions. The reasons for this difference in approach to evidence-based practice 
between Medicine and Nursing evidence based research are unclear. The perceived 
weaknesses of the RCT methodology by nurses may account for some of the 
preferred use of other methods such as qualitative enquiry. Nursing research is 
sometimes viewed as distinct from medical research in terms of professional enquiry, 
and as a result has a different evidence base that reflects nursing’s holistic 
philosophical practice. It can also be argued that nursing practice can be seen as 
incompatible with the RCT reductionist requirement to distinguish and test separate 
interventions (Hicks 1998). Traditionally, Nursing views practice as delivering 
complex care via a holistic intervention (Coates 2004).  Specific outcomes relating to 
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practice change may be difficult to implement. The RCT is more resource-intensive 
in terms of money, time and participant numbers than less rigorous methods, and it 
may be more difficult for nurses to access these essential ingredients (Bench et al 
2013). Bowling (2002) suggests a fourth reason could be because “there is often 
professional resistance” (p. 227) to the use of the RCT and suggests this is due to 
ingrained and philosophical opposition.  
Nursing has assumed a mainly qualitative methodology and embraced an 
individualised holistic approach to the accumulation of a nursing evidence base. 
Robson (2002), in the aptly titled Real World Research, offers unequivocal support 
of the RCT and urges all researchers to consider the RCT as research methodology 
“if you can find a feasible and ethical means of doing this” (p 114) because of its 
power to deliver “the best evidence for effectiveness, for whether something 
‘works’” (Robson p116). There is acknowledgement that nursing whilst constituting 
the majority of healthcare employees does lack a strong voice for its evidence base. 
Seers (1997), recommends that a “core culture change” (p1) in nursing research is 
needed to rectify the imbalance between nursing developing new tested interventions 
and requiring a robust research base. 
So what 
Literature recounting reflections of nurse researchers’ carrying out RCTs are 
rare. Brooker et al (1999) qualitatively researched why a RCT conducted within an 
A&E department failed to recruit enough participants to the intervention, and why 
the trial was discontinued.  Many of the reasons were nursing related 
                    “stress and poor morale… differences in perception concerning 
the value of the research”  
                                                           (Brooker et al 1999)  
Brooker also cites that nurses did not believe that the intervention was being 
tested appropriately, and that the load of work for the unit nurses was 
disproportionate. Newall (2009) also found that Nurses conducting an RCT found 
that it was more time intensive Duncan and Haig (2007) also list may difficulties 
encountered during their RCT. In a section entitled “reflection” they list “extraneous 
components” such as poor recruiters to the study and nurses who did not complete 
data collection adequately. It was noted however, that Nurses miss an opportunity to 
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express how these difficulties made them feel. Newall (2009) does list some positive 
experiences of an RCT listed by the interviewees in the focus groups including 
finding the trial “exciting and stimulating” (p27), being able to provide enhanced 
patient care and “raising the profile of the organisation” (p28).  
We successfully carried out the ELIJAH randomised feasibility controlled 
trial, and I can recognise and felt many of the frustrations and disappointments listed 
above, but also the positive aspects of carrying out an RCT. The experience was 
arduous, frustrating, challenging in the extreme, tiring and resulted in instability in 
existing work practices and difficulties in work and study relationships particularly 
within the research team.  
These difficulties resulted in some professional and academic isolation 
resulting from an acute and repeated voicing of the unorthodox choice of a nurse to 
conduct an RCT. The choice was met with suspicion, fear and sometimes high 
emotion. The intervention and study were dismissed because they purportedly had 
less nursing and a more medical emphasis and my role as a nurse and position within 
the team was discredited.  
Perhaps if the trial had been halted prematurely or been adversely affected by 
external influences all I would reflect is that the journey had been extremely 
difficult. However, ELIJAH has proved more than a chore.  
The experience of working within such a long-standing, influential and 
generous team has provided the stability and advice needed to tackle each challenge 
in turn: from ethical consent to protocol writing, design of the intervention to 
recruitment and statistical analysis planning.  
The research funds awarded paid for specialist time, health economics, 
methodology and information science, and gave kudos to the project.  
We also had unqualified support from clinical, nursing and managerial staff 
within the work environment in which the intervention was applied.  
My time to conduct ELIJAH was protected, was flexible, and, used 
effectively by holding regular and well-attended research team meetings which 
concentrated on planning the phased research. 
 129 
 
The highs of the trial period have far outweighed any lows. Educationally, I 
have unusually had experiential research training, rather than the more traditional 
front-loading of theory.  
Clinically I feel I have been able to offer my patients an innovative, more 
patient orientated and personalised way of care. I have also learned much about 
patient medical, nursing history and treatment. I also feel I have improved my 
clinical confidence.  
Personally, I feel as though I have experienced more about myself and my 
patients’ experiences by carrying out the RCT than the usual clinical setting allows 
given the constraints of time and hectic schedules.  
I have learnt that I have previously untapped depths of tenacity, problem 
solving, enthusiasm, persistence and resolve. Each step of the RCT was an exciting 
challenge and completing them gave me enormous personal satisfaction and 
confidence to approach the next task. I enjoyed the process of carrying out the RCT 
enormously. I have thrived professionally on the work and felt enormously proud of 
the project and my part in it.  Lomas et al (2002) advised that research projects 
should be:  
   “of interest, exciting and innovative as well as simple in design and easy to 
manage”  
                                                                  (Lomas et al 2002 p. 35).  
ELIJAH has fulfilled each of these requirements.  
ELIJAH has largely achieved the feasibility criteria to allow progression to a 
Phase III protocol development. However, ELIJAH has delivered far more 
educationally, professionally and personally to me than the success of the trial. 
Now what 
Although a small feasibility trial, our learning from the trial has provided a 
robust evidence base for a phase III trial. I will refine and develop the intervention 
and methodology in light of the trial findings.   
I would like to work in research teams in the future and aim to recreate many 
of the aspects that contributed to our team cohesiveness. Culotta (1993) states that 
research teams made up of multi-professionals who bring with them diverse 
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expertise, experience and ideas are becoming more usual, and two decades later 
Shneiderman (2016) states that collaborative research teams are now becoming a 
normal way of conducting complex research.  
I would like to continue as a practitioner-researcher after ELIJAH, and fully 
integrate these two symbiotic roles. Robson (2002) calls these roles “the true hybrid: 
someone whose job is officially part-practitioner, part-researcher”. In ELIJAH, the 
service intervention arose from questions from my practice, and by working with my 
patients as participants I was able to provide higher clinical care to all my patients by 
integrating found theory and research findings into practice. I would like to evaluate 
practice with further RCTs and try to redress the imbalance of too few RCTs being 
carried out by nurses, about nursing interventions.  
I also wish to provide the support and advice to others that I was fortunate to 
have had in abundance from the research team. Wang Vedelø and Lomborg (2010) 
state that there is a need for nurse researchers and clinical nurses to work more 
openly together and provide more “education, training and support … (to) increase 
the success rate and quality of nurse-led … RCT” (p. 199). 
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5.3 Conclusion 
In reflecting on my research journey of carrying out an RCT, and particularly 
the exploration of some of the nursing views of the use of the methodology, I have 
identified that my experience described is probably not unique.  I have highlighted 
some of the wider nursing views about the methodology and why some nurses may 
not, or may not be encouraged, to choose this methodology for their research.   
The RCT is possible in nursing research and can be the most appropriate 
methodology applied to an exploration of an intervention. It can also be enjoyable 
and can contribute to the evidence base for nursing and in wider contexts such as the 
Cochran library. Whilst nursing has not had a strong tradition of conducting RCTs, 
the opportunities to redress this by nurses conducting rigorous, well designed, 
funded and supported original research to impact patient care and experience, seems 
to be available, possible and necessary in order for nursing to advance its evidence 
base.  
This chapter has explored part of my experience whilst carrying out a 
randomised controlled feasibility trial of the ELIJAH intervention. In the next 
chapter I will combine the learning from the trial (modifications identified to 
progress the trial) and my experiential learning, to describe a protocol for a fully 
powered phase III randomised controlled trial of ELIJAH.  
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Chapter six: Systematic literature review 
6.1 Background 
So far within this thesis I have described how we identified a deficit in the 
capacity of our IBD service to meet patient demand for services and information, and 
I have discussed how we addressed this issue and tested our ideas. In the 
introduction I described the service pressures that led to our consideration of new 
ways to provide additional services that would inform and empower patients to better 
self manage their condition. In chapter two I explained the findings of a focus group 
that we undertook to explore patients’ views of individualised patient held reports 
that provided additional education about IBD. The participants of the focus group 
endorsed the ideas we proposed and gave very useful insight into the development of 
personalised, educationally enriched IBD reports. The adjustment of our electronic 
health record to generate these reports was related in the following chapter, and the 
testing of the intervention via a randomised feasibility trial was relayed in chapter 
four. The feasibility trial found that “My folder” intervention was feasible with no 
adverse events or safety concerns. A reflection of the experience of conducting the 
trial has been included in the previous chapter.  
Within this chapter I will explore how our approach to the identified problem 
fits with the existing body of contemporaneous evidence. In 2010 to 2011 when we 
held the focus group, built the intervention and carried out the feasibility trial, we 
conducted a short literature review of use of electronic healthcare records and looked 
to see if others had described similar interventions. The literature trawl identified 
only a few studies at that time. During this time I was enrolled on a Doctorate course 
in the School of Healthcare Sciences and a formal systematic literature review was 
not required.  When the doctorate program was wound down in 2013, I took a one 
year sabbatical, moved to the Medical School and transferred to a PhD in Medical 
and Healthcare studies to complete my candidature. The criteria for a PhD in 
Medical Healthcare Studies did required the submission of a thesis and I undertook 
an additional up-to-date systematic literature review in 2018 to help inform the thesis 
and to illustrate any new developments in the field that would not have been 
apparent when we first started the research. I have included the systematic literature 
within the thesis here to reflect accurately the chronological order of the research.  
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This systematic literature review, carried out in 2018, aimed to review the 
current literature pertaining to the creation and trials of individualised educationally 
enriched IBD information, the use of this by patients and its outcomes. Our focus 
was to identify and appraise the current processes and research described in the 
literature that addressed our area of interest, to reflect on the findings from the focus 
group and feasibility trial in light of this new evidence, and amass evidence to assess 
if further research in this field would be pertinent.   
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6.2 Methods  
Search strategy 
The methods used in this systematic literature review followed the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta Analysis) 2009 
guidelines and statement (see appendix 21).  
We wanted to ensure all relevant studies were included, and as such a wide 
search strategy was employed.  We searched the following eleven electronic 
databases via Ovid SP:  AMED, BNI, CINHAL, Cochrane, EMBASE, EMCARE, 
Google Scholar, Medline, Psychinfo, TRIP and Web of Science. The detailed search 
strategy per database are found in appendix 22.  
A search filter was used for the databases including inclusion and exclusion 
criteria.  Table 27 highlights the inclusion / exclusion criteria used for study 
selection.  
Table 27: Systematic literature review inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Citations published between 2000 - 
2018 
Citations pre 2000 
Worldwide publications Acute disease 
Target population: IBD and variations 
of IBD 
 
Chronic disease  
Construct: Individualised patient 
education 
 
 
The inclusion criteria, like the systematic literature review were broad. We 
did limit the search to the years 2000-2018 as we hypothesised that prior to this date 
there was little interest from legislators or researchers in EHR’s, digitalisation of 
patient information or sharing of information with patients. We included 
international publications to capture the global developments in this area and 
included papers particularly reporting IBD or chronic disease as this was the 
condition suffered by our patient group. We were particularly interested in amassing 
information on any interventions and / or trials of individualised patient information 
as this development was closely aligned to our idea for expansion of GeneCIS.  
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We employed a text search within the electronic databases to identify peer-
reviewed research publications. The search terms included variations of the search 
inclusion criteria. The search terms used were:  
 Health records 
 Personal health record 
 Patient portal 
 Medical records 
 Electronic medical records 
 Patient access to records 
 Patient held record 
 Personalised / personalized patient held 
 Individual patient record 
 Individualised / individualized patient record 
 Chronic disease / chronic illness or Inflammatory bowel disease : Colitis / 
Ulcerative colitis/ Crohn’s disease/ proctitis 
 
The key search terms were created from relevant terms within three main 
areas:  firstly, the construction of various platforms to give patient information held 
in records to patients, how patient could access these and effects of this, secondly, 
whether these records were individualised, and lastly, whether the records were for 
IBD or chronic disease patients.  The list below shows how these search terms were 
grouped:  
1. Health records, Personal health record, Medical records , Electronic medical 
records, Patient access to records, Patient held record,  
2. Personalised / personalized patient held, Individual patient record, 
Individualised / individualized patient record, Patient portal 
3. Chronic disease / chronic illness or Inflammatory bowel disease : Colitis / 
Ulcerative colitis/ Crohn’s disease/ proctitis  
These three topic areas were merged together.  The search term combinations 
were Medical Subject Heading (MeSH) terms, text words and word variants for the 
three topic areas.  Key word combinations were developed in consultation with a 
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medical librarian and based on the topics and used in the literature search (see table 
28: Key word combinations) 
Table 28: Key word combinations 
Words And Or 
Health records Inflammatory bowel 
disease 
Chronic disease 
Personal health record Colitis Chronic illness 
Patient portal Ulcerative colitis  
Medical records Crohn’s disease  
Electronic medical 
records 
Proctitis  
Patient access to records   
Patient held record   
Personalised / 
personalized patient held 
  
Individual patient record   
Individualised/ 
individualized patient 
record 
  
 
Key words were searched in each of the databases with IBD and chronic 
disease variations separately to maximise the opportunity of identifying citations. 
We hypothesised that if we searched with IBD terms only our yield of relevant 
articles may have been very low, unrepresentative of the wider developments and we 
would miss areas of development that could be relevant and transferrable from other 
chronic disease groups.   
Targeted hand searches using publications identified in the initial searches 
were carried out and the references of all primary studies and review articles were 
hand-searched in order to identify studies missed in the electronic search. Additional 
publications were identified by contacting relevant clinical experts and the grey 
literature was sought by searching abstracts including research reports, conference 
publications, government reports and policy documents.  
Study selection 
We employed a two stage process for assessing and selecting the literature to 
be included in the systematic review. Two researchers independently screened the 
title and abstract of all citations identified by the search strategy. If there were 
differences in outcome of their scrutiny of the evidence, a meeting was held to 
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discuss the articles and agreement was sought.  We independently assessed the 
citations based on relevance to the identified topic areas and intervention 
development.  The references of these articles were scrutinised to obtain any 
additional relevant articles. Full texts of the eligible articles were obtained and the 
full paper analysed by the two researches using the same two-stage process.  
Data collection 
Data of the evidence were collected and captured. We recorded information 
about the year of publication, population, location of trial or authors, study design, 
number of participants or articles included and quality of the paper. We then 
extracted topics or themes addressed by the papers and identified findings and 
outcomes.  
The papers were grouped according to whether they were published pre or 
post our feasibility trial in 2011, whether the research or authors were based in the 
UK or were worldwide, whether the literature was from peer reviewed papers or 
from grey literature, whether the paper addressed IBD patient care particularly or 
other chronic disease and the quality of the articles.  Topics and themes running 
through the gathered literature were identified.   
Quality assessment 
We included all original articles in English describing the development and / 
or the qualitative or quantitative evaluation of patient accessed individualised 
records.  Articles were included if they assessed or described one element of our 
proposed intervention.  
We decided to assess and evaluate the primary studies identified by 
reviewing the effectiveness of the interventions described and presented the findings 
as a narrative synthesis as the majority of the studies were qualitative. We adapted an 
existing validated relevant criteria specifically designed for this, described by 
Thomas et al 2004: the EPHPP instrument (Effective Public Health Practice 
Project), see Table 27. We changed the tool from descriptive outcomes (strong, 
moderate and weak) to a scoring system for easier comparison between studies and 
ranked the studies from the highest score (best quality) to lowest numerical score 
(poorest quality). Each quality marker (selection bias, design, confounding factors, 
blinding, use of data collection tools and number of withdrawals) was assessed using 
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the two-stage process we used when selecting the studies to be included in the 
systematic review. I and a second independent reviewer quality assessed each paper 
and discussed disparities in the marking. Where there was disagreement after 
discussion, I met with my academic supervisor to agree the scoring. 
While the EPHPP was designed specifically for use in systematic literature 
reviews related to public health nursing, the tool has been tested for its flexibility to 
adapt to up to date methods of systematic review (Thomas et al 2004). The EPHPP 
instrument has been used successfully in chronic disease prevention systematic 
reviews and so relates well to our thematic area.  
 The articles we identified for inclusion in the systematic review were 
numerically scored according to the criteria below (Table 29).   
Table 29. Quality of studies 
Selection bias Selected cohort was very likely to be representative of the IBD 
or chronic disease population and greater than 80% 
participation rate (2) 
Selected cohort was somewhat likely to be representative of the  
IBD or chronic disease population and 69 – 79% participant rate 
(1) 
All other responses or not stated.  
Design Randomised Controlled Trials and Controlled Clinical Trials 
(2) 
Cohort analytical, case control, cohort or an interrupted time 
series (1) 
All other designs or design not stated (0) 
Confounding 
factors  
Controlled for > 80% of confounders (2) 
Controlled for 60% - 79% of confounders (1) 
Confounders not controlled or not accounted for (0) 
Blinding Blinding of outcome assessor and study participants (2) 
Blinding of outcome assessor or study participants (1) 
No blinding to intervention status or research question (0) 
Data collection 
tools 
Tools are valid and reliable (2) 
Tools are valid but reliability not described (1) 
No evidence of validity or reliability (0) 
Withdrawals and 
dropouts 
Follow up rate of > 80% of participants (2) 
Follow up rate of 60% - 79% of participants (1) 
Follow up rate of < 60% of participants or withdrawals and 
dropouts not described (0) 
 
The full scoring table of the articles is included in appendix 23. The 
maximum achievable score was 12. No studies were removed from the systematic 
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literature review because of their quality assigned scores or issues highlighted in the 
discussion of the results of the systematic literature review.  
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6.3 Results 
A total of 1203 citations were identified from the electronic database 
searches (see appendix 22) and 43 publications through other sources obtained 
through searches of the grey literature. Fourteen duplicates were identified and 
removed, and 1232 records were screened and reviewed via a title and abstract 
review of the paper.  Of these a further 1020 were deemed ineligible for inclusion in 
the systematic literature review. A total of 212 full-text citations were retrieved for 
detailed evaluation. Following critical appraisal of the publications 65 were included 
in the literature review (60 of which were identified from the electronic database 
search, see appendix 4). A total of 147 studies were excluded; 142 were identified as 
off topic, three were unavailable in English and two were unobtainable. The 
PRISMA 2009 Flow Diagram below (see figure 10) pictorially represents these 
results.  
Figure 10: PRISMA 2009 Flow Diagram 
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A summary of the articles included in the systematic literature review 
synthesis and their main characteristics are detailed below (table 30). Because of the 
heterogeneity of the papers found we will carry out a narrative synthesis.  
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Table 30: Summary of articles included in literature review 
Article 
number 
Author Year Population Location Study design Number of participants / articles Quality 
score of 
the article 
1.  Al-Sahan A.  2016 Primary and 
secondary care 
Saudi 
Arabia 
Qualitative questionnaire 
and focus group 
n= 424 patients 2 
2.  Archer J.S. et al.  2014 Chronic illness Canada Systematic review n= 11 articles N/A 
3.  Bartlett C. et al.  2012 Renal medicine UK Qualitative survey n=583 patients, n= 99 staff 0 
4.  Bell S.K. et al.  2015  USA Qualitative survey n=99 clinicians 0 
5.  Bhavnani V. et al.  2010 Primary Care UK Quantitative survey  n=231 patients 2 
6.  Bidmead E. et al.  2016 IBD UK Qualitative interviews and 
Case study  
n=56 patients, n=5 healthcare 
professionals 
0 
7.  Casey I. et al 2016 Chronic disease USA Qualitative questionnaire n=50 patients 1 
8.  Chunchu J.J. et al. 2012 Chronic illness USA Pilot feasibility study Focus group n= 8 patients, Trial n= 58 
patients n= 14 Doctors, n= 2 medical 
assistants 
4 
9.  Cimino J.J. et al. 2000 Secondary care USA Observational study  n=11 patients 1 
10.  Cimino J.J. et al. 2002 Secondary care USA Qualitative questionnaire 
and telephone interview 
n=13 patients, n= 3 physicians 1 
11.  Cimino J.J. et al. 2001 Primary care  USA Qualitative questionnaire / 
telephone interview  
n=11 patients n=3 Doctors 1 
12.  Cruickshank J. et al 2012 Chronic disease 
and generic 
UK Qualitative survey n=262 patients 0 
13.  Di Marco C. et al. 2006 Surgery Canada Description of product in 
development 
N/A N/A 
14.  Druss B.G. et al. 2014 Mental health USA Quantitative Randomised 
trial:  
n=170 patients 7 
15.  Farrelly S. et al. 2013 Mental illness UK Cochrane review n= 4 randomised controlled trials N/A 
16.  Ferreira A. et al. 2007 Healthcare UK Systematic review  n=14 articles N/A 
17.  Fisher B. et al. 2009 Primary care UK Qualitative study: focus 
group and interviews 
n= 43 patients and clinicians 0 
18.  Forbes M. et al. 2017 Glaucoma UK Randomised controlled 
trial  
n=122 patients 6 
19.  Garcia-Lizana F. et 
al. 
2007 Chronic disease Spain Systematic review  n=24 articles  N/A 
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20.  Gee P.M. et al. 2015 Chronic disease USA Qualitative interviews  n=18 patients N/A 
21.  Gerard M. et al. 2017 Primary Care USA Qualitative questionnaire  n=260 patients 1 
22.  Giardina T.D. et al. 2013 Adult populations USA Systematic review  n=27 articles  N/A 
23.  Greenberg A.J. et 
al. 
2017 Chronic disease USA Secondary data analysis n=3497 patient notes 3 
24.  Hassol A. et al. 2004 Primary care USA Qualitative survey  n=1421 patients, Focus group n=25 
patients, Interview n=10 Doctors 
2 
25.  Hemsley B. et al. 2018 Primary and 
secondary care 
Australia Systematic literature 
review  
n=24 articles N/A 
26.  Honeyman A. et al. 2005 Primary care UK Qualitative interviews  n=109 patients 3 
27.  Jeong D.E. et al. 2015 IBD Korea Retrospective audit  n=152 patients 2 
28.  Kerns J.W. et al 2013 Primary care USA Qualitative focus group n=3 focus groups, n= 28 patients 1 
29.  Kelstrup A.M. et al.  2014 IBD USA Qualitative survey  n=197 patients 6 
30.  Khaneghan P.A. et 
al.  
2014 Diabetes Canada Qualitative survey n=54 patients, n= 9 clinicians 2 
31.  Ko H. et al. 2010 Chronic disease Australia Systematic literature 
review  
n=14 articles N/A 
32.  Laugesen J. et al. 2016 Diabetes Canada Qualitative survey n= 230 patients 7 
33.  Masys D. et al.  2002  USA Qualitative feedback & 
quantitative use of system  
n=216 clinicians n= 41 patients 2 
34.  McKinstry B. et al.  2006 Hypertension UK Randomised controlled 
trial 
n= 1 site, n=294 patients 8 
35.  Mold F. et al 2015 Primary care UK Systematic literature 
review 
n=17 articles N/A 
36.  Muhammad R. et 
al. 
2012 IBD UK Description of product  N/A N/A 
37.  Nahm E-S. et al. 2017 Diabetes USA RCT Feasibility study  n=74 patients 7 
38.  Palen T.E. et al. 2012 Primary care USA Retrospective 
observational cohort study  
n=88642 patients 2 
39.  Papoutsi C. et al. 2015 Primary and 
secondary care 
UK Qualitative survey  
 
n=2761 patients 
Focus group n=114 patients, n= 6 
clinicians 
0 
40.  Pavlik V. et al. 2014 Primary care USA Qualitative interviews 
Randomised trial  
Interviews n= 12 Doctors and 48 patients 
Trial n=272 patients 
8 
41.  Phelps R.G. et al.  2014 Chronic Renal 
disease 
UK Qualitative evaluation of 
database  
n=11352 patients 2 
 144 
 
42.  Politi P. et al.  2008 IBD Europe Qualitative questionnaire n=917 patients 3 
43.  Powell H. et al.  2002 Asthma Australia Cochrane review n= 15 trials N/A 
44.  Price M. et al. 2015 Older adults USA Qualitative study diary 
analysis  
 
n=41 patients 
 
2 
45.  Price M.M. et al. 2012 Chronic 
conditions 
Canada Systematic literature 
review  
n=23 articles N/A 
46.  Riippa I. et al. 2014 Chronic illness Finland Observational study  n=222 patients 2 
47.  Ross S.E. et al.  2003 Medical and 
psychiatric  
USA Systematic literature 
review 
n= 30 articles N/A 
48.  Ross S.E. et al.  2005 Primary care USA Qualitative questionnaire  n=601 patients 
n=564 Doctors 
4 
49.  Royal College of 
Physicians 
2016 UK primary and 
secondary care 
UK Qualitative survey, 
literature review, case 
studies 
n=98 clinicians and providers (survey) 
n=17 articles 
n=6 case studies 
3 
50.  Royal College of 
Physicians 
2017 Nephrology UK Case study N/A N/A 
51.  Royal College of 
Physicians 
2017 Primary care UK Case study N/A N/A 
52.  Royal College of 
Physicians 
2017 Ulcerative colitis UK User insight & patient 
story 
N/A N/A 
53.  Royal College of 
Physicians 
2017 Nephrology, IBD, 
Cardiology, 
Diabetes 
UK Case study N/A N/A 
54.  Royal College of 
Physicians 
2017 Gastroenterology UK Case study N/A N/A 
55.  Royal College of 
Physicians 
2017 Chronic 
conditions 
including 
ulcerative colitis 
UK Qualitative study: focus 
groups  
Focus group n=88 patients 
Interviews n=27 patients 
4 
56.  Sartain S.A. et al.  2014 Primary and 
secondary care 
patients 
UK Systematic literature 
review 
n=10 articles N/A 
57.  Showell C. 2017 Primary and 
secondary care 
Australia Structured literature 
review 
n=34 articles N/A 
58.  Somner J.E.A. et al. 2013 Glaucoma UK Qualitative study: focus 
group  
n=42 patients, 3 clinicians, 11 carers 2 
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59.  Tenforde M. et al.  2011 Chronic disease USA Systematic literature 
review  
n=3 articles N/A 
60.  Wagner P.J. et al. 2012 Hypertension USA Cluster Randomised Trial  n=24 Doctors, n=443 patients 5 
61.  Wells S. et al. 2014 Health delivery 
organisations 
USA Qualitative Interviews n= 16 organisations, n= 30 participants 1 
62.  Wells S. et al. 2014 Chronic disease USA Qualitative interviews  n=30 PHR leaders, questionnaire n=16 
organisations 
1 
63.  Williams J.G. et al.  2001 Cancer UK Randomised trial n=501 patients 5 
64.  Winkleman W.J. et 
al.  
2005 IBD Canada Qualitative interview  n=12 patients N/A 
65.  Zarcadoolas C. et 
al. 
2013 Primary care USA Qualitative focus group  n=28 patients 2 
 
Key: literature from years 2000 – 2010, Pre ELIJAH feasibility study  
         literature from years 2011 – 2018, Post ELIJAH feasibility study  
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The articles (listed in table 28.) were analysed and their main characteristics 
were identified as: year, population, location, study design, number of participants 
and articles, quality score of the article. We reported each of these categories 
individually.  
Year 
We divided the articles into two groups based on the year of publication. The 
two groups were 2000-2010 (pre our ELIJAH intervention detailed in chapter three), 
and from 2011 to current (post ELIJAH intervention). We split the articles between 
these groups as we were interested to identify which publications were 
contemporaneous at the time of our focus group, intervention and feasibility trial, 
and how these studies compared with our findings, we also sought to identify the 
literature since our feasibility trial to view the further developments and identify 
expansion in this area and further gaps.  
From 2000 to 2010, 19 articles were identified for inclusion in the literature 
review. From 2010 to 2018, 46 articles were retrieved. We found that since 2000 
there has been a steady increase in publications related to our area of interest. More 
than twice the number of articles have been published since 2010 (70.77%) than pre 
2010 (29.23%), with half of these published in the last three years from 2015-2018.  
There were differences noted between the year groupings. From 2000 to 2010 
the highest number of articles were found to report findings related to patients in 
primary care (32%) (e.g. Bhavnani et al 2010, Cimino et al 2001, Fisher et al 2009). 
From 2011 to 2018 there were only 15% of articles concerned with primary care 
findings and we found there had been shift toward research related to chronic 
disease: 26% as opposed to 11% in the earlier years. We identified that authors from 
2010 to 2018 studied generic chronic disease and disease specific chronic disease 
more, and the range of chronic diseases specified in studies increased e.g. Forbes et 
al (2017) looked at Glaucoma patients, Khaneghan et al (2014) and Nahm et al 
(2017) studied diabetic groups of patients and Phelps et al (2014) used renal disease 
participants in their study.    
There were similarities in the years 2000 to 2010 and 2011 to 2018 in terms 
of the location of studies or authors. In both year groups most papers originated from 
the USA (37% and 43% respectively), and the U.K. (32% and 39% respectively). 
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The spread of research has not differed in the year differentials, and the increase in 
location has been marginal from six locations to seven, mostly based in Northern 
American or European destinations with a few notable exceptions in the Middle East 
(Al-Sahan 2016) or Asia (Jeong et al 2015).  
When we looked at study design and distinguished the two year categories, 
we found that by far most studies across both 2000 to 2010 and 2011 to 2018 
employed qualitative research methodology (47% and 65% respectively). The 
proportion of literature reviews carried out during both time frames remained steady 
at about a fifth of the articles. Surprisingly the number of quantitative studies fell in 
the later year group from 16% of studies in 2000 to 2010 to 11% in later years, even 
as the research area matured. Early researchers using rigorous quantitative 
methodology and carrying out randomised trials (i.e.: Williams et al (2001) studying 
a cohort of Cancer patients in the U.K. and McKinstry et al (2006) who looked at 
hypertensive participants in the U.K.) were rare,  and their pioneering work  had not 
been greatly expanded upon in the intervening years. Later RCTs in this area include 
Wagner et.al (2012) who studied patients with hypertension, Druss et al (2014) 
looking at mental health, Pavlik et al (2014) using primary care patients and Forbes 
et al (2017) including glaucoma patients. Chunchu et al 2012 carried out the only 
identified pilot feasibility study, and used chronic disease as their patient population.  
The small number of identified quantitative studies reflects, and correlates 
well with our findings of the quality of the articles. Most studies had low scoring 
when analysed for the quality of the article. Most papers across both year groupings 
scored two or less. In both year groups the highest score was eight: McKinstry et al 
in 2006, and Pavlik et al in 2014 reporting findings from a study conducted within a 
primary care setting.  
The maturation of this area of research has seen an increase number of 
studies from 2000 to 2018. When divided into our two timelines of interest (pre and 
post the ELIJAH feasibility study), we have found that there has been a shift in 
research population from primary care to chronic disease and disease specific 
research, the location where research has taken place has remained the same with 
concentration in the USA or U.K. and most studies use qualitative methodology and 
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are of poor quality. These main characteristics will be discussed individually below 
for the total year group 2000 to 2018.  
Population  
Within the articles we noted the populations studied by the authors. We 
found 16 different population types (see table 31: Population). 
Table 31. Population 
Population Number of articles 
Chronic illness and / or chronic disease n=13 (20.00%) 
Primary care n=13 (20.00%) 
Primary and secondary care n=10 (15.38%) 
Inflammatory bowel disease n=8 (12.31%) 
Diabetes n=3 (4.12%) 
Mental health n=3 (4.12%) 
Renal disease n=3 (4.12%) 
Glaucoma n=2 (3.08%) 
Hypertension n=2 (3.08%) 
Secondary care n=2 (3.08%) 
Asthma n=1 (1.54%) 
Cancer n=1 (1.54%) 
Gastroenterology n=1 (1.54%) 
Other n=1 (1.54%) 
Older adults n=1 (1.54%) 
Surgery n=1 (1.54%) 
 
The different population types were spread over differing health sectors: 
primary, and / or secondary care (58.46%), and a minority of articles were disease or 
specialty specific (38.53%). The highest number of disease specific articles were 
found for inflammatory bowel disease. This was expected as this was our area of 
interest and was a key word search within the systematic literature review.  
There were only two studies looking specifically at IBD in the years before 
our ELIJAH feasibility study. Both conducted their research using qualitative 
methodology and both scored low for the quality of the article. Winkleman et al 
(2005) reported a study that explored via interview, whether twelve Canadian IBD 
patients found access to their on-line records valuable. Four themes arose from the 
study all in support of the initiative, but the study concluded that there was “little 
usefulness on its own” (p306). The authors hypothesised that information alone was 
meaningless, and tailoring of information would be necessary to improve outcomes. 
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The anticipated transformational benefits of the patient access to their information 
was not realised but provided an early assessment of an information technology 
system acceptance by patients. 
Three years later, in 2008, Politi et al, in a larger study of nearly a thousand 
European IBD patient questionnaires, found that communication of information to 
IBD patients should be increasingly be via electronic methods, even though they 
found most patients wanted paper-based communication. They concurred with 
Winkleman (2005) that the information whilst acceptable to patients needs to be 
individualised to their needs.  
Post the ELIJAH feasibility trial, most of the seven reported articles 
including IBD patients were from the U.K. We found there had been a stepped 
approach in the development of the quality of IBD research, from a description of 
product, to qualitative testing and then larger testing and mixed methods research 
supported by a national clinical organisation (The Royal College of Physicians).  
In 2012 Muhammad et al described a product “The IBD passport” (261), 
which was designed to be held by patients when travelling and detailed the main 
pertinent points of the patients’ disease including “IBD diagnosis … history … 
investigations …. (and) medication”. But the article does not state if it has been, or 
will be tested.  No further papers describing the product were found, and so it can be 
assumed the product remained a local, un-tested innovation.  Bidmead et al (2016) 
did test a new innovation “Patients Know Best (PKB)” via interviews with clinicians 
and a survey of patients. However, only five clinicians were interviewed and the 
response rate of patients was low at 17%. They found clinicians were supportive of 
the innovation as it was expected that better self-management would result from it, 
and patients concurred with this, but several issues were identified that were thought 
to contribute to possible lack of use of the system “security … perceptions …. (and) 
Data integration” (p. 8-10) One finding that the authors did note was that “patients 
were more frank and to the point in emails” (p. 10) especially when relaying 
information of a sensitive nature, which was found to be beneficial to the clinician as 
they had a more holistic and full knowledge of the symptoms of the patient, and 
more benefit to the patient in being empowered to discuss it and get the appropriate 
help.  
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The finding of increased patient empowerment was replicated by The Royal 
College of Physicians in 2017 in the published range of case studies giving 
exemplars of systems using personal health records. Two of these case studies 
included IBD patients. The final report of the range of case studies reported findings 
of a focus group that included IBD patients. One case study described how a PHR 
for chronic disease was developed and is used by patients, the other case study 
follows one patient’s IBD journey supported by a PHR. The patient with ulcerative 
colitis describes, in diary form, her use and her perceived benefits of using a PHR, 
including how she has maintained privacy of her disease information, and how “she 
feels more equipped to control her condition” (p. 2). She also uses the PHR to 
communicate with her clinical team. She relays how help was initially required to 
use the system but now it delivers on the anticipated functions. The Royal College of 
Physicians final report, collating the case studies thematically and reporting a 
qualitative study of chronic disease patients (nine focus groups and 27 interviews), 
found that patients used a PHR because they believed it would enhance their 
empowerment to “take control of health and improve health” (p. 7) and also help 
communication. But barriers to use came from lack of education and knowledge of 
systems and reluctance of clinicians. There were data and security concerns, but the 
report stated that many of these concerns could be overcome from increased 
awareness, training and help when needed. However, the report very clearly states 
that the use of a PHR and increased patient empowerment and self-care does not 
negate the importance of a combined and varied approach to providing care. The 
PHR would not replace the need for traditional care-giving and would work best and 
be a tool and used “best if it forms part of a person-centred service” (p. 10).  
Other IBD populations worldwide, when studied, found similar findings to 
the U.K. experience. In 2014, Kelstrup et al reported findings of a survey of 197 IBD 
patients in the USA looking at whether the participants were reliable in reporting 
their disease history, and it found they were especially for “type of disease and 
surgical procedures” (p 349). But, when scrutinised carefully they found that those 
who were better educated were more able to provide more accurate information and 
found their patient cohort were not representative of wider populations because of 
variations in educational attainment and self-selected bias.  
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A year later Jeong et al (2015) reported a retrospective audit of 152 Korean 
IBD patients using an extended IBD symptom diary that was further developed to 
include a free text area for questioning to the clinician or updating of events. The 
system enabled two-way communication between patients and their Doctors. The 
outcome was that patients were more likely to receive advice outside of the 
scheduled outpatient appointment and a small minority of patients (7.3%) 
necessitated additional or expedited appointments, but communication was 
enhanced.  
The IBD population was found to have been researched, especially in the 
U.K. the studies found that IBD patients largely favoured having a PHR as part of 
their care package and found it empowered them within their care to better self-
manage and communicate more effectively.  
Location 
We identified the country in which the included studies were conducted, or, 
in the case of a systematic review or case study where the article authors were from. 
We found a wide geographical spread covering nine countries (see table 32. Location 
of articles/ authors).  
Table 32. Location of articles / authors 
Country Number of articles 
USA n=26 (40.00%) 
U.K. n=24 (36.92%) 
Canada n=6 (9.23%) 
Australia n=4 (6.15%) 
Europe wide n=1 (1.54%) 
Finland n=1 (1.54%) 
South Korea n=1 (1.54%) 
Saudi Arabia n=1 (1.54%) 
 
The majority of articles were from North America (49.23%) and Europe 
(40.00%), with few from Australia (6.15%), Asia (1.54%) and the Middle East 
(1.54%). One of this reasons for these findings may have been the legal 
developments around PHR by the USA.  
Of the 26 articles that originated from the USA, 18 in the introductions 
propose that one of the reasons for carrying out the research was to illustrate whether 
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the legislature around the use of PHR, and central financial incentives for the use of 
PHR had been realised. We found papers dating from the early 2000’s through to 
2017 consistently stating that their research was needed to address the impact of 
national legal frameworks around patient access to records.  
The country noted to have the second highest number of articles found in this 
literature review was the UK. Perhaps this is because my search base is within the 
UK, as there has not been the central push toward PHR development and 
implementation by the British government and embedding of this into the legal 
rights of patients.  
The development of PHRs have been slower in the UK than in the USA 
between 2000 to 1 2018, but in the last few years the pace has been gathering.  
Study design 
We categorised articles by their stated study design. From analysis of the 
literature we found four main groups: qualitative, quantitative, mixed methods, 
systematic review or case study. Within these groups we identified the 
methodologies employed by the researchers (see table 33. Study design).  
Table 33. Study design. 
Study design Methodology Number of 
articles 
Total 
Qualitative study Survey n=9 (13.85%)  
 Interviews n=5 (7.69%)  
 Case study n=5 (7.69%)  
 Focus group n=4 (6.15%)  
 Questionnaire n=4 (6.15%)  
 Observational study n=3 (4.62%)  
 Diary analysis n=1 (1.54%)  
   n=31 
(47.69%) 
Quantitative study Randomised controlled trial n=5(7.69%)  
 Feasibility study n=2 (3.08%)  
 Secondary data analysis n=1 (1.54%)  
 Retrospective audit n=1 (1.54%)  
 Database evaluation n=1 (1.54%)  
   n=10 
(15.38%) 
Mixed methods Questionnaire and 
interviews 
n=2 (3.08%)  
 Focus group and interview n=1 (1.54%)  
 153 
 
 Survey and quantitative use 
of product 
n=1 (1.54%)  
    
 Interviews and case study n=1 (1.54%)  
 Interviews and randomised 
controlled trial 
n=1 (1.54%)  
 Questionnaire and focus 
group 
n=1 (1.54%)  
 Survey and case study n=1 (1.54%)  
   n=8 
(12.31%) 
Literature review Systematic literature review n=11 (16.92%)  
 Cochrane review n=2 (3.08%)  
 Structured literature review n=1 (1.54%)  
   n=14 
(21.54%) 
Other Description of product n=2 (3.08%)  
   n=2(3.08%) 
 
The results show that the majority of articles described research studies 
(75.38%). These studies were executed using a range of methodologies, most notably 
qualitative methods. Surveys were the most used research methodology.  
Surveys have been conducted throughout the search years of this literature 
review (e.g. by Hassol et al (2004), by Bell et al (2015) and by Laugesen et at 
(2016)). The surveys have been carried out mostly in the two main locations 
identified as the research origin: the USA and UK. The surveys carried out 
encompass qualitative research results deduced from analysis of patient or clinician 
participation, and sometimes a mixture of the two (e.g. Bartlett et al 2012, 
Khaneghan et al 2014, and Royal College of Physicians 2016).  
In the largest survey of patients and clinicians (Bartlett et al 2012), 583 UK 
based patients and 99 staff were asked their opinions on receiving raw investigative 
blood results electronically. Overwhelmingly the renal patients reported that they felt 
more knowledgeable about their disease, a few patients “had security concerns” (p. 
1), but these fears were mostly alleviated after use of the system. Clinicians endorsed 
the system and reported better disease management was facilitated as a result.  
The largest survey was carried out by Papoutsi et al (2015), and sought 
feedback from 2761 UK patients about their views on the security of their electronic 
health records and the privacy of their personal information. The questions were 
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hypothetical as the patients did not have access to a system to enable this, and they 
were asked questions about a proposed available system to be located in a national 
PHR programme run by the NHS. More than three quarters of patients had concerns 
in two areas: security and privacy, however, just over half of the patients endorsed 
the development of a system which would allow them to access their information 
electronically. Of note is that these results arise from questioning of a conceptual 
system that is a concept, rather than a useable product. These findings contradict 
those of If Bartlett et al 2012 who showed that when patients’ use PHRs their 
confidence grows in the security measures embedded in systems, and fears are 
allayed with system use.   
More rigorous research methodologies i.e. those employing a randomised 
controlled trial accounted for only 9.23% of the articles. Of the six studies, two were 
conducted before our ELIJAH feasibility trial; Williams et al 2001, and McKinstry et 
al 2006. Both these studies were carried out in the UK, and both looked a disease 
specific participant population (cancer and hypertension respectively). Neither study 
found statistically significant outcomes of their trials. Williams et al (2001) powered 
the study to identify differences in quality of life and health resource use, and 
McKinstry’s outcome measures sought to highlight differences in clinical outcomes, 
primarily a lowering of blood pressure. In each study good recruitment numbers and 
low numbers of drop outs were noted, and yet they concluded no discernable 
difference between their control and intervention groups. No randomised controlled 
trials of IBD were found within the literature search period 2000 to 2010.   
From 2011, four further randomised controlled trials of PHR had been 
trialled. Again, none used an IBD patient population. Hypertension was studied 
again by Wagner et al (2012), Pavlik et al (2014) studied adult primary care patients 
with at least one chronic disease such as diabetes or hypertension, psychiatric 
patients were included in the trial reported by Druss et al (2014), and Forbes studied 
patients with glaucoma. Of these studies only one found a significant outcome of a 
patient having a PHR. Druss et al (2014) found that patients diagnosed with “a 
serious mental disorder” did benefit from having a PHR. Patients had “significantly 
improved quality of medical care and increased use of medical services” and 
statistically significant increased education levels about their care.  
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Few studies ran mixed methods research, and where this was carried out few 
combined a qualitative and quantitative approach (3.08%). Of these only one, Pavlik 
et al (2014) combined a randomised trial with interviews. This study scored highly 
for quality of the article (8) but the trial methodology has not be replicated in the 
intervening years from the study.  
Reviews of the literature, whether using a systematic or structured approach 
have been explored by many authors (18.46% of the articles). There have been more 
literature reviews carried out in this area of research (14) than rigorous trials of the 
effects of PHRs. Of these studies: twelve systematic literature reviews and two 
Cochrane reviews were carried out. 
The literature reviews were conducted from a broad geographical spread and 
are fairly evenly spread between the UK (4), USA (3), Australia (4), Canada (2), and 
Spain (1). Some literature reviews looked at general chronic disease patient 
populations; Garcia-Lizana (2007), Ko et al (2010), Tenforde et al (2011) and Archer 
(2014).  Price et al (2012) studied older patients, Showell (2017) limited the search 
to “marginalised populations” (p. 1), and primary care patients were the focus of the 
literature search by Mold (2015).  
Sartain et al (2014) looked at general patient populations across primary and 
secondary care, as did Ross et al (2003), Ferreira et al (2007) Giardina et al (2013) 
and Hemsley et al (2018).  
None of the literature reviews specifically sought articles related to IBD.  
Within the systematic literature reviews there is general broad consensus that 
PHRs can have some patient benefits, especially in increasing the level of patient 
understanding of their condition (Ross 2003, Ferreira et al 2007, Price et al 2012, 
Mold et al 2015). However, there was a paucity of evidence to support the assertion 
that PHRs can improve quality of life or disease outcomes (Garcia-Lizana et al 2007, 
Giardina et al 2014), and Ko et al 2010 disputes that any positive outcomes have yet 
been demonstrated.  Ko et al (2010) argues that “there is no clear benefit of 
implementing a PHR” (e. 41), and deduces this because many of the 14 studies they 
identified had low quality and high levels of bias and so were not definitive. This 
finding of poor quality of studies was also shown, seven years earlier by Ross et al 
(2003).  
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The most recent, and most comprehensive, systematic literature review was 
conducted by Hemsley et al in 2018. They found 24 studies that they analysed and 
synthesised. They found six themes emerged from their exploration that they stated 
could have an effect on the use of PHRs by patients. These topics were patient  
“level of education  ... computer literacy  ... attitudes to sharing health 
information, … executive function, verbal expression, and understanding of .. 
language”. (p. 2) 
Showell (2017) concurred and noted many of these themes could be due to 
low socio-economic factors.  
Hemsley et al (2018) concluded that further rigorous research, specifically 
trials, are required to demonstrate the impact of PHRs on patients. They insinuate 
that rather than more qualitative studies: finding out what participants think of the 
systems they are using, testing should employ head to head methodologies, such as 
the randomised controlled trial, to aim to statistically significantly prove outcomes. 
This is a repetition of Tenforde et al conclusions of 2011 and Sartain et al in 2014.    
There were few Cochrane reviews (3.08%). Neither include IBD within the 
patient population groups (asthma, Powell et al 2009 and mental illness, Farrelly et 
al 2013).  
Farrelly et al (2013) found no effect of patient having personalised 
information, and Powell et al (2009) concluded that a similar intervention was equal 
to outcomes noted when patients regularly attended outpatient clinic. Neither report 
concluded there was evidence of a demonstrable improvement in patient outcomes 
when patients had their individualised information.  
Number of participants / articles 
We looked at how many participants had been included within the studies, or, 
if the article reported a systematic review, how many articles were included (see 
table 34. Number of participants / articles). We divided the number of participants or 
articles by study design and methodology, and divided the participants into patients 
or healthcare professionals. We looked at the range within each group 
We found that the highest number of participants was within the qualitative 
study design group. This was anticipated as this was the group with the highest 
number of articles found as identified by study design. Within the qualitative study 
 157 
 
design group the highest number of participants was within the observation study 
sub-group. Palen et al (2012) conducted a retrospective audit of electronic 
communication to clinicians by patients. They paired 88,642 patients. One of the pair 
used the electronic communication method, one of the pair did not have access to the 
innovation. They found that the group with access to the enhanced communication 
methods utilised greater health services than those who lacked the facilities.  
Few research findings based on survey results included patient data from 
large numbers of patients. Only two studies included thousands of patients (Hassol et 
al 2004, Papoutsi et al 2015).  
Within the quantitative group the highest number of participants was within 
the database evaluation sub-set.  
The questionnaire and focus group methodology type within the mixed 
methods study design group had the largest number of participants.  
Consistently across these three groups of study design more patients than 
healthcare professionals were included and studied and more articles were included 
in systematic and structured literature reviews than in Cochrane reviews, but 
numbers remain relatively low.  
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Table 34. Number of participants / articles 
Study design  Methodology Number of Participants Number of articles Total 
  Patients Healthcare 
professionals 
  
Qualitative study Survey n= 5739 (r= 54-2761) n= 207 (r= 9-99)  n= 5946 
 Interviews n= 166 (r= 12-109) n= 70 (r= 10-30)  n= 236 
 Case study n= 5 n= 0  n= 5 
 Focus group n= 325 (r= 25-114) n= 20 (r= 6-14)  n= 345 
 Questionnaire n= 1828 (r= 50-917) n= 564 (r= N/A)  n= 2392 
 Observational study n= 88875 (r= 11-88642) N/A  n= 88875 
 Diary analysis n= 41 N/A  n= 41 
     n= 97840 
Quantitative study Randomised controlled trial n= 1604 (r= 74-501) n= 24 (r= N/A)  n= 1628 
 Feasibility study n= 66 (r= 8-58) n= 16 (r= N/A)  n= 82 
 Secondary data analysis n= 3497 (r= N/A) N/A  n= 3497 
 Retrospective audit n= 152 (r= N/A) N/A  n= 152 
 Database evaluation n= 11352 (r= N/A) N/ A  n= 11352 
     n= 16711 
Mixed methods Questionnaire and interviews n= 24 (r=11-13) n= 6 (r= 3)  n=30 
 Focus group and interview n=43 (r= N/A) N/A  n= 43 
 Survey and quantitative use of 
product 
n= 41 (r= N/A) n=216 (r= N/A)  n= 257 
 Interviews and case study n=56 (r= N/A) n= 5 (r=N/A)  n= 61 
 Interviews and randomised controlled 
trial 
n= 48 (r=N/A) Interview 
n= 272 (r= N/A) RCT 
n= 12 (r= N/A)  n= 332 
 Questionnaire and focus group n= 424 (r=N/A) N/A  n= 424 
 Survey and case study n= 6 (r= N/A) n= 98 (r=N/A)  n= 104 
     n= 1251 
Literature review Systematic literature review   n= 214 (r= 3-30) n= 214 
 Cochrane review   n= 19 (n= 4-15) n= 19 
 Structured literature review   n= 34 (r= N/A) n= 34 
     n= 267 
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Quality score of the article 
We   score the articles according to the quality scoring   grid (see table 29. 
Quality of studies).  Literature reviews were deemed ineligible for assessment 
scoring as they were not research trials and so did not report the criteria of selection 
bias, design, confounders, blinding, data collection and withdrawals, these are scored 
as not applicable (N/A). A full table of the quality scoring of the articles can be 
found in Appendix. 23.  
  A summary of the number of articles and their quality score is displayed in 
table 35. (Quality score) 
Table 35. Quality score 
Quality score Number of articles 
N/A n= 23 (35.38%) 
0 n= 6 (9.23%) 
1 n= 8 (12.31%) 
2 n= 12 (18.46%) 
3 n= 4 (6.15%) 
4 n= 3 (4.62%) 
5 n= 2 (3.08%) 
6 n= 2 (3.08%) 
7 n= 3 (4.62%) 
8 n= 2 (3.08%) 
9 n= 0  
10 n= 0 
11 n= 0 
12 n= 0 
 
The scores of the research studies varied from zero to the highest scoring of 
eight. The scoring with the highest number of studies was two with 18.46 %, mostly 
these were qualitative studies. As the study scores rose from zero to eight, the higher 
number denoting the higher quality of the article, the numbers in the categories 
scoring the higher scores lessened.  
The highest scoring articles were those reporting randomised controlled trials 
(McKinstry et al 2006 and Pavlik et al 2014).  
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Thematic analysis 
We identified themes within the 65 papers of the literature search and 
grouped these into main themes and sub-themes. We reported the main findings of 
the papers (see table 36. Thematic identification). 
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Table 36. Thematic identification      
Theme category Sub-theme  Findings of paper  Examples within the sourced literature 
Self management Self management support by IT Patients with chronic illness may find difficulties 
using IT for self management 
2 
 
  Improved self-management 6, 8, 20, 35, 45, 55 
Patient access to 
medical records via 
EHR or PHR 
Preferences 
 
Feasible and popular with patients and 
professionals.  
3, 10, 18, 21, 24, 26, 30, 33, 35, 42, 46, 53, 58,  
64 
  Not popular with Clinicians 24, 33, 48, 55,  61 
 Use of healthcare Decreased use of healthcare services.  3, 54 
  Increased use of healthcare services 14, 38 
  No change 63 
 Outcomes of patients use of 
access to their records 
Access did not harm the patient / Doctor 
relationship 
4 
  Improved patient trust in Doctors 17, 27 
  Patients felt more partners in care, increased 
collaboration & empowerment 
5, 17, 21, 35, 49, 50, 55, 56, 63, 65 
 
  Improved health care advice adherence 5, 30 
  Enhanced communication and understanding 5, 10, 11, 16, 20, 28, 30, 35, 49, 52, 55, 58, 65 
  Improved sharing of information 21, 27, 56 
  Increased patient knowledge 28, 56 
  Unwanted responsibility 56 
 Health improvement No improvement in health condition 6, 15, 18, 19, 22, 31, 34, 43, 59 
  Improved health condition 60 
 Safety No increased anxiety noted 3, 10, 14, 55 
  No risks / adverse events 3, 35 
 Health education Improved 9, 19, 45, 47 
  No change 20 
 Differences noted in patient 
groups 
Disabled and vulnerable patients 
 
25, 37, 40 
 
  Deprivation 23, 41, 48, 57 
Design and 
implementation of PHR 
Support required Needs organisational & IT support 14, 55, 61, 64 
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 Generic PHR Educational support needed about PHR 7, 32, 50 
  Few condition specific examples 61 
 Legislature drivers for PHRs USA 7, 9, 10, 11, 20, 21, 23, 28, 33, 37, 40, 47, 48, 59, 62, 
65 
  UK 3, 5, 12, 26, 34, 36, 41, 49 
Security Control of records Patient control 20 
  Security measures trusted & successful 26, 33, 44, 54, 61, 65 
  Patient concerns 12, 28, 40, 50, 55 
  Patient trust 1, 64 
Accuracy  Completion of record Patient concern 24, 28, 35, 51 
Patient additions to the 
record 
Updating of the record by 
patients 
Wanted by patients 26 
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We identified six main themes and 14 sub-themes from the review of the 
articles.  
Papers mostly reported themes related to legislature in the USA driving the 
development of PHRs and patients access to medical records or information via 
either an electronic health record or personal health record. The thematic category 
which had the most number of sub-themes (seven) was regarding patient access to 
medical information. The sub-themes with the highest number of articles: were those 
concerned with testing the implementation of PHRs to meet the US legislative 
requirements for patient accessed information.  
One of the earliest papers found during the literature review regarding the US 
legal requirements for patient accessed information was by Cimino et al (2000). They 
stated that the “Health Insurance Portability and Accountability Act of 1998” 
(HIPAA) (p.151) has led the way in the USA for patients to access their electronic 
health records. Centrally, at national and state government level there had been the 
expectation that with greater access to their information patients’ knowledge of their 
health and disease would result in reduced health service use. Clinicians were 
expected to embrace this development positively as a result of this entitled access. 
However, Cimino et al (2000) recognised that these expectations were hypothetical 
and had not been tested. Over the following two years (2001, 2002) Cimino et al 
trialled interventions that enabled the consequences of the legal framework to be 
realised. They found no adverse events from patient electronic access to their 
information, better levels of patient knowledge and improved patient / doctor 
communication consistently. But, the studies were small with less than 15 subjects 
enrolled in each one and were conducted in single centres, and so were of poor 
quality. Nevertheless this early research did provide a limited case for the expansion 
of the research area in years to come.  
Many other authors commented on the positive influence of the HIPAA and 
its fundamental impact on patient’s freedom to access health records. The authors 
cited the legislature within their papers as justification for their research (Ross et al 
2003, Ross et al 2005). 
Masys et al (2002) reported on a system development of a PHR and how this 
abided by the statutory requirements of the “existing and emerging federal and state 
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laws and regulations regarding health information security and patient privacy” (p. 
182). They describe in detail how they built the IT system and then tested it both 
conceptually and in real life with patients and doctors. The system was found to be 
safe but was difficult to use by doctors, however patients liked it more than 
traditional forms of care that did not involve automatic free access to health records 
online.  
Ross et al (2003) acknowledge that the USA, at this time, was ahead of other 
initiatives worldwide. The UK at this time was considering, but had not yet 
implemented the legal right of patients to easily view their records, and enable 
patients to make changes as deemed necessary by the patient.  
From 2013, papers cite new legal requirements introduced at this time to 
recognise patient-centred care; the “Meaningful Use Roadmap” (Kerns et al 2013). 
Kerns 2013 explains how financial incentives had been interwoven with the 
legislation to introduce PHRs. The aim by government was to increase the use and 
proliferation of the technological advances and increase patient autonomy to access 
information. The interweaving of legislature as a push to encourage keepers of the 
information to release information, and payment to providers as a pull to comply, 
may have been because uptake of these new options by patients had been low. 
Tenforde et al (2011) concludes that in the period 2009 to 2010 “only 7% of 
Americans reported having used a PHR” despite the national importance given to 
this area of health.  
The researchers following 2013, including Pavlik et al (2014), Wells et al 
(2014) and Zarcadoolas et al (2013) state that further legislation, notable the “Health 
Information Technology for Economic and Clinical Health (HITECH)” (p. e169), 
has effectively married payments for providers with the enablement of patients to 
“access  ... their health record with the ability to access, print, share or download 
their health information” (p. e169). Gee et al (2015) gives useful historical context 
and explains that the introduction of HITECH was as a result of lost medical records 
from the hurricane Katrina and the subsequent implementation of policies to avoid a 
similar event following a disaster. They state that financial incentives of up to 
“$44,000” (Gee et al 2015 p 230) are payable for implementation of PHRs that 
enable this, and there are financial penalties to organisations if a PHR is not enabled. 
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Yet still, with products in place and unilateral legally sanctioned support, researchers 
state that there had not been sufficient research of the effect of PHR introduction on 
patient and clinical staff (Casey et al 2016, Greenberg et al 2017, Nahm et al 2017). 
Gerard et al (2017) makes the point that although there has been widespread 
coverage of patients using PHRs , “over 15 million patients in 40 states … we 
understand little about what they value in doing so” and so research continues.  
In the U.K. Bhavnavi et al (2010) and Bartlett (2012) both acknowledge the 
legal precedents set by the experience of USA in terms of formalising the 
requirement for PHR introduction, and they state that the UK is following the trend 
by aiming for similar adoption. Cruikshank et al (2012) state that the UK government 
aimed to enable all primary care patients electronic access to their EHR by 2015, and 
in their study found that patients were generally in favour of using a PHR but there 
were a paucity of health providers equipped with the facilities to provide this. 
Cruikshank et al found only 1% of primary care facilities ready for the change. 
Honeyman et al (2005) stipulates that patients in the UK have had the right to access 
their records since 1984 as stated within “the Data Protection Act” (p55), but the 
processes for patients to enact access have been laborious and difficult to negotiate 
and as a result low numbers of patients have sought access.  
In the UK, many products and systems have emerged from lone interested 
health organisations pioneering the concepts of patient accessed PHR, and have done 
so without the formal guidance from government. There have not been the financial 
incentives to encourage the system developments, nor any penalties if healthcare 
providers don’t provide patient access (McKinstry et al 2006, Muhammed et al 2012, 
Phelps et al 2014, and Royal College of Physicians 2017).  
In the UK it seems research is being conducted prior to statutory requirement 
to implement PHRs, but legislature is expected. In the USA it seems legal 
requirements came prior to the bulk of research carried out. Both the UK and USA 
do seem to be leaders in this area of research in terms of articles included in this 
literature review.  
Within the sub-theme addressing whether patients and clinicians found access 
to their medical record feasible or popular, overwhelmingly the response was 
positive (e.g. Bartlett et al (2012), Cimino et al (2002), Hassol et al (2004)). This 
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finding was identified even when there had been no improvement in clinical outcome 
shown. Forbes et al (2017) studied the effects of a disease specific PHR (for 
glaucoma), and found that there was equivalence in results when patient knowledge 
was assessed, and yet patients still “welcomed” (p. 546) the innovation of accessing 
their own records. Somner et al (2013), four years earlier, and studying patients with 
the same disease group (glaucoma), echoed these findings and found patients 
demonstrated “enthusiasm for PHRs”.  
Patients were asked why they liked accessing their records by Gerard et al 
(2017), and it was found that four broad reasons were identified: patients were more 
able to remember future health plans, they could have quicker investigative results, 
were able to more fully discuss and share the information received and had “positive 
emotions” (pe238). These findings were reminiscent of Winkleman et al (2005) who 
also elicited four similar broad themes that support the use of PHRs by IBD patients: 
“illness ownership … patient-driven communication … personalized support, and  ... 
mutual trust” (p. 306).   
No papers reported patients disliking access to their records, but there were 
articles relaying that clinicians had concerns with patients accessing their 
information. Hassol et al (2004) found that clinicians were unsupportive of patients 
having access to their clinician via email because of a perceived increased workload, 
and clinicians preferred more traditional methods of contact such as telephone or 
letter. Patients though, resolutely preferred electronic access. Ross et al (2005) 
concurs with this finding, and reports that patients had fewer worries about access 
than clinicians, and patients identified more potential improvements in care. Indeed 
the Ross et al (2005) conclude that the two opposing groups (patients and clinicians) 
“may need to be reconciled” (p. e.14) for broad integration of the PHR into everyday 
healthcare. The Royal College of Physicians (2017) outlined that one of the reasons 
for these differences between the groups may be that the clinicians have not fully 
tried PHR systems and so have not incorporated the PHR into everyday clinical 
practice, but patients are eager for the benefits of a PHR, whether perceived or 
envisaged.  However, even when a system was used, Masys et al (2002) found 
significant discrepancy between the clinicians and patients: patients found the system 
they were using worked well, providers did not.  
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There was broad positive consensus within the sub-theme category 
addressing the outcomes of patients’ use of an EHR or PHR to access information.  
The majority of papers illustrated that patients using a PHR felt more trust in their 
doctor (Fisher et al 2009), with increased levels of collaboration between patients 
and clinicians (e.g. Bhavnavi et al 2010, Mold et al 2015). Perhaps as a by product of 
this there was greater empowerment of patients to control their healthcare and 
improved self-management. Gee et al (2015) appraised the experiences of 
chronically ill patients using a PHR and found complete agreement of the 
participants “all found … the PHR … useful for self-management  ... and for 
productive interactions”. This emphatic endorsement does have a caveat and there 
was acknowledgement that there were some difficulties in use of the PHR.   
Patients found improved communication with their healthcare providers and 
gained greater understanding of their disease or condition, with few identified 
adverse outcomes (e.g. Ferreira et al 2007) and the knowledge patient’s hold of their 
health had improved overall with raised levels of health education (Garcia-Lizana et 
al 2007). Conversely, one systematic review paper reported that patients found the 
ability to view, hold and assimilate their information a burden (Sartain 2014), but this 
lone paper did acknowledge that there was poor quality research in the area.  
The majority of articles reported improved self-management of disease, 
communication with doctors and understanding of information, potential the health 
improvement value of this was realised by only one paper. Wagner et al (2012) in a 
randomised trial of PHRs and hypertension found that overall there was no impact on 
blood pressure measurements of patients having a PHR, but in a sub-analysis of 
intervention patients, a small difference and lowering of blood pressure was noted. 
However, the authors discuss that this may be because few patients within the study 
used the PHR regularly and this sub-group of patients may be more pre-disposed to 
lowering of blood pressure i.e. are younger. These findings re-iterate McKinstry et al 
(2006) who had not found any clinical benefit from a PHR for patients with 
hypertension.   
The other disease groups in which no discernable clinical benefit of a PHR 
was identified were: IBD (Bidmead et al 2016), mental illness (Farrelly et al 2013, 
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glaucoma (Forbes et al 2017, chronic disease (Garcia-Lizana et al 2007, Ko 2010, 
Tenforde et al 20111) and asthma (Powell et al 2009).  
Some papers looked at other and different patient groups in an attempt to 
identify which patient groups would most benefit from PHRs and how systems could 
be tailored to meet differing patient needs. Hemsley et al (2018) conducted a 
systematic literature review of “The health literacy demands of electronic … 
(PHRs)” p 2. They found that the expansion of the PHR to provide electronic 
information access to large scale health populations, that could include many disease 
types, age groups, geographical and socio -economic  patient variations, may prove 
challenging and rely upon more than the patients IT skills. They identified factors 
such as “executive function, verbal expression, and understanding of spoken and 
written language” (p. 2) and testified that these could prove central to the imbedding 
of PHRs into patient care, and would most probably affect the successful 
implementation of PHRs. Greenberg et al (2017) outlined that patients with lower 
incomes and/ or greater age were less likely to use a PHR. But when these patients 
did use a PHR, they may have the greatest potential benefits.  Phelps et al (2014) 
supports this finding, and showed that patients with higher levels of deprivation and 
lower socio-economic status were less likely to use the PHR but those that did used 
the system more often and did not withdraw from using the PHR. Pavlik et al (2014) 
looked at whether there were differences in satisfaction and recall following use of a 
PHR between different gender and ethnic groups (Hispanic and African American). 
They found that gender and ethnicity did not affect the outcomes.  
There was broad consensus that patients accessing a PHR was safe; with no 
significant risks, adverse events or increase in patient anxiety reported (e.g. Bartlett 
et al 2012).  
Whilst system planning, implementation, testing and use of PHRs and patient 
access to information was reported, it was in a minority of papers only. Most articles 
discussed security and control of systems, and release of information to patients, and 
differences were noted in the findings. Some papers reported that patients and 
clinicians trusted the governance measures that existed for the sharing of information 
with patients. Honeyman et al (2005) found that UK based patients were pragmatic 
in their expectations of access to their electronic records. Patients wanted to see their 
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information and “generally trusted in the security of their records” (p. 55), but also 
accepted there may be errors within the information. The patients wanted to correct 
these errors and also update the records themselves to provide up-to-date information 
to their clinicians. Zarcadoolas et al (2013) echoes these findings and suggests that 
from their qualitative research from the USA, patients were eager to have their 
information and security was not a major worry. When security measures were 
specifically tested (i.e. Masys et al 2002), the systems held up well against targeted 
attacks. There were papers however, that refuted these findings and they outlined 
evidence that patients did have worries over the security of their information and the 
accuracy of their information. Cruikshank et al (2012) reported that over 70% of the 
patients they polled did have anxiety about security and the accuracy of the 
information, and Kerns et al (2013) relayed similar findings.  
Generally the systematic literature review thematic analysis found broad 
consensus but also areas of disparate findings.  Patient access to medical information 
was broadly well received and the use of systems was mostly feasible and popular, 
but some clinicians voiced concerns. It was found that use of PHRs principally 
increased collaboration in care between patients and clinicians, enhanced 
communication and improved patient empowerment. The studies found the systems 
that enable patient access were safe, but most reported no improvement in health 
outcomes or status as a result. Patients sometimes trusted the systems security but 
there were some concerns about this and the accuracy of information held within the 
records.  
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6.4 Discussion  
Summary of the results 
We conducted this systematic literature review to identify and summarise the 
contemporaneous evidence for individually enriched IBD information and the use of 
this by patients and their health care professionals. We wanted compare the 
published evidence with the outcomes of our focus group, design of intervention and 
feasibility trial (chapters two, three and four), to deduce if there had been significant 
advances since our trial in 2011 and identify further areas of research in this area.  
We carried out a broad literature search over eleven electronic databases, 
using worldwide publications and an 18-year time limit (2000-2018). Our search 
terms were also broad. We had anticipated few literature finds if more narrow 
searches and terms were used. Whilst IBD was our main focus of our disease 
population search, as this was the disease population studied within our research, we 
widened the search terms to include chronic illness and disease, as IBD is a 
gastroenterological chronic disease. We also used broad search terms for the ways 
that patients might access their medical information or records. We used ‘and’ and 
‘or’ key word combinations to try to ensure we retrieved as comprehensive a 
literature search within the keyword parameters.  
We carried out a two-stage process for the study selection and to assess the 
quality of the articles, and collated comparable data from the literature over six 
categories and classified common themes.  
Of the 1203 examined citations, 65 were identified for inclusion in the 
systematic literature review. We found that of these papers less than 30% were 
published before our trials in 2010, and less than 13% reported findings related to 
IBD. Most articles were published in the USA and nearly half of the research papers 
reported qualitative studies with few quantitative or mixed methods studies. The 
numbers of participants within the studies was variable but some large (>1000 
participants) studies had been carried out. The quality analysis of the papers found 
that less than 10% of the studies scored six out of 12 or over, and so were of poor 
data quality with few reporting in each of the scoring criteria and we found few peer 
reviewed studies had been carried out in this area that were of high quality.  
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Main themes  
The studies identified varied greatly in terms of their characteristics, and 
there was a high degree of heterogeneity found. We identified six high-level criteria 
for comparing the papers; year, population, location, study design, number of 
participants / articles and quality score of the article. We found variation within each 
category.  
From 2000 to 2018 we identified a steadily growing interest in the area of 
patient access to information and in the last three years we found a noticeably more 
rapid increase in the number of studies. The bulk of the studies had been carried out 
from 2011 – 2018 (46), and half of these (23 studies) have been published in the last 
three years, from 2015 onwards. The trend is increasing, potentially because of 
different factors.  
From 2000 to 2010 we identified studies looked at mostly primary care 
patients (e.g. Ciminio et al 2001), but from 2010 there was a shift toward research 
into chronic disease patients. The pioneering work of the early 2000’s has now 
become a more mainstream research area. This was probably because of the 
recognition of the rising global incidence of chronic disease, associated with an 
increasing aging population. There was no evidence to suggest that research into 
primary care patients had been exhausted or conclusive, and we found most studies 
were of poor quality. The pressure upon healthcare systems to meet the challenges of 
chronic diseases within finite resources was stipulated by authors as a reason for their 
studies (i.e. Chunchu et al 2012) and had prompted health providers to look at new 
and innovative ways of providing care and including improved patient self-
empowerment and self-management.   
Most of the literature, identified originating in the later years of the literature 
search parameters, centred on chronic disease or a disease specific exemplar of 
chronic disease (e.g. Forbes et al 2017, patients with glaucoma,  Nahm 2017 patients 
with diabetes). Consistently the main way that was identified to encourage and 
enable patient to better self-manage and consequently have less load upon healthcare 
services was via access to their information and in particular a PHR (e.g. Bartlett et 
al 2012, Bidmead et al 2012, and Royal College of Physicians 2017).  
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Shifts in technological use and increasing legal requirements since 2000 were 
identified as a driving force in the development and investigation of PHRs (Hassol et 
al 2004). The information technology developments within the last 18 years have 
been wide-ranging, swift-moving and all-encompassing, within healthcare and wider 
society but paradoxically, it was noted by many studies, that uptake of PHRs were 
low (Tenforde et al 2011). It was noted that patients use technology to access, use 
and control their own information in a variety of different areas e.g. on-line banking, 
shopping and IT was viewed as accepted and available within the work and home 
environments but underused by patients in healthcare (Cruikshank et al 2012). Many 
studies aimed to identify product alterations that may counter this pattern but few 
identified crucial factors that could unlock the potential. Indeed, Winkleman (2005) 
alluded to the breakthrough coming through cultural shifts and more subtle 
integration of patient accessed electronic records with traditional care rather than a 
replacement of the care; “simply providing access … has little usefulness on its 
own”.  It was identified that patients do want access to their records (Gerard et al 
2017) but there was some reluctance from their clinicians to endorse this (Hassol et 
al 2004), because of increased workload commitments and worries about legal issues 
or complaints.  
 The infrastructure and technology to enable patient access to their 
information was described as increasingly sophisticated and more embedded as a 
concept in modern healthcare. This resulted in more systems being available for 
research and this may account for growth within this area. Legislation in the USA, 
enforcing the introduction of PHRs by incentivising the introduction and financially 
penalising providers who do not comply, was identified as a key push toward the 
widespread use of the PHR (Pavlik et al 2014). Worldwide, governments had 
identified the potential to control resource spending by empowering patients to 
access their information, better self manage and reduce load upon healthcare 
services. In the UK the underlying ethical concepts of partnership in care between 
patients and doctors, a move away from paternalism and increased autonomy for 
patients to control their information was appreciated, however it was not enshrined in 
law yet, but was expected. Perhaps because of this, few systems allowing patients 
access had been developed (Royal College of Physicians 2017), and most were 
reported as case studies (Cruikshank 2012) rather than trialled.  
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The literature identified indicated that few studies were of high quality and a 
small number were carried out using rigorous research methodology. There were 
many surveys of patients and clinicians use, or anticipated thoughts of use of PHRs 
(e.g. Bell et al 2015), some large (Papoutsi et al 2015), but mostly small, and none 
were of high quality. Overwhelmingly patients were in favour of PHRs. The 
randomised controlled trials carried out scored higher in terms of quality (McKinstry 
et al 2006 and Pavlik et al 2014), but the trials were carried out less frequently in the 
later years of the literature search parameters than in earlier years. The randomised 
trials mostly aimed to identify a disease effect from patients having increased 
information. McKinstry et al (2006) and Wagner et al (2012) studied patients with 
hypertension, Forbes et al (2017) included patients with glaucoma, Williams et al 
(2001) looked at patients with a diagnosis of cancer, Nahm et al (2017) involved 
patients with diabetes and Pavlik et al (2014) more broadly included primary care 
patients.  
Only one study found clinical benefit of patients with mental health issues 
holding more of their own information (Druss et al 2014). No study found a 
detectable improvement in physical clinical outcomes. Likewise our ELIJAH trial, 
although not powered to detect statistically significant findings as it was designed as 
a feasibility trial, did not detect any obvious improvement in patient symptoms. This 
could be because patient specific information can affect the way patients feel about 
their care, and increase their knowledge base, but it does not substitute for medical 
intervention and treatment and so does not impact on quality of life of the patient or 
resource use. We could not find evidence of a demonstrable link between patients 
liking having more information and being clinically better.  
Largely the literature concentrated on patient accessing their information 
electronically via a PHR. No studies were identified in the later years of the search 
years that provided information in paper form. The use of technology to give patients 
access and information was universal, probably due to ease of production and 
dissemination of the information to patients and the ability to control security and 
privacy via built in controls such as passwords and secure logins (Masys et al 2002). 
Research has largely covered the safety of patients and we found agreement within 
the literature that there were no adverse effects on patients of them receiving their 
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information and patients were unilaterally in favour of receiving more health 
information.  
Positive outcomes of patients receiving their information were plentiful. 
Patients levels of communication with their doctors improved (Ferrier et al 2006), 
with improved trust (Fisher et al 2009) and greater enablement of patients and 
empowerment. Even when the IT systems were difficult to use (Gee et al 2015), or 
security concerns were raised (Zarcadoolas et al 2013), patients still wanted to access 
their information. Patients perhaps are realistic in expectations of health providers to 
provide safe systems, but appreciate these may not be perfect,  or conversely patients 
can relate to experiences of having paper notes only and appreciate that there were 
issues with the storage and security of these too. Surprisingly it was found that 
patients voiced more concerns if discussing the hypothetical introduction of access to 
records rather than when they had them. Perhaps because using a PHR gave 
reassurance and allowed facilities to amend mistakes (Honeyman et al 2005).  
Overall the systematic literature review found that patients liked access to 
their information, but clinicians remain more sceptical. Governments back the 
introduction of increased access particularly through PHRs but there remains a 
paucity of evidence to show this will significantly improve patients’ clinical 
outcomes. The concerns regarding security of the information are less prevalent than 
expected and providers have taken these issues into account. The systems are safe 
and are feasible but not yet widely used. The literature base is small, with 
considerable variation and the majority of sourced literature is of low quality and not 
comprehensive, however our detailed analysis has shown that research in this area is 
still in development, and there is a growing and emerging research base with more 
research needed.   
Strengths and weaknesses 
We performed the literature search systematically to identify all IBD and 
chronic disease patient access to records. We acknowledge this could be a limitation 
of the review because of inherent bias within the process such as publication bias. 
We included a number of methods to reduce publication bias and our systematic 
literature search strategy was broad, and this proved both a strength and weakness 
within the review. We deliberately cast our search widely within the specified search 
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areas, as we hypothesised we may retrieve only a small amount of literature with a 
narrower strategy, and used several strategies to achieve this.  
We pragmatically decided to use ‘and’ in the search strategy to net a 
maximum yield of papers.  
We employed an 18 year time period to encompass papers published pre and 
post our ELIJAH feasibility trial. This enabled us to identify the evidence that 
compared to our trial, and importantly, view developments in the areas subsequent to 
our trial. The review year parameters (2000-2018) may have inadvertently excluded 
some studies from the search strategy. There may have been earlier papers we missed 
that were seminal in the pioneering of patient accessed records. But, we recognise 
that patient access to information, particularly via electronic methods; via an EHR or 
PHR is a relatively new innovation.  
We included ‘chronic disease’ as a separate key word from ‘IBD’, and 
searched using these terms within each electronic database, and this proved a 
strength as very few papers looked at IBD. We excluded acute disease from the 
search and we may have missed literature included within this category. We included 
all papers reporting findings, not only trials, and we did not limit the search to those 
papers written and published in English only.  
A strength of our deliberate broad search strategy was that we identified a 
large number of papers. Many of the identified systematic reviews in this area found 
smaller numbers of articles. However, we did not find consensus or homogeneity 
between the literature. There were high levels of variation between the literature in 
terms of the six main characteristics identified, main themes and sub-themes. No 
paper emerged as a definitive study or seminal trial and we were mindful to interpret 
each study individually and collectively with caution. Heterogeneity was noted in 
terms of the IT systems used, patient populations studied, locations of studies, 
outcome measures and research methodology used.  
We adjusted the EPHPP instrument (see table 27. Quality of studies), to 
differentiate the amassed literature in terms of quality using six markers. Very few 
high quality studies were identified and many of the studies scored extremely poorly 
or were not eligible for scoring as they were not trials. Few other systematic reviews 
had scored articles for quality. Most of the papers were of low quality and only one 
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study had carried out mixed methods research employing both quantitative and 
qualitative methodology. The findings of this literature review are based, therefore, 
on only a small number of high quality studies and because of this we carried out a 
narrative analysis and not meta-analysis. A meta-analysis would have strengthened 
the review but was not possible because of the paucity of good quality papers with 
comparable data for analysis.  
Previous systematic reviews within this area have concentrated on PHRs 
specifically, or looked at generic patient populations such as chronic disease. There 
is no review in the literature that has specifically looked at IBD. One of the strengths 
of this systematic review is that it did not focus on only on one intervention for the 
delivery of patient specific accessed records, but took into account different ways 
patients may access their information.  
To our knowledge, this is the first systematic review that has specifically 
looked at IBD patients and chronic disease patients and access to records using a 
robust and standardised approach. New research is emerging within this field and our 
review contributes to the evidence base.  
How our research findings compare to the literature review results 
We carried out two research trials looking at the outcomes of IBD patient 
having access to their health records. We carried out a focus group with IBD patients 
to find out what patients want from access to their health records, this is reported in 
chapter two, we developed an intervention to enable access to the health reports 
(reported in chapter three), and then tested this via a randomised controlled 
feasibility study (see chapter four).   
Focus group 
We identified one focus group that was carried out prior to our study (Fisher 
et al 2009). This UK based research looked at patient access to records and gathered 
views on this from primary care patients and their clinicians. Our focus group, in 
2010, reported that IBD patients were eager to receive more personalised information 
and they wanted access to their health information. These findings were substantiated 
by Fisher et al (2009), and there were many qualitative studies, using different 
methods to capture opinions, carried out after our study in 2010 to corroborate our 
conclusions (e.g. Royal College of Physicians 2017). The majority of other articles 
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pre 2010 reported findings from primary care. Post 2010 there was a switch to papers 
reporting chronic disease and disease specific conditions (e.g. Nahm et al 2017).  
Our findings suggested that patients felt they would be more able to 
understand their health information, have greater empowerment, and quicker access 
to relevant information. Participants stated they may be more able to self manage 
their condition particularly at time of need because of having increased access to 
their health reports. Four years after our study, Kelstrup et al (2014) found similar 
outcomes when surveying IBD patients from the USA. Our participants did voice 
concerns over privacy and security though, and these findings were echoed by other 
authors (e.g. Zarcadoolas et al 2013), but similarly we found that these fears did not 
over-ride their desire to have access to their records.  
The intervention 
Pre 2010 two articles were sourced that included patients with inflammatory 
bowel disease. Winkleman et al (2005) reported that patient required individualised 
information and Politi et al (2008) endorsed the sharing of this information by 
electronic means. These findings were influential for our trial preparation in 2010. 
We incorporated these design recommendations into our intervention and offered 
paper based and electronic information, and found it was feasible to produce 
individualised information.  
There was only one paper that discussed the building of an intervention 
allowing patients access to records pre our 2010 trial; Di Marco et al 2006, but their 
system was for surgical patients and the product was designed to fit with the 
Canadian health care environment.  
After our ELIJAH product development there was one paper describing an 
idea for an “IBD passport” (Muhammad et al 2012), it is unknown if the product was 
tested. There were other descriptions of product innovation to enable patient access 
to health information, but only one was specifically for IBD patients but was not 
rigorously tested and reported only as a case study (Royal College of Physicians 
2017).  
Many of the articles reported findings from the implementation of PHR and 
our intervention differed considerably from this. Our development of GeneCIS; to 
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produce individualised patient reports, did not include patients having direct access 
through the fire-wall to the electronic health record. The intervention was not 
designed to enable patients to view their medical records, but rather to hold an 
individualised educationally enriched IBD report. There were no papers describing a 
similar intervention.  
The randomised controlled feasibility trial 
As far as we know, no other study had sought to test a similar intervention 
with IBD patients, nor were there any mixed methodology studies identified that 
included IBD patients.   
Only 1 feasibility study was published (Chunchu et al 2012), and there were 
very few randomised trials. The Chunchu et al (2012) feasibility trial differed for our 
trial in numerous ways. The trial was based in a US primary care setting rather than 
our UK secondary care environment. Whilst patients with chronic disease were 
included in the trial the details of the patient diagnoses were not described. Most 
patients in the Chunchu et al trial had upwards of four chronic disease diagnosis. We 
included patients specifically with a diagnosis of IBD, although it is acknowledged 
the patients may have had other concurrent co-morbidities.  The intervention differed 
for our patient groups in the ELIJAH feasibility trial from the Chunchu et al 
intervention. Our intervention was specifically aimed at sharing individual 
educationally information with patients, the Chunchu et al trial intervention focused 
on applying the EHR information throughout a multi-disciplinary team and testing 
whether this could be used to enhance patient care. Their findings and ours were 
similar in terms of meeting feasibility outcomes.  
None of the rigorous randomised trials included IBD patients.  
Two trials had been carried out using rigorous methodology prior to our trial 
(i.e. Williams et al 2001, McKinstry et al 2006). Both were based within the UK but 
neither included IBD populations. Both trials reported equivocal results for quality of 
life improvement and / or reduced resource use. Williams et al (2001) looked at 
patients with cancer and McKinstry et al (2006) included patients with hypertension. 
These patient groups differ from our IBD patient cohort in terms severity of disease 
of site of treatment, follow up and age range. The intervention used by the two 
studies and ours differed. Whilst all three provided extra information to patients 
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McKinstry et al (2006) provided a generic leaflet for hypertensive patients plus a 
written guidance on how healthcare professions should manage their care and ways 
to question their care if needed. Williams et al (2001) gave intervention patients a 
patient held record which was held by the patients and was designed to be carried by 
patients to appointments, completed by patients and health care professionals and 
was designed to be used as a diary. Our intervention was more extensive than 
Williams or McKinstry interventions and provided educationally enhanced 
individualised information that covered a patients IBD history, a plan if symptoms 
arose and a summary of recent IBD care interventions. 
 There may be different reasons why Williams et al, McKinstry et al 
randomised controlled trials and our ELIJAH feasibility trial did not show any 
improvement in patient outcomes related to quality of life, nor reductions in 
healthcare resource expenditure as a result of the different interventions. It may be 
that whilst patients may favour having more information about their care (in 
whatever way it is packaged or presented), this constitutes a benign addition to the 
central elements of formal medical interventions. Interventions that may have more 
effect on patient quality of life or resource use could be a clinical consultation, the 
patient ability to ask questions and receiving answers in real time from health 
professionals, treatment regimes and the interpersonal relationship between clinician 
and patient. It can be speculated that whilst some patients may gain some reassurance 
from holding more information about their care they may want to verify the 
information with their health provider and some may not be confident to use 
information independently. However, further research would be needed to explore 
these theories in full.  
From 2010, four further randomised trials had been published, but none 
included IBD patients and none found significant improvement of physical 
symptoms within the intervention group (e.g. Wagner et al 2012, Druss et al 2014). 
There was only one other study that carried out mixed methods research, and only 
one used a combination of qualitative and quantitative methodology (Pavlik et al 
2014).  
In our ELIJAH feasibility trial we found similar outcomes to the published 
literature - that patients liked the intervention (Hassol et al 2004), but there was no 
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detectable physical improvement (Forbes et al 2017), and the intervention was safe 
(Bartlett et al 2012).  
Our research findings did compare well when compared to the existing 
literature and we concluded that we had produced evidence that could contribute to 
the contemporaneous body of evidence surrounding the topics explored in this 
literature review in terms of rigorous methodology, patient population, intervention 
and outcomes. 
Identified need for further research 
This systematic review will better guide the use of patient access to 
individualised information for IBD patients and chronic disease patients. It can be 
used to help clinicians, researchers and national policy makers to better assess the 
current literature on what patients want from access to their health information, 
particularly from a PHR, and what likely outcomes of the introduction of such 
systems may be.  
Research in this area remains to be evolving and is gathering pace. Different 
systems for providing patients with more information and wider variety of 
communication methods are being developed. As yet, there has been no formal 
testing of these systems published. One example of these developments is ‘My IBD 
Portal’ which has been developed by the IBD team at Salford Royal Hospital 
Foundation Trust (Mclaughlin et al 2018). The web based system is much evolved 
from the ELIJAH intervention developed eight years earlier in 2010 which was 
largely paper based and prescriptive in the information shared. My IBD portal 
delivers patients the ability to access a broader amount of their information on line. 
Patients can access links to information resources and real-time retrieval of 
investigations and full clinic letters. Access to clinician opinion can be requested 
through the portal and patients can track their disease progression over time via 
PROMs. Similarly to the ELIJAH intervention patients can glean diagnosis 
information, visual aids and have an individualised care plan. The Salford My IBD 
Portal does not provide educationally enhanced information, nor provides summary 
reports of patient information, so patients may have to review a large amount of 
information to gain pertinent information.  
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As yet the “My IBD Portal” is used in one site in the U.K. and has had not 
been formally evaluated in a RCT to determine effectiveness, although usability and 
satisfaction have been noted to be high.  
There are a paucity of published rigorous trials in IBD and PHRs. It may be 
that technological advancements are being developed far quicker than research in this 
area can keep up with. Developments in this area are often created by single teams or 
small clinical and research collaborative groups who may not be able to co-ordinate 
swift clinical developments and high level research simultaneously possibly because 
of time and cost constraints. The risk of running research trials in this fast moving 
area is that once the trial is conducted and published the intervention has been 
superseded. 
Research in IBD and PHRs may prove an important area of future global 
health policy and could influence future legislature, but further studies are required. 
The information gathered and relayed within this literature review concludes that 
there is no seminal paper or conclusive research paper, and many of the studies are of 
low quality. There is also a paucity of rigorous testing of interventions, particularly 
with large disease specific patient populations. For the PHR or similar interventions 
to be widely used and implemented, and the potential benefits of them to be realised 
(i.e. reduced health costs, greater patient empowerment and self-management and 
increased health status), further research is required. The trials could reduce the risk 
of expensive system development with little secure evidence to support innovation 
direction.  
There does seem to be a trans-Atlantic move toward the use of PHRs by 
patients, and further multi-centre, international trials are required that utilise a 
rigorous mixed methods approach. Studies based within the UK are required prior to 
government directives for implementation of PHRs. In the USA, where legislation 
has largely preceded system implementation, studies are required post 
implementation to inform tailoring of services that could enhance patient take up of 
systems and increase clinician confidence.  
It can be interpreted that PHRs are wanted by patients and liked when they 
are used, but so far the evidence shows that this does not translate into improved 
patient outcomes such as improved quality of life, lower healthcare resource use. 
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There are findings that suggest the anticipated results of patient access to their 
information resulting in reduce illness burden on patients and healthcare providers, 
less use of healthcare resources and reduced healthcare budgets have not yet been 
shown. As a result trials are required into various diseases to identify which ones 
respond more favourably to PHRs and why.  
Within trials there is a need to focus on health economic evaluation for 
patients and healthcare systems that gives answers as to whether PHRs are a cost 
effective way to provide healthcare, particularly as system development can be very 
costly to develop and implement. Clinicians and patients need to be involved in 
future research to try to marry their system requirements and tailor information and 
communication pathways that meet both groups needs.   
Further prospective studies are required to complete validation of the findings 
of the selected studies discussed within this systematic literature review.  
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6.5 Conclusion  
The evidence presented in this chapter/ literature review indicates that 
patients want access to their medical health records and like having this opportunity. 
Patients can envisage, or report experiencing, more benefits of this access than 
clinicians, and are more comfortable accepting they may be some risks concerning 
security of the systems. Patients report increased levels of empowerment, improved 
communication with their clinicians and are better able to self manage, and there 
have been no reported adverse events. But no trials found significant improvement in 
physical symptoms or condition as a result of patients having access to their 
information.  
Governments, particularly in the USA and UK, have looked at this issue and 
there is legislation that enables patients to have these facilities, and as a result 
patients increasingly access their information via a PHR. However, there remains a 
paucity of high quality, rigorous trials in this area. Many of the existing trials have 
low participant numbers or are exclusively qualitative in methodology.  
Further prospective mixed methods and randomised controlled trials are 
required to assess outcomes of this approach, especially in disease specific 
conditions such as IBD care, as this has been under-represented in the literature.  
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Chapter seven: Future research protocol design and conclusion 
7.1 Introduction 
The previous chapter of this thesis reported a systematic literature review of 
patient accessed health information, with a particular focus on IBD patients and those 
with chronic disease. We concluded that patients welcomed and liked interventions 
that could facilitate greater access to their own information (substantiated by Phelps 
et al 2014), systems were safe for patients (supported by Bartlett et al findings 2012), 
and benefits were envisaged by patients and governmental health care legislators 
(echoed by Forbes et al 2017), but few studies had shown significant benefits on 
physical symptoms and health improvements (McKinstry et al 2006).  
We compared our experience of conducting mixed methods research (a focus 
group and randomised controlled feasibility trial) with IBD patients, with the 
contemporaneous literature and found few similar studies. We identified a need for 
further research in this area, because there were few high quality prospective 
rigorous trials reported, none that specifically included IBD participants, and a dearth 
of secure evidence base (Tenforde et al 2011) to substantiate the hypothesised health 
economic benefits of patient accessed information (Wagner et al 2012).  
Within this chapter we will build upon our experience of our feasibility trial, 
apply the learning gained and propose undertaking a cluster-randomised controlled 
trial with IBD participants to address these gaps noted in the existing evidence. 
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7.2 Background  
We identified, (in chapter one: Introduction), that there is a global 
phenomenon of a rising incidence of chronic illness, and this is mirrored within the 
UK. It was recognised that there is an urgent need to find innovative ways to meet 
the increased demand upon services, particularly in healthcare systems that are 
stretched and have finite funding due to periods of national austerity.   
We recognised IBD as an exemplar of a gastroenterological chronic disease 
and included this as our disease group population for our research.  We found that 
the two largest disease groups within the umbrella term of IBD are; Ulcerative 
Colitis and Crohn’s disease and that in the UK alone there are 150,000 known 
patients with IBD, with 8,500 new diagnoses made annually (Carter et al 2004). We 
recognised there is no known cure. IBD, we reported, is characterised as a chronic 
gastro-intestinal disease that can have unpredictable episodes of remission and acute 
relapse, and can display mild to severe, and occasional catastrophic symptoms, 
including frequent urgent bloody diarrhoea, weight loss, nutritional depletion, 
anaemia, bowel obstruction and stricturing, fistulation and rarely death. The high 
degrees of morbidity and mortality associated with IBD and the medical and surgical 
interventions for disease control and treatment can have varying success rates and are 
not without additional physical and psychological effects on the patients (Carter et al 
2004).  
We discussed how, until now, the majority of IBD follow up care had been 
traditionally delivered in routine outpatient clinics based in secondary care, with 
some appointments available for urgent assessment. Most IBD services were found 
to have remote telephone helplines established to answer patient queries or triage 
contact particularly at time of need and IBD patient information is largely generic. 
Although this organisation of care remains prevalent in the UK, we explained how 
IBD care remains costly as it relies heavily on primary and secondary care resources, 
and patients require long-term specialised follow up. The current systems we stated, 
are mostly inflexible to demand as they are dependent upon rapid availability of 
clinic appointments or swift contact with healthcare professionals especially during 
times of unpredictable flare and potentially risky exacerbation of symptoms. These 
schemes we predicted, could result in patients having appointments when well but 
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finding difficulty in securing appointments when needed to address increased 
symptoms (Hall 2007).   
We proposed that new ways to provide patients with their individualised 
information were needed; to enable patients to better self-manage especially at time 
of need, in conjunction with better access to outpatient clinics and open access 
services. We understood though, that for this to be realised,  patients would need to 
be well-educated in their own disease history and care pathway, understand an 
agreed medical escalation plan of care, be able to take responsibility for their care, 
and be able to communicate easily with their clinicians to report their health status. 
Such arrangements, we postulated, could help reduce patients’ symptoms more 
quickly than via traditional follow up methods, and may circumnavigate the need for 
clinical intervention in secondary care. This could be achieved by arming patients 
with the knowledge of how to quickly initiate prescribed treatment programmes and 
so try to limit the effects of increased symptoms. These self-care programmes could, 
we hypothesised, reduce costs by decreasing the load upon secondary care services, 
preserve the safety profile of IBD care, and increase patient satisfaction. We noted 
that few innovations like this had been tested rigorously.  
One way we identified to achieve better patient self-care was through 
increasing patients understanding and knowledge of their own disease by giving 
them and their GPs personalised and educationally enriched IBD information.  In our 
literature review (chapter six) we discovered that currently, worldwide, there seems 
to be a move toward providing this individualised patient information via a PHR.  
In 2010, we developed an intervention (detailed in chapter three) that 
extended our existing EHR facility (ELIJAH) to provide a detailed patient history, 
agreed individualised care plan with particular focus on what patients were to do at 
time of flare, and provided an update of each IBD care episode. This tri-part product 
was called “My Folder”. Each part was educationally enriched in order to provide 
patients with an opportunity to gain greater knowledge and understanding of their 
disease, and better self manage through improved patient empowerment. We tested 
this unique intervention using mixed methods research.  
We first held a patient focus group (see chapter two) consisting of IBD 
patients. We sought to identify views from patients about IBD information, care 
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planning, and communication. We also asked patients to give their views on a 
prototype intervention that had not been formally evaluated. We then developed the 
intervention (see chapter three) and then conducted a randomised controlled 
feasibility trial (see chapter four) of the intervention in a single site, using a small 
number of participants.  
We found the intervention was feasible to produce, we were able to recruit 
clinicians and patients and trial the intervention. Our data collection tools (ELIJAH 
Adverse Events form, Data Abstraction Form (DAF) and Inflammatory bowel 
disease Service Satisfaction Questionnaire were found to be efficient. We identified 
that of the four outcomes measures, three were feasible to collate reliably (cost, 
safety, and satisfaction), with one: timeliness, proving not to meet the feasibility 
criteria due to difficulty in sourcing data in this area. The intervention was deemed 
safe for patients with no significant unexpected serious adverse reactions 
(SUSAR’s). 
All feasibility criteria were met and we were able to identify a potential 
primary outcome: cost. The trial also met the progression criteria required to advance 
to a fully powered randomised trial and we acknowledged that modifications were 
required to our feasibility protocol to achieve this. Our trial progression 
recommendations were that:  
 The total trial costs need to be increased resulting in an increased cost per 
participant in the trial. 
 The length of patient follow up of the trial should be increased to one year.  
 The trial should be multi-centre in order to include a range of patients to 
ensure wider generalizability of the findings and have enough participants to 
ensure that the trial is fully powered.  
 A band 6 IBD nurse specialist should deliver the intervention.  
 The trial should explore the satisfaction of participants and health 
professionals.  
  “My Update” should not be included as a part of “My folder”, instead 
changes should be made to “My Plan”.  
 The intervention should be populated by information from the primary and 
secondary care EPR.  
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 The intervention should be offered via IT only.  
 Timeliness should not be included as an outcome measure.  
 The DAF, AE form and ISSQ should be used for data collection but in 
electronic form and linked to the EPR and automatically populated from it 
where possible.  
 The ISSQ should be shortened and include the EQ5D plus thermometer.  
 
Within this chapter we will reflect on the outcomes from the findings and 
incorporate our learning of our focus group, intervention, randomised feasibility trial 
and systematic literature review. We will discuss a proposed future trial protocol that 
acknowledges our reported strengths and addresses the issues identified.   
Study aim 
The aim of the project is to evaluate the extent to which shared IBD 
educationally enriched health reports and access to an IBD PHR will reduce demand 
on health resources, by facilitating better patient understanding and knowledge, 
improving communication and greater patient empowerment and individual patient 
responsibility for self- care. 
Objectives 
1. To gather views from clinicians and patients on the proposed introduction of 
patient accessed IBD reports via a PHR.  
2. To estimate the cost of implementing ELIJAH, and evaluate the reduction or 
increase in total NHS health resource use and cost.  
3. To assess the cost effectiveness of ELIJAH by identifying cost per quality-
adjusted life year based on patient reported changes in health status. 
4. To evaluate the safety of ELIJAH by the collation and analysis of patient 
adverse events.  
5. To assess the effect of ELIJAH upon patient and clinician satisfaction rates.  
6. To reassessment of the perspective of patients and clinicians of ELIJAH post 
use.   
Design 
Our learning, from the focus group and prospective randomised controlled 
feasibility trial, told us that this research methodology is feasible when studying IBD 
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patients who are given individualised educationally enriched health reports as an 
intervention. When carrying out a larger trial in this area we will replicate the basis 
of the intervention but change some of the elements.   
We will increase the size and range of the trial to enable greater numbers of 
patients to be included as we recognised that our feasibility trial was not planned, or 
powered to detect statistically significant results of the outcome measures. We found 
that there were few examples of high quality mixed methods research in this area that 
had been carried out, and that there is a gap in the evidence base that we will address 
with our trial. We will plan for a large scale, multi-centre, cluster (step-wedge) 
randomised controlled trial that has adequate power.  
The trial will be sited across the UK, in identified centres that provide large 
scale IBD care within secondary care settings (i.e. district general hospitals, acute 
hospitals and tertiary referral centres). We will aim to recruit patients from a wide 
range of geographically disparate sites (n=20) with the aim of a yield of large 
numbers per site. This approach will reduce the risk of cross infection of 
participating locations. 
 Similarly, to our previous mixed methods research, we will hold qualitative 
focus groups with IBD patients, but will also separately interview clinicians. We did 
not include clinicians in the qualitative research initially, and it could be that we 
missed important information that could have affected our intervention development 
and feasibility trial. The literature review did show there is some evidence to suggest 
there are differences in clinician and patient views about patient accessed 
information (Hassol et al 2004, Ross et al 2005). In our study we conducted one 
focus group, but in the full trial we will hold multiple patient focus group and 
conduct clinician interviews in half of the study sites. We will carry out the focus 
groups and interviews before the trial starts as we did in our studies, but will 
additionally hold them also at the end of the study period. This will enable us to 
identify expectations of patients and clinicians prior to receiving the intervention (as 
we collected in our focus group), but also collate patient and clinician views of the 
intervention and their experiences of using the intervention as part of their IBD care 
package.  
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We will use the useful patient and clinician views gathered prior to the trial to 
further develop and refine the intervention as we did in our building of the 
intervention.  
We will test the intervention using a randomised controlled approach as we 
found this quantitative methodology was feasible to carry out for the intervention. 
Within the reflective chapter (chapter five) we acknowledged that the RCT was the 
gold standard of clinical evaluation as it had an essential feature of a division of 
participants into subgroups to enable comparison: those receiving the intervention 
and the control group who have care as usual.  
The identification of intervention participants via remote electronic 
randomisation process worked well within our feasibility trial for the small number 
of participants included. However, we realised there were issues with slow 
recruitment and we identified a potential for ‘resentful demoralisation’ of the control 
group who did not receive the intervention. In the full trial we will again use a 
randomised approach, but this time we will carry out a step-wedge cluster 
randomised trial (Brown et al 2006, Beard et al 2015). This design modification 
could address our identified issues, and will enable each site to receive the 
intervention. It will reduce potential bias and differences in study sites, reduce 
potential contamination between sites and minimise the effects of any national health 
policy shifts during the trial period.  
All sites will begin as control sites and participants will receive IBD care as 
usual. Sites will be randomly allocated staggered timings for commencement of the 
intervention (see Fig. 11 randomised multiple interrupted time series study design 
overview).  
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Figure 11. Randomised cluster step-wedge study design overview 
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Training will take place before the implementation of the intervention. Six 
weeks before sites start the intervention they will receive notification of their date of 
training dates and date of commencement of the intervention. Immediately prior to 
sites converting from control to intervention sites, clinician and participant training 
will take place to ensure both groups can effectively use the system. This training 
will be via e-learning for patients and e-learning plus site study days for clinicians. 
T 
Q 
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 The staggering of site education and training will help the intervention 
trainers to ensure that adequate time can be spent with each site and queries can be 
addressed before the intervention is started. The sites and participants will, after 
training, be able to access the remote centralised technical support facility.  
Each site will have training for clinicians and patients on use of the ELIJAH 
system including the log-in functionality, usability and built in security measures. It 
is expected this will increase use of the intervention and limit queries once the trial 
has commenced. We found evidence within the systematic literature review that this 
combined approach of training and support was wanted by patients to enable them to 
better use systems that allowed access to their health information (Casey et al 2016, 
Laugesen et al 2016, and Royal College of Physicians 2017).  
Four times during the year long trial period patients will be asked to complete 
a satisfaction questionnaire – the ISSQ – Inflammatory bowel disease Service 
Satisfaction Questionnaire, i.e.: before trial commencement, then twice within the 
intervention period, and at completion of the trial. Within our feasibility trial we 
found this was a feasible method of collecting satisfaction data, but we identified 
there may have been some participant fatigue with completion of the questionnaire, 
as we had asked our participants to complete it four times in six months. This time 
we will require participants to complete the questionnaire the same amount of times 
but over an elongated trial period time of one year. We will repeat our reminder 
process to participants who have not returned their ISSQ within two weeks after 
dispatch, and shorten the ISSQ, this we believe may reduce the amount of missing or 
incomplete data.  
We will, once again use the EQ5D, but this time, utilise the complete quality 
of life measurement and include the health thermometer. This will provide additional 
detail and evidence.  
In our feasibility trial we sent the ISSQ in paper form, but in the main trial we 
will send and collect the forms electronically through the PHR with notification of 
this via participants email.  
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The ELIJAH intervention 
We developed the ELIJAH intervention with the aid of very useful patient 
feedback received during the focus group (see chapter 2). Patients reported that they 
were very keen to receive individualised IBD information as the generic leaflets and 
booklets given as education material were too generic. Patients felt frustrated having 
to repeat their information with multiple professionals at different appointments and 
found it difficult to contact health professionals at time of need to get advice and 
guidance on how to treat flares. Patients believed they could look after their records 
more carefully than healthcare providers had, as many had reported experiencing 
lost, inaccurate or disparate notes. They voiced concerns over the lack of sharing of 
important information between primary and secondary care and particularly they felt 
left out of important clinical knowledge that they could use to better self treat.  
“Information  ... should be uniform right through the NHS, every place should 
have exactly the same information wherever you go” (participant number 019).  
Many of these views and opinions were echoed within the findings of the 
systematic literature review.  
As a result of this learning, we developed a modified output of our existing 
EHR to create educationally enriched individualised IBD reports. These were created 
in three parts (My History, My Plan and My Update), and combined formed “My 
folder”. These products were created by manual entry into the EHR of information 
extracted from the patient paper notes, secondary care EHR GeneCIS, patient 
information system, and from investigative results stored on another separate IT 
system. We found this method of manual transference of data from different IT 
sources to one programme time consuming and laborious. We also identified there 
could be a potential for inaccuracies of data input through human error. In the full 
trial we will automate this system to allow population of the reports directly from the 
patient record system and primary and secondary care IT systems.  
In trialling the feasibility of the intervention we found that two of the three 
reports (My History and My Plan) were feasible to produce from the available patient 
information. However the third part of the package “My update” was too difficult to 
produce because sometimes we were unaware of patients visiting for IBD care, and it 
proved difficult to provide updates to patients in a timely fashion.  
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We recognise that in the intervening eight years since we developed our 
ELIJAH intervention there have been vast technological advances and increasing IT 
functionality, and so we harness these advances with a modification of the ELIJAH 
intervention.  We would preserve the structural integrity of “My History” and “My 
Plan” and remain producing these as electronic reports, but enable patients to access 
“My Update” information directly into a PHR, rather than using reports (see Figure 
12. Components of the intervention). Patients would access clinician letters to 
primary care providers and their investigative results directly. Information security 
will be preserved via secure log-ins with preserved security features for the 
healthcare providers. The systematic review showed that this approach using patient 
accessed PHRs is used currently, is safe and trusted (Masys et al 2002, Price et al 
2012, Zarcadoolas et al 2013). Clinicians and patients will, once again, receive 
exactly the same IBD information in the same way.  
Figure 12. Proposed components of the intervention 
Patient and clinician training  An e-learning package available to 
patients and clinicians available 
immediately prior to commencing the 
intervention. 
ELIJAH reports My History and My Plan available to 
patients and clinicians electronically 
ELIJAH PHR Available as an app or via a PC allowing 
patient access to their most recent 
clinical information including clinic 
letters to GPs and investigative results.  
Technical support Remote centralised support for patients 
and clinicians to report inaccuracies in 
the data and receive support with using 
the system.  
 
In 2010 we offered the intervention in paper and electronic form via email, 
but for the full trial we will reflect the eight year hiatus, the growing use of IT within 
the wider society and the acceptance of IT integration into every day life, and offer 
the intervention by electronic means only. We will provide information via an app 
for ease of transportation which could be especially helpful for patients requiring 
their IBD information at clinical appointments in primary and secondary care and 
when travelling. Patients and clinicians will also be able to access the intervention 
via PC’s. There will be a facility for patients and clinicians to print the information 
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as a PDF if wished. We will test the new intervention elements fidelity prior to the 
trial commencement, with participants who would not be included in the main trial.  
We will, again, provide patients with an email facility through the portal to 
contact their IBD provider so that patients can get queries answered, give health 
updates, receive advice or triage to other appropriate services quickly without the 
need for a secondary care appointment. Patients who already have email access to 
their clinical team will be able to access this without any change. Patients or staff 
will be enabled to report inaccuracies or seek help using the system by contact with 
remote IT technical support, this will be separate from the email facility for clinical 
advice.  
The intervention will for a second time be built using ELIJAH educationally 
enriched IBD reports (My History and My Plan), but will additionally include patient 
and clinician access to an IBD personal health record that will provide updates of 
care. Structured training and support when using the system will be available.  
Outcomes 
As we did in the feasibility study, we will have a pragmatic, defined set of 
outcomes. Following the commencement of sites converting from to intervention 
sites, we will compare outcomes between the intervention and control group. Our 
outcome measures will be: 
Primary outcome 
Cost-effectiveness - our primary outcome with will be a health economic 
evaluation of total NHS resource use and costs per patient, including use of all 
primary and secondary care health resources, combined with QALYs (Quality-
Adjusted Life Year) as determined using the EQ5D. Cost resource use data was 
identified within our feasibility study as a suitable primary outcome because of ease 
of data capture and acknowledgement of the financial frontloading required to 
develop and implement the intervention. We will expand upon the cost use data set 
used in our feasibility trial and carry out a full health economic evaluation of the 
intervention, testing cost and effectiveness.  
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Secondary outcomes 
 Safety – the number of adverse events leading to hospital admission or 
otherwise threatening the health and well-being of participating patients that 
have been reported to a health professional. 
 Patient centeredness – the satisfaction of participants with the care they receive 
over the study period.  
We will collect data on these outcome measures using a rigorous electronic 
data collection system such as REDCap (Harris 2018). We will use different forms to 
collect data per outcome measure via the following means:  
 Cost effectiveness will be captured using two forms. Total NHS cost resource 
data will be collated via the ELIJAH Data Abstraction Form. Although the 
process of formulating the two ELIJAH reports will be automated, any 
additional clinical time to formulate the elements of “My folder” will be 
captured. Total NHS costs of participants across primary and secondary 
services will be collected; including inpatient, outpatient, GP appointments, 
open access service use and medication use. Effectiveness data will be captured 
via the EQ5D included within the IBD Service Satisfaction Questionnaire 
(ISSQ).   
 Safety will be assessed via the monitoring of IBD patient adverse events. 
Electronic GP and hospital records for the patient will automatically populate 
the ELIJAH Adverse Events form and provide information relating to primary 
and secondary care attendances. We will search for all admissions to acute care 
facilities and identify any hospital admissions and outpatient visits.  
 
 Patient centeredness. Data will be collected from participants at baseline, twice 
during the intervention period and at the end of the study at 1 year trial period 
using the validated, adapted and shortened IBD Service Satisfaction 
Questionnaire (ISSQ). These will be sent to patients, and returned to the 
researchers electronically.  
Timeliness was included as an outcome measure in our feasibility trial. We 
had looked at the speed of response by health care providers to patient reporting of 
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symptoms. We monitored this by assessing the time differences between patients’ 
duration of symptoms, patient reporting of symptoms and health professional 
reaction to symptoms.  However, we found did not find this outcome measure 
feasible to collect data because of difficulty in accessing the information and there 
was a large degree of missing data for this outcome measure. We therefore will not 
include it within the full trial.  
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7.2. Methods / design 
Summary of the proposed trial  
Figure 13. Summary of the proposed trial  
Aim:  
 
The aim of the project is to evaluate the extent to which shared 
IBD educationally enriched health reports and access to an 
IBD PHR will reduce demand on health resources, by 
facilitating better patient understanding and knowledge, 
improving communication and greater patient empowerment 
and individual patient responsibility for self- care. 
Objectives: 
 
1.  To gain better understanding of what patients and 
clinicians want from access to IBD health reports and PHRs.  
2. To develop personalised health reports and enable access 
to an IBD PHR, and to make these available to patients, 
hospital doctors, and general practitioners (GPs). 
3.  To use this to facilitate better communication, and to 
enable patients to take greater responsibility for their health 
care. 
4. To evaluate the effects of this intervention on patients; 
primarily on the use of health service resources and costs, 
and also on safety and satisfaction. 
5. To evaluate the effects of this intervention qualitatively via 
focus groups with patients and interviews with clinicians.  
6.  To evaluate the wider benefits. 
Design: A. Qualitative patient focus group and clinician interviews 
B. Pragmatic cluster randomised controlled trial, phase III. 2 
arms: 1 intervention, 1 control. 
C. Qualitative patient focus group and clinician interviews 
Setting: 20 IBD sites in the UK  
Participants: A. 10 randomised patients from 10 of the trial sites. 3 
Clinicians from the same 10 trial sites.  
B. Trial patients from each of the 20 sites will be sought to 
meet the sample size requirements.  Sites randomised to 
timing of commencement of intervention.  
C. Same 10 randomised patients from 10 of the trial sites. 3 
Clinicians from the same 10 trial sites as included in A. 
Replacement may be necessary for some contacts if originals 
are unobtainable.  
 
 
Inclusion / exclusion criteria: 
Inclusion: 
Patient with confirmed diagnosis of Ulcerative Colitis or 
Crohn’s Disease 
Aged 18 to 90 years. 
Under current IBD secondary follow up care  
Patient registered with collaborating site. 
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Exclusion: 
Patients who are unable to comprehend the study. 
Method of 
randomisation: 
Central randomisation through the coordinating trials unit.  
Interventions: 
 
At the beginning of the study 100 patients will divided into 10 
geographically disparate focus groups to ensure we have a 
clear picture of what information patients would like to access 
via their electronic health record. 
Patients gathered from 20 IBD sites will be included in the 
randomised controlled trial. Randomisation will assign sites to 
a staggered commencement of the intervention. All 
participants and all sites will receive the intervention. All 
participants will be asked to complete the “IBD Service 
Satisfaction Questionnaire” with integrated EQ5D at the start, 
twice during the intervention, and at the end of the study, to 
monitor impact of the intervention on satisfaction with IBD 
care, and general health related quality of life. The patients and 
their clinicians in primary and secondary care will receive 
electronic individualised educationally enriched IBD health 
reports, have access to an IBD PHR.  
During the control period each site and their patients will 
receive care as usual.   
 
Random sampling of the IBD population of each site will be carried out and 
then assessed for suitability to be trial participants against the inclusion and 
exclusion criteria. For the full trial our inclusion and exclusion criteria will remain 
the same as that used within our feasibility trial, as it proved practicable to stratify 
patients by this means.  
The patients identified will be anonymised and coded for the study. A 
research assistant will invite potential ELIJAH patients to take part in the study by 
sending participant information sheets and consent forms sent by post. A clinician 
information invitation letter and summarised protocol will be sent simultaneously.  
Consent will be sought by local research assistants from eligible patients at 
agreed meetings with the participants. The research assistant will provide further 
clarification of the participant information sheet if needed and answer any questions 
they may have.  
A central randomisation through the coordinating trials unit will allocate the 
timing of sites to join the intervention.   
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Data collection and sources 
Focus groups and interviews 
We will collect qualitative data from patients participating in focus groups, 
and from clinicians during interviews to enable us to identify differences in data over 
time. The focus groups and interviews will be carried out at two time points: at 
baseline, and then immediately after the intervention period has completed.  
We will explore patient and clinician views on expectations of increased 
patient access to IBD information prior to the trial. After the trial we will investigate 
whether these expectations had been met and whether there were other unexpected 
findings from use of the intervention. We will gather the feedback to inform future 
developments.  
Questions pre-intervention will centre on how the intervention was expected 
to change the way patients’ access and use their information to better self-manage 
and post-trial whether this expectation was realised. We will seek detailed 
information on facilitators that helped influence patients use of the intervention and 
identify barriers that restricted their use of the intervention.  
The patient focus groups will be held in geographically disparate areas to 
reduce cross-contamination bias. The ten randomised participants per focus group 
will enable us to garner and explore different views, experiences and encourage 
group discussion.  
The one-to-one, face-to-face clinician interviews will be held prior to, and 
then post the trial intervention period. Where face-to-face interviews are not possible 
we will hold the interview by video conferencing. The interviews will enable us to 
explore the historical and cultural views of clinicians on patient accessed records and 
how they feel it may impact on their clinical practice and patient relationship.  
Cluster randomised step-wedge controlled trial 
Cost effectiveness data for analysis will be collected. Costs will be collated 
using the ELIJAH Data Abstraction Form (DAF) designed for our feasibility trial. 
However, in the full trial, this form will be populated electronically from direct 
communications with primary and secondary care EHR’s. Effectiveness will be 
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assessed using data collected from the EQ5D included in the ISSQ patient 
questionnaire. 
The time taken to formulate the elements of “My folder” will be analysed. 
This is the direct cost of the intervention. In our feasibility trial a sister-grade Band 7 
Nurse developed each ELIJAH “My Folder” intervention for patients. In the full trial 
the intervention will be populated electronically from EHR’s and so we would be 
able to employ a lower band nurse to deliver the intervention i.e.: a band 6 IBD nurse 
specialist.   
As we did in the feasibility study we will also collate data on the indirect 
costs of the intervention. We will amass data on the total NHS use by participants 
across primary and secondary services. We will include all GP appointments, 
inpatient stays, operations, outpatient visits, investigations, A&E attendances, 
investigations, open access service use and medication used. Similarly we will again 
assess health related quality of life data using the EuroQol (EQ-5D) tool, but also 
include the EQ5D thermometer.  
We will replicate our safety data collection method used in our feasibility 
study and capture data via the monitoring of Adverse Events. Where possible 
electronic GP and hospital patient records will automatically populate the ELIJAH 
AE form. We will look for information relating to primary and secondary care 
attendances, acute admissions and outpatient visits.  
We will seek IBD patient centeredness information by analysing patient 
service satisfaction. We will seek this at four trial timeline points: at baseline, twice 
during the intervention period and at completion of the intervention period, as we did 
in our feasibility trial, but the full trial will extend for one year, rather than the six 
months of the feasibility trial.  
During our feasibility trial the ISSQ was piloted and validated by patients 
with inflammatory bowel disease. These patients were not included in our feasibility 
trial because of GP practice exclusion. Within the full trial we will adopt the same 
validation process of the shortened ISSQ.   
If the participant wishes to be withdrawn from the study, identifiable data 
already collected with consent would be retained and used in the study. No further 
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data would be collected or any other research procedures carried out on or in relation 
to the participant. 
Data management 
We will use a rigorous data collection systems i.e.:  REDCap www.project-
redcap.org that will be managed by the registered trials unit (Swansea Trials Unit). 
Using REDCap will enable us to gather and securely store our sensitive trial data 
using a validated and auditable data management system.  
Sample size and power  
We will base our sample size calculation on our primary outcome. We 
identified cost as a primary outcome for a full trial during our feasibility trial. The 
feasibility trial was not designed or powered to detect differences between the 
intervention and control group, but in a larger trial we would expect cost differences 
between the two groups. We will replicate our collation of total NHS resource use 
(cost) and extend this to include effectiveness as assessed by QALYs evaluated using 
the EQ5D.  
We project a fall in individual consultations across primary and secondary 
care for IBD patients (resource use) when using the intervention. It is anticipated that 
patients having increased access to their educationally enriched information and 
electronic access to their clinicians will increase patient empowerment, self-care and 
self-management, particularly at time of need. The increased self-management will 
lead to a reduced need to use primary and secondary care services such as GP 
appointments, follow up outpatient appointments and remote services such as 
telephone help-lines. 
We acknowledge that outliers (such as a small number of emergency in-
patient admissions or significant escalation in treatment) could skew the results, 
however we will collect and analyse all cost data. We will analyse the cost-
effectiveness data with, and without outlier data to minimise the effect upon the 
outcome results.  
The full trial will have adequate statistical power to detect the resulting 
difference between the intervention and control groups. The sample size will need to 
reflect current IBD practice at the time of the trial. We will base our calculations on 
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the latest data from pertinent literature at the time of the trial and use local hospital 
data gleaned from consultations with local clinical teams and patients to be included 
in the trial.  
All participant data will be analysed whether or not the intervention 
participants complete the trial documentation, receive treatment or withdraw from 
the trial. 
Analysis 
The trial will comply with the Standard Operating Procedures (SOPs) of the 
Swansea Trials Unit, based at Swansea University. We will fully utilise and adhere to 
the range of SOPs for the conduct, management and monitoring of the trial e.g. for 
the development of the full protocol and statistical analysis plan, production of 
participant information, informed consent, randomisation, user inclusion, and data 
collection and management .  
To minimise the amount of missing data we will encourage all participants to 
provide data wherever possible. As in our feasibility trial we will send reminders two 
weeks after a non-response from patients. We will use a response analysis to check 
that the people who replied are not demographically or clinically different from those 
who did not, to minimise bias.  
To reduce bias we will check the retention rate and missing data rate between 
the 2 groups to avoid bias and secure an independent statistician to verify the 
analysis. Our rules for calculating derived variables will follow the published 
standard EuroQol procedure for calculating EQ5D scores. Within the analysis of 
ISSQ data we will give equal weight to each question. 
Project management 
The trial will be adopted by the Swansea Trial Unit and comply with its 
relevant SOPs.  
From learning during our feasibility trial, we will ensure early set up of a 
Research Management Group (RMG). The success of our feasibility trial relied 
heavily upon the well co-ordinated multi-disciplinary and multi-professional nature 
of our trial team, and the pervasive can-do attitude of the members. We will source 
and recruit a similar range of expertise to form our RMG, including a health 
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economist, statistician, methodologist in qualitative and quantitative trials and health 
economics, a clinical gastroenterologist (Chief Investigator), G.P. and patient 
representatives. More widely we will recruit research staff and local clinical health 
workers; doctors and nurses.  
The RMG will be responsible for the strategic management of the trial and 
will meet quarterly. Operational meetings will be held monthly by the Research 
Team (RT). The RT will be a pared down version of the RMG and have as members 
the Principal Investigator, researchers and a co-applicant. A research manager will be 
employed to ensure timescales, data management and analysis are adhered to.  
An independent Trial Steering Committee (TSC) and Data Monitoring and 
Ethics Committee (DMC) will meet bi-annually to ensure oversight, safety and 
reporting of the trial. Membership of this group will include appropriate expertise as 
outlined in the NIHR guidance.  
During the feasibility trial it was recognised that the funding of the trial was 
financially tight in terms of overall budget and per participant. In a full trial the cost 
per participant would need to be carefully accounted to reflect the evolved 
intervention and larger multi-site trial and the staff input required.  
Including service and research users 
We will adhere to the Swansea Trials Unit SOP for Service User Inclusion 
during the trial. 
During the focus group, piloting of the intervention and development of the 
data collection tools we found patient feedback incredibly insightful and valuable. 
We carefully listened to all comments and criticism, and adapted and modified the 
intervention and data collection resources in line with the feedback given. We will 
replicate these forms of service user inclusion within the full trial, and extend the 
involvement of service users to enable the patient voice to be heard fully in the RMG 
and TSC/ DMC. In the feasibility trial we did not have a patient representative within 
the research team and we may as a result have lost valuable advice and opinion. We 
will recruit the patient representatives through The Involving People Network 
(www.gov.uk/healthandcareresearch/public ) and reimburse appropriately according 
to recommended rates and include travel costs. Support and training will be provided 
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and individual needs will be considered when planning and booking meetings and 
seeking input.  
As in the feasibility trial, we will have early involvement from the patients’ 
charity Crohn’s & Colitis UK, the leading IBD charity in the UK. The organisation 
provides educational material which we used, with permission, to develop our 
educational enriched individualised patient information. The charity also supports 
IBD research to improve patient lives with IBD and provides health professional 
information and forums.  
All trial participants will be given a copy of the trial results and a final report 
of the trial will be produced for the funding body and the Research Ethics 
Committee.  
Ethics and dissemination 
The trial will be carried out in strict accordance with the principles of the 
Declaration of Helsinki and Good Clinical Practice. We will apply for full ethical 
approval for the trial from the Multi-Centre Research Ethics (MREC) Committee for 
Wales. We will seek research and development (R&D) permissions from each 
participating site and liaise with each NHS Trust (England, Scotland and Northern 
Ireland), and NHS Health Board (Wales) to achieve this.  
If there are amendments to the trial design or processes we will submit 
amendments to the MREC and R&D committees as needed and we will adhere to 
CONSORT guidelines for the reporting of the trial.  
Written informed consent will be sought from all participants prior to the trial 
commencement. Any serious adverse events identified will be reported to the 
Swansea Trials Unit and the ethics committee and to the DMC and TSC, all 
participating research trial sites will be notified of the occurrence.  
We plan to submit our findings and evaluation of the trial to peer reviewed 
journals for publication. By conducting a randomised controlled trial we aim to 
evidence a lack of bias, and that the intervention was the cause of the outcome results 
rather than other factors such as NHS redesign. In publishing the trial in journals, and 
presenting the findings at national and international conferences, we aim to 
disseminate our findings as widely as possible.  We hope this will stimulate the 
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introduction of similar interventions in other disciplines, thereby increasing multi-
professional seamless working, and providing evidence based personalised patient 
information that can be shared by all in the multi-disciplinary team. 
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7.3 Discussion 
We found during the systematic literature review (chapter six), that there is a 
lack of high quality evidence from large and randomised trials regarding 
individualised information for IBD patients. There is a paucity of reliable trial data to 
suggest this intervention has an effect on cost-effectiveness, safety and patient 
centeredness.  
Our unique format and delivery of educationally enriched patient information 
has proved feasible to produce and trial in a small scale, single centre feasibility trial.  
The proposed study, detailed in this chapter, of a large, fully powered, multi-centred, 
randomised controlled, cluster step-wedge will provide information on cost via 
comparison of total NHS use, safety by the evaluation of adverse events, and patient 
centeredness by the assessment of patient satisfaction. We will evaluate how the 
intervention works in the clinical setting, how it used and viewed by health 
professionals and patients and identify the barriers and facilitators to its imbedding in 
IBD patient care.  
We will identify the cost-effectiveness of the intervention and also gather 
useful qualitative information about the perceived value of the sharing of patient 
information in this way for patients and health professionals. We will aim to uncover 
cultural norms that may hinder or benefit the adoption of the intervention by 
engaging patients and professionals in discussions before and after the intervention 
phase of the trial.  
The trial will provide important evidence to support the future direction of 
patient interaction with their health providers and guide predictive modelling in this 
area. The findings will have national and international bearing on the future 
management of patients and applicability to change current guidelines. The trial is 
timely as there is currently a heightened focus by health providers and governments 
on chronic disease, IBD care, PHRs and increased patient access to their own health 
information.  
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7.4 Conclusion 
In this chapter we have explored how a larger, fully powered trial is now 
needed to consolidate the feasibility trial of the ELIJAH intervention. This will make 
a major contribution to the existing lack of evidence around chronic disease 
including IBD, PHR and the way this can help empower patients to make informed 
decisions in their care, and enable patients to better self-care.  
This final chapter of my thesis represents the culmination of my ELIJAH 
research that commenced in 2010. This chapter exemplifies my experiences and 
embodies my learning gained during the last eight years.  
In the introduction (chapter one), I explained how our rising demand for IBD 
outpatient services, and lack of opportunities to traditionally expand the service by 
employing additional staff, challenged our clinical team and led us to explore new 
ways of delivering care. We identified that our electronic patient record could be 
expanded to facilitate the delivery of improved individualised and educationally 
enriched patient information, and this could empower patients enabling them to 
better self-manage through increased understanding of their own disease pathway 
and treatment. In chapter two (the focus group), I discussed how we held a focus 
group to gauge patient opinion about the proposed intervention. We found that 
patients were overwhelmingly supportive of the development of an intervention to 
facilitate them having increased IBD information and they welcomed knowing more 
about their IBD and what to do if symptoms increased.  
The development of the intervention via adaptation of the existing EHR was 
described in chapter three, and in chapter four the testing of the intervention via a 
randomised feasibility trial was presented. The intervention was found to be feasible 
to produce and test. The feasibility and progression criteria were met with 
recommended modifications. My reflection relayed in chapter five extolled my 
experiences of carrying out the trial.  
A systematic literature review laid out in chapter six, found that there is a 
lack of high quality trials in the area of IBD and chronic disease individualised 
patient information. Conversely, there is much UK and international interest in the 
area of PHR and patients accessing their own information and using this to better 
self-care. Chapter seven provides a protocol to address the paucity of evidence 
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available to policy makers, legislators and health care providers to decide how best 
patients and clinicians wish to develop interventions in this field, and the trial will 
provide reliable data that can be used to inform future developments.  
Conducting the research detailed in this thesis has allowed me the opportunity 
to be part of a great research team, to extend and apply my learning to enhance my 
clinical practice, and most importantly, to provide additional opportunities and better 
care for my patients.   
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Appendix 1. Consolidated criteria for reporting qualitative studies (COREQ): 
32-item checklist 
Number Item Guide questions / description 
Domain 1: 
research team 
& reflexivity 
Personal 
characteristics 
 
 
 
 
 
 
Relationship 
with 
participants 
 
 
 
 
1 Interviewer / 
facilitator 
 
2 Credentials 
 
3 Occupation 
4 Gender 
5 Experience & training 
 
6 Relationship 
established 
 
7 Participant knowledge 
of the interviewer 
 
8 Interviewer 
characteristics 
 
 
 
Which author/ s conducted the interview or 
focus group 
What were the researcher’s credentials? E.g. 
PhD, MD 
What was their occupation at the time of 
the study 
Was the researcher male or female 
What experience or training did the 
researcher have 
Was a relationship established prior to study 
commencement 
What did the participants know about the 
researcher? E.g. personal goals, reasons for 
doing the research 
What characteristics were reported about 
the interviewer / facilitator? E.g. bias, 
assumptions, reasons & interests in the 
research topic 
Domain 2: 
Study design 
Theoretical 
framework 
 
Participant 
selection 
 
 
 
 
 
 
Setting 
 
 
 
 
 
Data 
collection 
 
 
9 Methodological 
orientation & theory 
 
 
10 Sampling 
 
11 Method of approach 
 
12 Sample size 
13 Non-participation 
 
14 Setting of data 
collection 
15 Presence of non-
participants 
16 Description of sample 
 
17 Interview guide 
 
18 Repeat interviews 
 
19 Audio/ visual 
recording 
 
20. Field notes 
 
 
What methodological orientation was stated 
to underpin the study? E.g. grounded 
theory, discourse analysis, phenomenology, 
content analysis 
How were participants selected? E.g. 
purposive, convenience, consecutive, 
snowball 
How were participants approached? E.g. 
face-to-face, telephone, mail, email 
How many participants were in the study 
How many people refused to participate or 
dropped out? Reasons? 
Where was the data collected? E.g. home, 
clinic, workplace 
Was anyone else present besides the 
participants and researchers 
What are the important characteristics of 
the sample? E.g. demographic data, date 
Were questions, prompts, guides provided 
by the authors? Was it pilot tested? 
Were repeat interviews carried out? If yes, 
how many 
Did the researchers use audio or visual 
recording to collect the data? 
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21 Duration 
 
22 Data saturation 
23 Transcripts returned 
Were field notes made during & / or after 
the interview or focus group 
What was the duration of the interviews or 
focus group 
Was the data saturation discussed 
Were transcripts returned to participants for 
comment and / or correction 
Domain 3: 
analysis & 
findings 
Data analysis 
 
 
 
 
 
 
 
Reporting 
 
 
 
24 Number of data 
coders 
25 Description of the 
coding tree 
26 Derivation of themes 
 
27 Software 
 
28 Participant checking 
29 Quotations 
presented 
 
 
30 Data & findings 
consistent 
 
31 Clarity of major 
themes 
32 Clarity of minor 
themes 
 
 
 
How many data coders coded the data 
Did authors provide a description of the 
coding tree 
Were themes identified in advance or 
derived from the data 
What software, if applicable, was used to 
manage the data 
Did participants provide feedback on the 
findings 
Were participant quotations presented to 
illustrate the themes / findings? Was each 
quotation identified? E.g. participant 
number 
Was there consistency between the data 
presented and the findings 
Were major themes clearly presented in the 
findings 
Is there a description of diverse cases or 
discussion of minor themes 
  
Ref: Tong A. , Sainsbury P., Craig J. (2007) Consolidated criteria for reporting 
qualitative research (COREQ): a 32 – item checklist for interviews & focus groups 
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Appendix 2. TIDier checklist 
 
Items included in the Template for Intervention Description and Replication (TIDieR) checklist: information to include when 
describing an intervention.  
 
Item No Item 
Brief name 
1 Provide the name or a phrase that describes the intervention 
Why 
2 Describe any rationale, theory, or goal of the elements essential to the intervention 
What 
3 Materials: Describe any physical or informational materials used in the intervention, including those provided to participants 
or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be 
accessed (such as online appendix, URL) 
4 Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling 
or support activities 
Who provided 
5 For each category of intervention provider (such as psychologist, nursing assistant), describe their expertise, background, 
and any specific training given 
How 
6 Describe the modes of delivery (such as face to face or by some other mechanism, such as internet or telephone) of the 
intervention and whether it was provided individually or in a group 
Where 
7 Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features 
When and How Much 
8 Describe the number of times the intervention was delivered and over what period of time including the number of sessions, 
their schedule, and their duration, intensity, or dose 
Tailoring 
9 If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how 
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Modifications 
10* If the intervention was modified during the course of the study, describe the changes (what, why, when, and how) 
 
How well 
11 Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to 
maintain or improve fidelity, describe them 
12 *Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as 
planned 
*If checklist is completed for a protocol, these items are not relevant to protocol and cannot be described until study is complete. 
For 
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Appendix 3. ELIJAH participation information sheet 
 
Participant Information Sheet 
Electronic Linkage for Inflammatory bowel disease to deliver 
Joint Access to Health records (ELIJAH) 
 
Protocol reference            Version 5          Date 14/04/2010 
Dear  
We would like to invite you to take part in our research study on               June               2010 at 
the Endoscopy unit , Neath Port Talbot Hospital  
at                    . We will reimburse your travel and time expenses by giving you £20.00 for 
attending this appointment. Before you decide to take part we would like to explain why the 
research is being done and what it would involve for you. One of our team will go through this 
information sheet with you and answer any questions you have. We expect this to take about 30 
minutes. Talk to other people about the study if you think it will help you to decide.  
Part 1 of this participant information sheet will tell you why we are doing the research, part 2 will 
tell you how the study will take place. 
The research is looking at the effect of greater sharing of hospital reports about patients with 
inflammatory bowel disease with patients and their GPs. Inflammatory bowel disease (IBD) is the 
name used to describe the type of bowel problems that can cover Ulcerative Colitis, Crohn’s 
Disease and proctitis.  
This research study is being carried out by  Professor J.G. Williams, Consultant 
Gastroenterologist  Neath Port Talbot Hospital (01639 862041) and by Sister Phedra Dodds, 
Advanced Nurse Practitioner for Gastroenterology & Endoscopy, Neath Port Talbot Hospital  
(01639 862551).  
Please ask us if any of the information we give to you or talk to you about is unclear. If you have 
any queries please contact us on our direct line 01639 862551 and we will be happy to answer 
them. 
If you are not willing to take part in this research study it will not affect your on-going care from 
the hospital or your GP in any way. 
Please would you confirm your attendance by ringing Sister Phedra Dodds on 01639 
862551. 
Yours Sincerely 
 
Sister Phedra Dodds, Advanced Nurse Practitioner for Gastroenterology and Endoscopy, Neath 
Port Talbot Hospital 
Part 1. 
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What does the research study look at? 
We have records of your care from your gastroenterology clinic appointments and endoscopy 
tests. We keep these records on a computer system called GeneCIS and store them under your 
patient number. In this study we will give you and your GP the ability to have a report of the 
information we have and add to the information that we hold. You will be able to have an account 
of your past hospital records for IBD, with education about the management of your condition, a 
plan of what to do if your symptoms increase, and you will be able to up-date your records with 
any changes you have, ask questions about your care via email or telephone, and have 
information on how to get help if you need it.  
The aim of our study is to assess whether this is a good and efficient way of providing care. To 
do this we are using a research method called a randomised trial which means that out of about 
100 patients taking part, you will have an equal chance of getting to view your records or 
continuing as at present. We will put people who agree to take part in the study into the two groups 
by equal chance.  One group (the computer assisted group) will have access to their records.  
The other group (the control group) will receive care as normal. We will compare the effect on 
your care and your satisfaction with it, and see if there is a difference between the two groups.  
Why have I been asked to take part in the research study? 
You are under the care of Professor Williams or Dr Lai at the Endoscopy Unit, Neath Port Talbot 
Hospital because you have Ulcerative Colitis, Crohn’s Disease or proctitis and we have a record 
of your care on our computer system. We are inviting up to 102 patients who are registered with 
five GP practices in the Neath Port Talbot area to take part in the trial. 
Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this information 
sheet with you. If you agree to take part, we will then ask you to sign a consent form. You are free 
to withdraw from the study at any time without giving a reason. Not agreeing to take part in the 
study or withdrawing from the study will not affect the standard of care you receive. 
What will happen to me if I take part? 
If you take part in the trial, you will be involved in the study for 6 months. You will be asked to 
complete a questionnaire at the beginning and end of the study.  In between you will either receive 
care as at present (control group), or be given reports of your care (report assisted group), with 
education and encouragement to make more decisions about your care yourself, keeping us and 
your GP informed when your health changes, or you alter your treatment. You will have the same 
access to care from your GP or the hospital if you need it. 
What will I have to do in the trial? 
You will see the information either on your computer or in a paper copy referring to your clinic 
appointments for IBD and any endoscopies you may have. There will also be education how to 
manage your condition, and a care-plan for you to look at and use. This will be personal to you 
and take into account your diagnosis, treatment so far and medication. It will list what to do if you 
have increased symptoms and how and when to get in touch with your Doctor or Specialist Nurse. 
 
There will be space so you can tell us about any changes to your symptoms. 
You will be able to call us on the helpline or use email to tell us of changes or ask questions. 
At the beginning and end of the study we will ask you to complete a questionnaire. For the 
research to be worthwhile we need at least 40 patients to complete both questionnaires.  
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What are the alternatives for care? 
If you decide not to take part, your care will be the same as usual, with follow up appointments in 
clinic and the telephone helpline available at times of need or for questions. 
What are the possible disadvantages and risks of taking part? 
We know that patients with IBD can have times of wellness and times of increased symptoms, 
often without warning. The way that we provide care at time of increased symptoms will not 
change. If you are in the trial you will still be able to contact your GP or Hospital Consultant or 
Specialist Nurse. If you have increased symptoms or questions about your care you can email or 
telephone the Specialist Nurse. If you need a hospital outpatient appointment or endoscopy you 
will still have this.  
What are the possible benefits of taking part? 
We think that by taking part in the study you will have more information about IBD and more ways 
to contact a Doctor or Specialist Nurse if needed. We hope this will make you feel more in control 
of your condition and enable you to change your treatment with confidence when necessary. 
What happens when the research study stops? 
If the research proves that giving patients access to the information in their reports is a safe and 
effective use of NHS resources we will give all IBD patients a choice to have this type of care.  If 
you take part in the study as part of the control group and do not have access to your record 
because you are in the treatment as usual group you will be one of the first to be offered this 
opportunity when the study is finished. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. This information is provided in more detail in Part 2. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. This information is provided in more detail in part 2. 
This completes part 1. If this information has interested you and you are considering taking part 
in the research, please read the additional information in Part 2 before making any decision. 
If you have decided not to take part in the study after considering the information we would like 
to thank you for reading the information. 
 
Part 2. 
 
What if I don’t want to carry on with the study? 
If you withdraw from the study we will return your follow-up to the original method and the quality 
of care you receive will not be affected. We will need to use the information you have given us up 
to the point of your withdrawal for the research study. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should contact the researcher Phedra 
Dodds on 01639 862551 who will try her best to answer your questions. If you remain unhappy 
and wish to complain formally you can do this by following the Abertawe Bro Morgannwg 
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University Health Board advice in “A guide to making a complaint, or a compliment”. If you do not 
wish to discuss your concerns with a member of the research team you can contact the Trust 
Governance Support Unit on 01639 683316 during office hours. If you wish to make a formal 
complaint you may wish to put your concerns in writing to the Chief Executive of the Health Board 
David Sissling at: 
 ABMU Health Board 
One Talbot Gateway 
Seaway Parade 
Baglan Energy Park 
Port Talbot 
SA12 7BR 
Tel no: 01639 683326 
Your complaint will then be dealt with under the NHS Complaints Procedure. 
In the event that something does go wrong and you are harmed during the research and this is 
due to someone’s negligence then you may have grounds for a legal action for compensation 
against ABMU Health Board but you may have to pay your legal costs.  
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential. The questionnaires that you fill in will be coded so it does not have any of your 
personal details and will be anonymous. The way that you will look at and update your records 
will be secure and the email link between you and the hospital will be encrypted to ensure 
confidentiality.  
Any data from the research will be kept securely and if it is needed for further research it will have 
to be applied for through the appropriate channels. 
Does my GP know that I am taking part in the research? 
Yes. Your GP will also have access to the record so that he/she is informed about changes in 
your condition or treatment, and can also send you & your specialist and relevant information. 
 
What will happen to the results of the research study? 
The results will tell us whether it will be a good thing to introduce this change for all patients as a 
matter of routine. We will publish the results in Nursing and Medical journals, feedback through 
conference presentations and exhibit a poster in the Endoscopy Unit Neath Port Talbot Hospital. 
You will be able to request a copy of the results and or articles about the results. You will not be 
personally identified in the results. 
Who is funding the research? 
The Health Foundation SHINE Award scheme is funding the research. Swansea University is 
organising the research. Your Doctor (Professor Williams) and Specialist Nurse (Phedra Dodds) 
are not being paid by The Health Foundation for this research. 
Who has reviewed this study? 
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All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This research has been reviewed and given favourable 
opinion by South West Wales Research Ethics Committee. 
If you take part in the study you will be given a copy of this information sheet and a signed consent 
form to keep.  
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Appendix 4. ELIJAH consent form 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
Consent Form 
Title of Project: Electronic Linkage for Inflammatory bowel disease to deliver Joint Access to Health 
records (ELIJAH) 
Name of Researcher: Professor J G Williams 
                                                                                                  Please initial box 
1. I confirm that I have read and understand the information sheet dated   
    04/02/10 (version 4) for the above study. I have had the opportunity to 
    consider  the information, ask questions and have had these answered 
    satisfactorily. 
2. I understand that my participation is voluntary and that I am free to                
    withdraw at any time without giving any reason, without my medical care 
    or legal rights being affected. 
3. I understand that relevant sections of my medical notes and data collected  
    during the study, may be looked at by individuals from The Health  
    Foundation, from regulatory authorities or from the NHS Trust, where it is  
    relevant to my taking part in this research. I give permission for these  
    individuals to have access to my records. 
4. I understand that any spoken or written information I give can be used          
    as quotes in the research. These quotes will be anonymised, and I will 
    not be identified as the source of the quote. 
5. I agree to my GP being informed of my participation in the study and I am  
    aware that if I participate, my GP will have full access to my records. 
6. I agree to take part in the above study. 
_______________                _________________          _________________ 
Name of Patient                                      Date                                         Signature 
_________________                _________________          _________________ 
Name of Person taking consent                  Date                                         Signature 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes. 
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Appendix 5.  Example of My History 
My Inflammatory Bowel Disease History 
 
 
To: 
 Hospital ID:  
 
 NHS Number:   
  Date of Birth:  
  
  
Date: 10 December 2010  
 
Dear  
 
This summary of your inflammatory bowel disease condition to date is intended for you to keep as a record 
to help you and your doctor or nurse make decisions about your future management.  Please let us know if 
there are any inaccuracies.  Copies will also be held in your hospital and GP records. Future changes in your 
condition and treatment will recorded in a new document called “My Update”. 
 
Diagnosis: Crohn's disease 
Crohn's Disease is a type of Inflammatory Bowel Disease (IBD). Crohn's disease affects about 55,000 
people in the UK. Crohn's disease is not an infectious illness and cannot be passed from one person to 
another. In Crohn's disease the lining of the affected part of the gut or intestine becomes inflamed and 
swollen. This swelling can cause the intestine to narrow, which is called a stricture. Ulcers and abscesses 
can also develop on the surface of the intestine, which may bleed and produce pus.  The gut can be 
affected anywhere and in different places. The symptoms may include diarrhoea, blood in the motions, 
pain in the tummy, tiredness and weight loss. 
Pattern of disease: Stricturing 
A stricture is present in the descending colon. The inflammation has caused narrowing of the intestine. 
Distribution/extent 
of disease: 
Pan-colitis (whole colon): Patchy 
segments of ulceration & inflammation 
throughout the colon. 
 
 
 
Year diagnosed: 2009 Year symptoms 
started: 
2007 
Method of 
diagnosis: 
Colonoscopy: and biopsies 
Colonoscopy is an inspection of the intestine using a colonoscope inserted into the back passage. 
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Most recent 
investigations & 
procedures: 
Colonoscopy in 08/2010 
 
IBD surveillance: IBD surveillance not yet required 
Regular inspection of the bowel is recommended when the inflammation has been present for more than 
eight years, because there is a small risk of developing colorectal cancer.  The inspection (usually by 
colonoscopy) can detect unstable cells before cancer develops. 
Relevant surgical 
history: 
 
 
Relevant 
medication history: 
Oral 5 ASA: Mezavant XL 2.4g per day now stopped. Pentasa 500mg 2 four 
times a day. 
Oral prednisolone 
Oral azathioprine 
GI medication history: Ferrous sulphate 
Medication 
monitoring: 
FBC monitoring: weekly 
U&E monitoring: weekly 
Liver function monitoring: weekly 
A full blood count is taken to check for anaemia and evidence of active inflammation. 
The blood urea and salts are checked to assess kidney function. 
Liver function tests are taken to check the health of the liver.  
Medication 
sensitivities: 
No known medication sensitivities 
Past history of IBD 
related problems: 
No history of IBD related problems 
Inflammatory bowel disease can also cause problems that do not involve the bowel.  They can occur in 
about 20-30% of people with IBD. 
There is no past history of IBD related problems. 
Past history of non 
IBD problems: 
No history of non IBD health problems 
Smoking history: Non-smoker 
You are twice as likely to have Crohn's disease if you smoke. We do not know why this happens but it may 
be because nicotine alters the way the blood flows through the gut. Stopping smoking helps you to have 
fewer flare ups, less need for immunosuppressant drugs and surgery. For more information please ask your 
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doctor or nurse or see the National Association of Colitis and Crohn's (NACC) information about this. On 
their website www.NACC.org.uk, click the tab 'information' and the leaflet 'Smoking and IBD'. 
Dietary history: Normal diet history 
 
Family history: No relevant family history 
15% of patients with Crohn’s disease or ulcerative colitis have a relative who also has IBD, but only 10% 
of children will get IBD if a parent has it. 
Additional 
comments: 
 
No additional comments recorded. 
 
 
 
If you have any queries, please contact Sister Phedra Dodds by telephone on  or email her at 
elijah.gastro@wales.nhs.uk. 
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Appendix 6. Example of My Plan 
To: 
 Hospital ID:  
 
 NHS Number:   
  Date of Birth:  
  
  
Date: 10 December 2010  
 
Dear  
This plan is intended to summarise current plans for the investigation, treatment and care of your 
inflammatory bowel disease.  Copies will be held in your hospital and GP notes. 
 Your action plan has been changed 
Diagnosis: Crohn's disease 
Current medication: PT Mesalazine / Pentasa tablets 
   1000 milligrams (mg) 
   Four time daily (QDS) 
PN Prednisolone 
   5 milligrams (mg) 
   Once in morning (OD mane) 
Changes to current 
medication: 
Changes made to current medication 
Medication stopped: Pentasa. 
There have been changes to your medication. 
Some or all of your medication has been stopped, as shown in the current medication section. 
Medication 
sensitivities: 
No known medication sensitivities 
Planned 
investigations: 
No planned investigations 
 
Planned surgery: No GI surgery planned 
 
Medication 
monitoring: 
FBC monitoring: 3 weeks 
U&E monitoring: 3 weeks 
Liver function monitoring: 3 weeks 
A full blood count is taken to check for anaemia and evidence of active inflammation. 
The blood urea and salts are checked to assess kidney function. 
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Liver function tests are taken to check the health of the liver. 
IBD surveillance: IBD surveillance not yet required 
Regular inspection of the bowel is recommended when the inflammation has been present for more than 
eight years, because there is a small risk of developing colorectal cancer.  The inspection (usually by 
colonoscopy) can detect unstable cells before cancer develops. 
 
Dietary advice: Normal/usual diet advised 
Activity advice: Normal activity advised 
 
Work advice: Continue work as at present 
 
Communication 
plan: 
Email contact offered 
Telephone contact offered 
Open access appointment offered 
Please tell us about any increase in your symptoms and what you have done about it by emailing us at 
ELIJAH@abm-tr.wales.nhs.uk. 
Please tell us about any increase in your symptoms and what you have done about it by telephoning 
specialist nurse Phedra Dodds on . 
Please let us know if you want to see someone in the gastroenterology department and we will arrange an 
appointment for you as soon as we can. 
Follow up / review: You will be seen in the gastroenterology outpatients clinic in 3weeks: With Dr 
Lai 
Other review arrangement required (state): For infliximab infusion tomorrow. 
Referrals: Referral not required 
Additional 
comments: 
No additional comments recorded. 
 
If you have any queries, please contact Sister Phedra Dodds by telephone on  or email to 
elijah.gastro@wales.nhs.uk 
 
 
 
 
 
 225 
 
Appendix 7. Example of My Update 
To: 
 Hospital ID:  
 
 NHS Number:   
  Date of Birth:  
  
  
Date: 10 December 2010  
 
Dear  
 
This update of your inflammatory bowel disease condition is intended to summarise recent changes in your 
health, lifestyle or treatment.  Copies will be held in your hospital and GP notes. 
 
Diagnosis: Crohn's disease 
Healthcare contacts 
since last update: 
Last gastroenterology outpatient clinic visit on: Y: 24/11/2010 
Overall change in 
health status: 
Overall health has been worse for 1 weeks. 
Current symptoms: Intermittent abdominal pain 
Decreased appetite 
Malaise 
Intermittent pain in the abdomen. 
Decreased appetite. 
Feeling generally unwell. 
Weight: 66 kilograms 
Activity lifestyle: No activity or lifestyle changes due to IBD 
Other changes in 
condition: 
Condition changed: Increased CRP from baseline of 50 to 84. 
Relevant surgery 
since last update: 
No relevant surgical history recorded 
 
Current medication: 
1.1 PT Mesalazine / Pentasa tablets 
1.2    1000 milligrams (mg) 
   Four time daily (QDS) 
PN Prednisolone 
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   5 milligrams (mg) 
   Once in morning (OD mane) 
Medication 
sensitivities: 
No known medication sensitivities 
Investigation 
results: 
Haemoglobin 
  Result: 13.9 (g/dl) 
  Date: 24/11/2010 
White cell count 
  Result: 7.0 x10^9/l 
  Date: 24/11/2010 
Platelets 
  Result: 229 x10^9/l 
  Date: 24/11/2010 
CRP 
  Result: 98 mg/L 
  Date: 24/11/2010 
Urea 
  Result: 3.6 mmol/L 
  Date: 24/11/2010 
Creatinine 
  Result: 76 umol/L 
  Date: 24/11/2010 
Albumin 
  Result: 40 g/L 
  Date: 24/11/2010 
Bilirubin 
  Result: 6 umol/L 
  Date: 24/11/2010 
Imaging 
  Result: A Imaging findings: Normal small bowel. Contracted caecum, 
abnormality in transverse colon. 
  Date: 22/11/2010 
Haemoglobin can suggest anaemia if low. 
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White cell count can suggest inflammation if low. 
 
C-Reactive Protein is a measure of inflammation. 
 
 
Albumin can be low if there is inflammation or malnutrition. 
Bilirubin can cause jaundice if high. 
 
Additional 
comments: 
No additional comments recorded. 
 
If you have any queries, please contact Sister Phedra Dodds by telephone on  or email to 
elijah.gastro@wales.nhs.uk 
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Appendix 8. ELIJAH Data Abstraction Form DAF 
 Data Abstraction Form 
 
                                                                                          Email: Elijah.gastro@wales.nhs.uk 
 
Participant study ID:   
 
Section 1: Participant details 
 
1a: Participant demographics              
Name  
Date of Birth  
Gender  
NHS number  
Hospital number  
Home address & postcode 
 
 
 
1b: GP details 
GP full name  
GP ID code  
GP Practice name in full  
GP Practice Code  
GP Practice address & postcode 
 
 
 
Section 2: Hospital based services: 
2a. Open access services: 
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Telephone call/ email/ unscheduled 
drop in 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
NOTE: Date, time attended, ? if transport needed.  
2b. Outpatient services: 
Gastroenterology / other 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
 
2c. Multi-disciplinary team appointments 
E.g. dietician, physio 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
 
 
2d. A&E attendances 
Gastroenterology / other  
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Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
2e. Investigation appointments 
Gastroenterology / other 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
 
2f. Inpatient episodes 
Gastroenterology / other 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
NOTE: Any surgery, LOS ( definition overnight stay= 1 day, otherwise 
day episode), ward title, admitting diagnosis 
 
Section 3: Community based services 
3a. GP attendances 
Gastroenterology / other 
Time & duration of Recognition of 
problem 
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Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
 
3b Out of hours GP services 
Gastroenterology / other 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
Note: home visit or to e.g. prime care 
3c Multi-disciplinary team appointments 
E.g. dietician, physio, dentist 
Time & duration of Recognition of 
problem 
 
Time & duration of Reporting of 
problem 
 
Time & duration of Response to 
problem 
 
 
 
4. Medication History 
Drug Strength Dose Frequency Date & Duration 
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(Note: known compliance with medication is not required. No PRN medications to be listed) 
 
5. Time of ANP spend preparing My folder: Preparation number:  
 
Date, time & duration request notes 
 
 
Time & duration taken to read notes 
 
 
Time & duration taken to access GeneCIS patient history  
Time & duration taken to answer GeneCIS Elijah 
questionnaires 
 
 
Time & duration taken to print and send questionnaires 
 
 
First Follow up 
 
Date, time & duration taken to check GeneCIS for contacts  
Time & duration taken to update My Plan & My Update 
 
 
Time taken to print and send questionnaires 
 
 
 
 
Second Follow up 
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Date, time & duration taken to check GeneCIS for contacts  
Time & duration taken to update My Plan & My Update 
 
 
Time taken to print and send questionnaires 
 
 
 
Third Follow up 
 
Date, time & duration taken to check GeneCIS for contacts  
Time & duration taken to update My Plan & My Update 
 
 
 
Time taken to print and send questionnaires 
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Appendix 9 ELIJAH Adverse Events form 
 
Adverse Event (AE) Screening Form 
                                                                                 Email: Elijah.gastro@wales.nhs.uk 
Participant study ID :   __ __ __ 
 
Please complete this form if the participant reports untoward signs or symptoms and email it to the trial manager at 
Elijah@swansea.ac.uk.  
 
Start date:     DD  MM  YYYY       End Date:     DD  MM  YYY           (Code for on-going 88 88 8888) 
 
Question 1- Is the symptom/ problem a known, undesirable effect of IBD in terms of its nature and severity? (e.g. PR bleed, 
surveillance) 
 
 Yes (Only complete question 4a and 4b)  No (Go to question 2) 
 
Question 2 - Is the symptom/ problem in keeping with an exacerbation  or progression of the underlying IBD? NOTE: This does 
not include clinical consequences of disease progression. In such cases, the answer should be “no”. (e.g. extra-intestinal manifestations of IBD). 
 
 Yes (Only complete question 4a and 4b)  No (Go to question 3) 
 
Question 3 – Is the symptom / problem a stable symptom of a pre-existing condition other than IBD? This question only concerns 
symptoms of medical conditions (other than IBD) that were identified prior to the start of the trial, and have NOT significantly worsened since the trial 
commenced. If symptoms of a pre-existing condition e.g. asthma, diabetes have worsened following the start of the trial, this question should be answered 
“no”. 
 
 Yes (Only complete question 4a and 4b)  No (Go to question 4) 
 
Question 4 – Is the event an admission for a medical or surgical procedure? NOTE: This does not include the “triggering event” that leads 
to the procedure (which should be considered under its own merit). 
Event description 
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 Yes (Only complete question 4a and 4b)  No (Go to question 5) 
 
4a Relation to Elijah (causality)                     4b Seriousness of event 
 
Not related                   Is/was life threatening 
  Unlikely to be related                  Resulted in disability/incapacity 
Possibly related 
                Required         . 
hospitalisation/prolonged hospital stay 
Probably related                Not serious/ none of the above 
Definitely related 
 
Question 5 – AT THIS POINT THE EVENT HAS BEEN CATEGORISED AS AN UNEXPECTED EVENT. Please  
indicate the causality and seriousness of the event below e.g. fell off ladder. 
4a Relation to Elijah (causality)                         4b Seriousness of event 
1.Is/was life threatening 
2.Resulted in disability/incapacity 
3.Required hospitalisation /prolonged hospital stay 
Not serious/ none of the above 
 1.Not related 
 2.Unlikely to be related 
 3.Possibly related 
 4.Probably related                                          
 5.Definitely related 
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NOTE: If causality = 3,4 or 5 AND seriousness = 1,2 or 3 the event is a Suspected Unexpected Serious Adverse Reaction.  
Proceed to complete a SUSAR Report Form & send both forms to the Trial Office within 24 hours of becoming aware of the event. 
 
Initials of person completing this form:                        Signature:                                                   Date: 
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Appendix 10.  Inflammatory bowel disease Service Satisfaction Questionnaire (ISSQ) 
YOUR Feedback – to Neath Port Talbot Hospital 
 
We should be most grateful for YOUR views based on YOUR experience of 
having care for your condition, so we can improve the hospital service by 
taking full account of the replies from you and many other patients. We shall 
treat your answers as strictly confidential. They will not affect your treatment 
in any way.   
Answer every question by putting a tick in the appropriate box.  Do not tick 
more than one box in reply to each question.  If you are unsure about how to 
answer a question, please give the best answer you can. If you want to say more, 
please use the large box at the end of the questionnaire. 
 
1. What bowel condition do you have?  ____________________________ 
2. When were you diagnosed?   DD     MM      YYYY 
Your condition  
3. How much information have you had about your condition since you were 
diagnosed? 
                 
 
Far too 
much 
 A bit 
too 
much 
 Enough  A little  None 
 
 If none please go direct to question 6. 
4. How easy to understand was the information? 
                 
 
Very 
easy 
 Easy  Fair  Difficult  Very 
difficult 
 
5. How useful was the information? 
                 
 
Very 
useful 
 Useful  Fair  Not very 
useful 
 Not useful 
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6. How much opportunity have you had to ask questions about your condition? 
 
               
 
Very  
many 
opportunit
ies 
 Many 
opportunit
ies 
 Several 
opportunit
ies 
 Few 
opportunit
ies 
 No 
opportuni
ty 
 
Getting care when you need it 
7. How much explanation have you received about getting care when you need 
it? 
                 
 
Far too 
much 
 A bit 
too 
much 
 Enough  A little  None 
 
If none, please go direct to question 10. 
8. How easy was it to understand the explanation of how to get care when you 
need it? 
                 
 
Very 
easy 
 Easy  Fair  Difficult  Very 
difficult 
 
9. How useful was the explanation of how to get care when you need it? 
                 
 
Very 
useful 
 Useful  Fair  Not very 
useful 
 Not useful 
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10. How would you rate the communication skills (for example courtesy and 
friendliness) of the last person who gave you information about getting care 
when you need it? 
                 
 
Very good  Good  Fair  Poor  Very poor 
 
11.       How much difficulty did you experience in getting care the last time you 
needed it? 
                 
 
Extensiv
e 
difficulty 
 A lot of 
difficult
y 
 Some 
difficult
y 
 Little 
difficult
y 
 No 
difficult
y 
 
 
 
 
Quality of the care you received recently. 
12. How would you rate the quality (for example carefulness and competence) 
of the care you received on your last contact (visit or phone call) with Neath 
Port Talbot Endoscopy Unit?   
 
                 
 
Very good  Good  Fair  Poor  Very poor 
 
13. How would you rate the communication skills (for example courtesy and 
friendliness) of the main person you spoke to on that last contact? 
                 
 
Very good  Good  Fair  Poor  Very poor 
 
Please describe your experience if you wish: 
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14. The last time you needed care, how much discomfort did you experience 
from your symptoms?  
                 
 
None  Mild  Moderate  Severe  Very 
severe 
 
15. The last time you needed care, how much pain did you experience from your 
symptoms? 
                 
 
None  Mild  Moderate  Severe  Very 
severe 
 
16. How much discomfort did you have in the week following that experience? 
                 
 
None  Mild  Moderate  Severe  Very 
severe 
 
17. How much pain did you have in the week following that experience? 
                 
 
None  Mild  Moderate  Severe  Very 
severe 
 
18. Still thinking about the last time you needed care, how much opportunity did 
you have to ask questions? 
                 
 
Very 
good 
opportun
ity 
 Good 
opportun
ity 
 Fair 
opportun
ity 
 Limited 
opportun
ity 
 No 
opportun
ity 
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19. Still thinking about the last time you needed care, how much explanation did 
you receive? 
                 
 
Far too 
much 
 A bit 
too 
much 
 Enough  Too 
little 
 Far too 
little 
 
 If you did not receive an explanation, then please go direct to question 21. 
20. How easy to understand was the explanation given to you the last time you 
needed care? 
                 
 
Very 
easy 
 Easy  Fair  Difficult  Very 
difficult 
 
21. Was that explanation useful in answering your questions? 
                 
 
Very 
useful 
 Useful  Fair  Not very 
useful 
 Not at all 
useful 
 
General quality of the care you receive 
22. In general, how easy is it to get care when you need it? 
                 
 
Very good  Good  Fair  Poor  Very poor 
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23. In general, how satisfied are you with getting care when you need it? 
                 
 
Very 
satisfie
d 
 Satisfie
d 
 Neither 
satisfied 
nor 
dissatisfi
ed 
 Dissatisfi
ed 
 Very 
dissatisfi
ed 
 
24. How happy would you be to get care in the same way as last time, in future? 
 
                 
 
Very 
happy 
 Happy  Neither 
happy 
nor 
unhappy 
 Unhappy  Very 
unhappy 
 
25. In general how good is the care you receive for your bowel condition? 
 
                 
 
Very good  Good  Fair  Poor  Very poor 
 
Your general well being 
 
26.       Please tick which statement best describes your own health state 
today. 
Mobility 
  I have no problems in walking about     
  I have some problems in walking about    
  I am confined to bed       
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Self-Care 
I have no problems with self-care     
  I have some problems washing or dressing myself   
  I am unable to wash or dress myself     
Usual Activities (e.g. work, study, housework, family or leisure 
activities) 
I have no problems with performing my usual activities  
  I have some problems with performing my usual activities  
  I am unable to perform my usual activities    
Pain or Discomfort 
  I have no pain or discomfort      
  I have moderate pain or discomfort     
  I have extreme pain or discomfort     
Anxiety / Depression 
  I am not anxious or depressed     
  I am moderately anxious or depressed    
  I am extremely anxious or depressed    
 
Please use the following box if you want to say more about any question 
or any other aspect of your condition 
 
 
 
 
Many thanks for your invaluable help! 
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Appendix 11. Welsh Index of multiple deprivation – Neath Port Talbot 
 
StatsWales >Community safety and social inclusion >Welsh Index of Multiple Deprivation >Archive >WIMD 
2011 > Local authority maps.gov.uk 
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Appendix 12. Letter of confirmation of full ethical approval 
South West Wales REC 
Swansea 
36 Orchard Street 
SWANSEA 
SA1 5AQ 
 Telephone: 01792 607416  
Facsimile: 01792 607533 
05 March 2010 
Professor J G Williams 
Professor of Health Services Research 
Swansea University 
School of Medicine 
Grove Building 
Swansea University 
SA2 8PP 
Dear Professor Williams 
Study Title: Electronic linkage for inflammatory bowel disease to deliver 
joint access to health records (ELIJAH) 
REC reference number: 09/WMW02/61 
Protocol number: 1 
 
Thank you for your letter of 04 February 2010, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
The further information has been considered on behalf of the Committee by the Chairman.  
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below). 
Conditions of the favourable opinion 
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The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
Management permission or approval must be obtained from each host organisation prior 
to the start of the study at the site concerned. 
For NHS research sites only, management permission for research (“R&D approval”) should 
be obtained from the relevant care organisation(s) in accordance with NHS research 
governance arrangements.  Guidance on applying for NHS permission for research is 
available in the Integrated Research Application System or at http://www.rdforum.nhs.uk.  
Where the only involvement of the NHS organisation is as a Participant Identification 
Centre, management permission for research is not required but the R&D office should be 
notified of the study. Guidance should be sought from the R&D office where necessary. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document    Version    Date      
Covering Letter  1  04 February 2010    
REC application  1  04 January 2010    
Protocol  1  28 December 2009    
Investigator CV  1  28 December 2009    
Participant Information Sheet  2  22 April 2010    
Participant Consent Form  2  28 December 2009    
Shine email  1  17 December 2009    
Response to Request for Further Information  1  04 February 2010    
sponsor declaration  1  04 March 2010    
 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
After ethical review 
Now that you have completed the application process please visit the National Research 
Ethics Service website > After Review 
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You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Progress and safety reports 
 Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
We would also like to inform you that we consult regularly with stakeholders to improve 
our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk.  
09/WMW02/61 Please quote this number on all correspondence 
 
Yours sincerely 
 
 
Mr Roy L. Evans 
Chairman 
Email: penny.beresford@bscs.wales.nhs.uk 
Enclosures: “After ethical review – guidance for researchers”   
 
Copy to: Mrs  Phedra Dodds, Abertawe Bro Morgannwg University Local Health 
Board 
[R&D office for NHS care organisation at lead site] 
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Appendix 13 combined CONSORT reporting outline with 
appropriate extensions for the ELIJAH RCT feasibility trial 
(CONSORT 
2010 outline + extensions for patient reported outcomes, non-pharmacological 
treatment, pragmatic trials, parallel group randomised trials 
Excel & SPSS: re-run data files (outputs as appendix) 
CLINICAL TRIALS REGISTRY: Clinicaltrials.gov &  portfolio status 
FUNDING SOURCE, AMOUNT, TRIAL TEAM) 
 
CONSORT 2010, CENT 2015 
Extension: pilot or feasibility trial 
Extension: Patient reported outcomes 
Extension: Reporting of Harms (safety) 
Extension: Nonpharmacologic treatments  
Extension: Pragmatic trials  
(Checklist in appendix) 
Section / topic CONSORT 2010 
No.       Item 
CENT 2015 & extensions 
No.      Item 
Title & abstract 1a      Identification as a randomised 
trial in  title 
 
 
1b     Structured summary of trial 
design, methods, results, 
conclusions (see CONSORT for 
abstracts) 
Identification as a pilot or 
feasibility randomised trial in 
the title 
 
Structured summary of pilot 
trial design, methods, results 
and conslusions 
P1b The PRO should be 
identified in the abstract as a 
primary or secondary outcome 
If the study collected data on 
harms & benefits the title or 
abstract should state 
Description of the 
experimental treatment, 
comparator, care providers, 
centres, & blinding status 
Introduction 
Background & 
objectives 
 
2a Scientific background & 
explanation of rationale 
 
 
 
 
 
2b Specific objectives & hypotheses 
 
Scientific background & 
explanation of rationale for 
future definitive trial, & 
reasons for randomised pilot 
trial 
Including background & 
rationale for PRO assessment 
Specific objectives or research 
questions for pilot trial 
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Describe the health or health 
service problem that the 
intervention is intended to 
address & other interventions 
that may commonly be aimed 
at this problem 
P2b The PRO hypothesis 
should be stated and relevant 
domains identified , if 
applicable 
If the trial addresses both 
harms and benefits, the 
introduction should state so 
 
 
Methods 
Trial design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3a Description of trial design 
(parallel/ factorial) including 
allocation ratio 
3b Important changes to methods 
after trial start (e.g. eligibility 
criteria) with reasons 
 
 
 
 
 
 
 
 
 
 
 
 
4a Eligibility criteria for participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Describe trial design: planned 
number of periods, duration of 
each period 
In addition for series: whether 
& how the design was 
individualised to each 
participant & explain series 
design. 
 
Description of pilot trial design 
(such as parallel, factorial)  
including allocation ratio 
 
3b Important changes to 
methods after pilot trial  
commencement such as 
eligibility criteria with reasons 
 
Eligibility criteria for centres 
and those performing the 
interventions  
Precise details of both the 
experimental treatment & 
comparator 
4a Diagnosis, diagnostic 
criteria, comorbidities, 
concurrent therapies 
Description of the different 
components of the 
interventions & when 
applicable descriptions of the 
procedure for tailoring the 
interventions to  individual 
participants. 
Eligibility criteria  should be 
explicitly framed to show the 
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Interventions 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4b Settings & locations where data 
were collected 
 
 
 
 
 
 
 
 
 
4c How participants  were identified 
& consented 
 
 
 
 
5 The interventions for each group 
with sufficient details to allow 
replication , including how & when 
they were actually administered 
 
 
 
 
 
 
 
 
 
 
6a  Completely defined pre-
specified primary & secondary 
outcome measures, including how & 
when they were assessed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
degree to which they include 
typical  participants &/or, 
where applicable , typical 
providers (e.g. nurses), 
institutions (e.g. hospitals), 
communities (or localities e.g. 
towns) & settings of care (e.g. 
different healthcare financing 
systems) 
 
Details of how the 
interventions were 
standardised. 
4c Whether the trial 
represents a research study,  
whether institutional ethics 
approval was obtained 
 
 
Details of how adherence of 
care providers with the 
protocol was assessed or 
enhanced.  
Describe extra resources added 
to (or resources removed from) 
usual settings in order to 
implement intervention . 
Indicate if efforts were made to 
standardise the intervention or 
if the intervention & its delivery 
were allowed to vary between 
participants , practitioners, or 
study sites. 
Describe the comparator in 
similar detail to the 
intervention.  
6a Completely  defined 
prespecified assessments or 
measurements to address each 
pilot trial objective specified in 
2b, including how  and when  
they were assessed 
6a.2 Description & 
measurement properties 
(validity & reliability) of 
outcome assessment tools 
P6a Evidence of PRO 
instrument validity & reliability 
should be provided or cited if 
available including the person 
completing the PRO & 
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Sample size 
 
 
 
 
 
Randomisation: 
Sequence 
generation 
 
 
 
Allocation 
concealment 
mechanism 
 
Implementation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7a How sample size was determined 
 
7b When applicable , explanation of 
any interim analyses and stopping 
guidelines 
 
 
 
8a Method used to generate 
random allocation sequence 
8b Types of randomisation: details 
of any restriction 
 
 
9 Mechanism used to implement 
the random allocation sequence , 
describing any steps taken to  
methods of data collection 
(paper, tel, electronic, other) 
List addressed adverse events 
with definitions for each (with 
attention, when relevant, to 
grading, expected vs. 
unexpected events, reference 
to standardized & validated 
definitions, & description of 
new definitions).  
Clarify how harms-related 
information was collated 
(mode of data collection, 
timing,  attribution methods, 
intensity of ascertainment, & 
harms-related monitoring & 
stopping rules, if pertinent) 
Explain why the chosen 
outcomes & , when relevant, 
the length of follow up are 
considered important to those 
who will use the results of the 
trial. 
Details of whether & how the 
clustering by care providers or 
centres was addressed 
If calculated using the smallest 
difference considered 
important by the target  
decision maker audience (the 
minimally important 
difference) then report where 
this difference was obtained 
6b Any changes to  pilot trial 
assessments or  measurements 
after the pilot trial commenced 
, with reasons 
6c If applicable , prespecified 
criteria to judge whether, or 
how, to proceed with future 
definitive trial 
 
Rationale for numbers in the 
pilot trial 
When applicable, explanation 
of any interim analyses and 
stopping guidelines 
 
 
8a Whether the order of 
treatment periods was 
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Blinding 
 
 
 
 
 
 
 
 
Statistical 
methods 
conceal the sequence until 
interventions were assigned 
10 Who generated the random 
allocation sequence, who enrolled 
participants, who assigned 
participants to interventions 
11a If done , who was blinded after 
assignment to interventions (e.g. 
participants, those  assessing 
outcomes) & how 
11b If relevant description of 
similarity of interventions 
 
 
 
12a Statistical methods used to 
compare groups for primary & 
secondary outcomes 
12b Methods for additional analyses 
such as subgroup analyses & 
adjusted  analyses 
randomised, with rationale, 
method used to generate 
allocation sequence 
How care providers were 
allocated to each trial group 
 
 
 
 
 
 
 
Whether or not those 
administering co-interventions 
were blinded to  group 
assignment. 
If blinded , method of blinding 
& description of the similarity 
of interventions 
If blinding was not done , or 
was not possible, explain why 
Methods used to address each 
pilot trial objective whether 
qualitative or  quantitative 
12a Methods used to  
summarise data & compare 
interventions for primary & 
secondary outcomes 
P12a Statistical approaches for 
dealing with missing data are 
explicitly stated 
12c Statistical  methods used 
to  account for carryover 
effect, period effects & intra-
subject correlation 
Describe plans for presenting 
& analysing information on 
harms (including coding, 
handling of recurrent events, 
specification of timing issues, 
handling of continuous 
measures, & any statistical 
analyses).  
Details of whether & how the 
clustering by care providers or 
centres was addressed 
 
 
 
 
Results   
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Participant flow 
diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruitment 
 
 
Baseline data 
 
 
Number 
analysed 
 
 
 
 
 
 
 
 
 
 
 
 
Outcomes & 
estimation 
 
 
 
 
 
 
 
13a For each group , the no of 
participants who were randomly 
assigned, received intended 
treatment, & were analysed for the 
primary outcome 
 
 
13b For each group, losses & 
exclusions after randomisation, 
together with reasons 
 
 
 
 
 
 
 
 
 
 
 
 
14a Dates defining the periods of 
recruitment & follow up 
14b Why the trial ended or was 
stopped 
15 Table showing baseline 
demographic and clinical 
characteristics for each group 
 
16 Each group, no participants 
(denominator) included in each 
analysis and whether the analysis 
was by original assigned groups 
 
 
 
 
 
 
 
 
 
 
17a For each primary & secondary 
outcome, results for  each group & 
the estimated effect size and its 
precision (95% confidence interval) 
 
 
 
13a.1 No & sequence of 
periods completed, & any 
changes from original plan 
with reasons 
The no of PRO outcome data at 
baseline & at subsequent time 
points should be made 
transparent 
Describe for each arm the 
participant withdrawals that 
are due to harms & their 
experiences with the allocated 
treatment 
The number of care providers 
or centres performing the 
intervention in each group & 
the number of patients treated 
by each care provider or in 
each centre 
Implementation of 
intervention. Details of the 
experimental treatment & 
comparator as they were 
implemented 
The number of participants or 
units approached to take part 
in the trial, the number which 
were eligible, & reasons for 
non-participation should be 
reported 
 
 
Including baseline PRO data 
when collected 
A description of care providers 
& centres 
16 For each intervention , 
number of periods analysed 
Required for PRO results 
Provide the denominators for 
analysis on harm  
 
 
 
 
 
For each objective , number of 
participants (denominator) 
included in each analysis. If 
relevant, these numbers 
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Ancillary 
analyses 
 
 
 
Harms 
 
 
 
 
 
 
 
17b For binary outcomes, 
presentation of both absolute & 
relative effect sizes recommended 
 
 
 
 
 
 
18 Results of any other analyses 
performed, including assessment of 
subgroup analyses & adjustment 
analyses, distinguishing pre-
specified from exploratory 
19 All important harms or 
unintended effects in each group 
(SEE CONSORT FOR HARMS) 
should be by randomised 
group 
17a.1 For each primary & 
secondary outcome, results for 
each period: accompanying 
figure displaying the trial data 
17a.2 For each primary & 
secondary outcome,  the 
estimated effect size & its 
precision (95% confidence 
interval) 
For multidimensional PRO 
results from each domain & 
time point 
Present the absolute risk / arm 
& / adverse event type, grade 
& seriousness, & present 
appropriate metrics for 
recurrent events, continuous 
variables & scale variables, 
whenever pertinent (17,18,19) 
 
 
Results of any other analyses 
performed that could be used 
to inform the future definitive 
trial 
Including PRO analyses where 
relevant 
Describe any subgroup 
analyses & exploratory 
analyses for harms 
 
19 All harms or unintended 
effects for each intervention 
Discussion 
Limitations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 Trial limitations, addressing 
sources of potential bias, 
imprecision & if relevant, 
multiplicity of analyses 
 
 
 
 
 
 
 
 
 
 
 
 
Pilot trial limitations , 
addressing sources of potential 
bias  and remaining 
uncertainty about feasibility 
P20/21 PRO-specific limitations 
& implications for 
generalizability & clinical 
practice 
Provide a balanced discussion 
of benefits & harms with 
emphasis on study limitations, 
generalizability, & other 
sources of information on 
harms. (20,21,22) 
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Generalisability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interpretation 
 
 
 
21 Generalisability (external  
validity, applicability) of the trial 
findings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 Interpretation consistent with 
results, balancing benefits & harms, 
& considering other relevant 
evidence 
Take into account the choice of 
the comparator, lack of or 
partial blinding , & unequal 
expertise of care providers or 
centres in each group 
Generalisability 
(applicability)of pilot trial 
methods and findings to future 
definitive trial  and other 
studies 
Generalisability (external 
validity) of the trial findings 
according to the intervention, 
comparators, patients, & care 
providers & centres involved in 
the  trial 
Describe key aspects of the 
setting which determined the 
trial results. Discuss possible 
differences in other settings 
where clinical traditions , 
health service organisation, 
staffing or  resources may vary 
from those of the trial 
Implications for progression 
from pilot to future definitive 
trial, including any proposed 
ammendments 
PRO data should be 
interpreted in relation to 
clinical outcomes including 
survival data 
Other 
information 
Registration 
Protocol 
 
Funding 
 
 
23 Registration number & name of 
trial registry 
24 Where the full trial protocol can 
be accessed,  if available 
25 Sources of funding and other 
support (such as supply of drugs 
(information templates)), role of 
funders 
 
 
 
 
Where the  pilot trial  protocol 
can be accessed , if available 
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Appendix 14. List of treatments and investigations, frequency and likely linked to IBD  
Treatment/ investigation Frequency of treatment/ investigation Likely linked to IBD 
Admitted for 1 day 2 Yes 
Admitted for 4 days 1 Yes 
Admitted for 7 days 1 Yes 
Ambulance transfer 1  
Barium follow through 1 Yes 
Blood test  176 Yes 
C difficile cytotoxin  2 Yes 
C. difficile stool sample  1 Yes 
Catheterised 1  
Chest X ray 3  
Chlamydia PCR 3  
Colonoscopy  4 Yes 
Colposcopy 1  
Colposcopy histopathology  1  
CT abdomen & pelvis  2 Yes 
CT thorax 1  
Cystoscopy  1  
Cytology  3  
Doppla scan lower limb arteries  1  
ECG 1  
Faeces test microbiology  2 Yes 
Flexible sigmoidoscopy 4 Yes 
Histopathology  8 Yes 
Hydrogen breath test  2  
HVS culture 2  
Infusion in day unit 3 Yes 
Microbiology wound culture  1  
MRI 1 Yes 
MRSA screen  2  
OGD  1  
Random urine test  1  
Right hemicolectomy 1 Yes 
Sputum culture  1  
Stool sample microbiology  2 Yes 
Total colectomy & ileostomy  1 Yes 
Urine microbiology  9  
USS kidneys  1  
Wound culture microbiology  2  
X ray abdomen 4 Yes 
X ray ankle  1  
X ray both hand, knee, ankle  1  
X ray fingers  1  
X ray foot  2  
X ray foot, wrist, hand 1  
X ray hand  1  
X ray knee 1  
X ray pelvis 2 Yes 
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Appendix 15. Primary and secondary care appointments and frequency 
 
Primary care appointments 
 
Frequency of appointments 
Appointment with GP 152 
Appointment with GP minor surgery 1 
Telephone call with GP 31 
Home visit from GP 7 
Out of hours GP 1 
Appointment with nurse 129 
Telephone call with nurse 9 
Appointment with HCSW 11 
 
 
Secondary care appointments Frequency of appointments 
Email  with Nurse Practitioner (band 7) 2 
Outpatient with Consultant 43 
Outpatient with Nurse Practitioner (band 7) 17 
Telephone call with Nurse Practitioner (band 7) 20 
Postal review 2 
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Appendix 16. List of medication   
 
Medications 
Strength Dose Frequency Duration 
(days) in 
study 
period 
1/8/10-
31/1/11 
= 184 
days 
Number 
of 
patients 
Medication 
used to 
treat IBD 
or effects 
of IBD 
ACTOS 45mg 1 OD 184 1  
Adcal D3  1.5g 1 BD 184 1 
 
Adcal D3 1.5g 2  78 1 
 
Alendronic acid 70mg 1  1/ week 184 3 
 
Allopurinol 100mg 1 OD 184 1  
Amitryptiline 10mg 1 OD 184 1  
Amlodipine 5mg 1 OD 184 3  
Amlodipine 10mg 1 OD 184 1  
Asacol 400mg 1 BD 184 1 
 
Asacol  400mg 2 TDS 184 5 
 
Asacol  400mg 2 BD 184 3 
 
Asacol 400mg 2  136 1 
 
Asacol 400mg 3  48 1 
 
Asacol 400mg 2  39 1 
 
Asacol  400mg 3 BD 184 1 
 
Asacol  400mg 2 OD 184 1 
 
Asacol  400mg 2  184 1 
 
Aspirin  75mg 1 OD 184 12  
Atenolol 50mg 1 OD 184 1  
Atorvastatin 10mg 1 OD 184 2  
Atorvastatin 40mg 1 OD 184 1  
Azathioprine 75mg 1 OD 27 1 
 
Azathioprine 50mg 1 OD 4 1 
 
Azathioprine  175mg 1 OD 184 1 
 
Azathioprine 50mg 1 BD 184 1 
 
Azathioprine 50mg 2  142 1 
 
Azathioprine 50mg 4 OD 184 1 
 
Azathioprine 50mg 2 OD 184 1 
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Azathioprine 50mg 2  39 1 
 
Azathioprine 75mg 1  145 1 
 
Azathioprine 125mg 1 OD 184 1 
 
Azathioprine 25mg 1 OD 184 1 
 
Azathioprine 50mg 3 OD 184 1 
 
Azathioprine  3  157 1 
 
Azathioprine 50mg 3  184 1 
 
Balsalazide 750mg 3 TDS 184 1 
 
Beclometasone 50mcg 2 BD 184 1  
Bendroflumethazide 2.5mg 1 OD 184 6  
Betahistine   8mg 1 TDS 184 2  
Bisoprolol 2.5mg 1 OD 184 1  
Budesonide inhaler 100mcg 2 BD 184 1  
Buscopan 10mg 1  1 1 
 
Buscopan 20mg 1 OD 184 1 
 
Calcichew D3 Forte  1 BD 184 2 
 
Calcichew D3 Forte  1 OD 184 6 
 
Calcichew D3 Forte  1 BD 78 1 
 
Calcichew D3 Forte   2 BD 184 1 
 
Calcichew D3 forte   2 OD 184 1 
 
Cefatazidime  1  5 1  
Cefuroxime 750mg 3  4 1  
Celluvisc 0.5%  1 6/day 184 1  
Chlordiazepoxide 30mg 3  1 1  
Cilostazol 100mg 1 BD 184 1  
Clexane 40mg 1  10 1  
Clexane 40mg 1  4 1  
Coamilofruse  1  1   
Coamoxiclav 500/125  1  1 1  
Cocodamol 500/30  2 QDS 184 1  
Codydramol  2  78 1  
Codyramol 500mg 2 QDS 184 1  
Colazide 750mg 2 BD 184 2 
 
Cyclizine 50mg 1  1 1  
Cyclizine IV 50mg 1  7 1  
Cyclizine IV 50mg 1  1 1  
Diamorphine 1.5mg 1  1 1  
Diamorphine 1.25mg 1  1 1  
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Diclofenac 50mg 8  4 1  
Dihydrocodeine 30mg 1 OD 184 1  
Diltiazem SR 120mg 1 OD 184 1  
Doxazosin 4mg 1 OD 184 1  
Enoxaparin 120mg 1  6 1  
Erythromycin 250mg 1 OD 184 1  
Exemestane 25mg 1 OD 184 1  
Ezetimibe 10mg 1 OD 184 1  
Fecanide 50mg 1 BD 184 1  
Felodipine 5mg 1 OD 184 1  
Fentanyl IV 2.5mg 2  1 1  
Ferinject IV 500mg 2  1 1 
 
Ferrous Sulphate 200mg 1 OD 184 2 
 
Ferrous Sulphate 200mg 1 TDS 184 2 
 
Ferrous sulphate 200mg 1  95 1 
 
Fludrocortisone 100mcg 1 OD 184 1  
Folic acid 5mg 1 OD 184 4 
 
Fossamax 70mg 1 1/week 184 2  
Fossamax 70mg 1  125 1  
Fruosemide  40mg 1 OD 184 3  
Fruosemide  40MG 1 BD 184 1  
Frusemide 60mg 1 OD 184 1  
Fybogel  1  1 1  
Gliclazide  80mg 1 OD 184 1  
Gliclazide  80mg 1 BD 184 1  
Glucophage SR 500mg 2 OD 184 1  
Hartmanns 1l 8  3 1  
Hartmans 1l 1  5 1  
Human Mixtard 30 28u 1 OD 184 2  
Hydrocortisone 100mg 1  7 1 
 
Hydroxocobalamin 
inj 
1mg 1 Every 3 
months 
184 2  
Ibuprofen 400mg 1 TDS 184 1  
Infliximab 5mg/Kg 400mg 1 3 1 
 
Isosorbide 
mononitrate 
20mg 1 BD 184 1  
Lactose 50g 1  1 1  
Lactulose 5ml 1  106 1  
Lansoprazole 30mg 1 OD 184 1  
Lansoprazole 15mg 1  184 1  
Latanoprost 0.005%  2 OD 184 1  
Loratadine 10mg 1 OD 184 1  
Losec 20mg 1  184 1  
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Lymecycline 408mg 1 OD 184 1  
Mebeverine 135mg 1  62 1  
Metformin  500mg 1 QDS 184 1  
Metformin  500mg 1 TDS 184 1  
Metformin 500mg 2 BD 184 2  
Metformin  850mg 1 BD 184 1  
Metoclopramide 10mg 1  1 1  
Metoprolol 50mg  1 BD 184 1  
Metronidazole 500mg IV 1  4 1  
Mezavant 1200mg 2 OD 184 1 
 
Mezavant 1200mg 3 OD 184 1 
 
Mezavant XL 1200mg 1  184 1 
 
Mezavant XL 1200mg 1 OD 184 1 
 
Morphine 100mg 1  1 1  
Movicol  1  3 1  
Multivitamin  1  78 1  
Mysolin 250mg 1 BD 184 1  
Naproxen  1  92 1  
NONE     12  
Olmesartan 
Medoxomil 
20mg 1 OD 184 1  
Omeprazole  20mg 1 OD 184 4  
Ondansertron 8mg 2  1 1  
Ondansetron 4mg 1  1 1  
Otrivine nasal drops 
0.1% 
2-3 drops 1  1 1  
Oxycontin 10mg 1 OD 184 1  
Paracetamol 500mg 2  10 1  
PCA: Heavy 
Bupivcane 
0.50% 1  1 1  
Pentasa 500mg 2 QDS 184 4 
 
Pentasa 500mg 2 BD 184 7 
 
Pentasa 500mg 2 TDS 184 1 
 
Pentasa 500mg 2 QDS 64 1 
 
Pentasa 500mg 2  120 1 
 
Pentasa 500mg 1 TDS 184 1 
 
Pentasa 500mg 2 QDS 140 1 
 
Pentasa 500mg 2  83 1 
 
Pentasa 500mg 2  101 1 
 
Pentasa 500mg 2  37 1 
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Pentasa 500mg 4  146 1 
 
Pentasa enema 1g 1  1 1 
 
Pentasa enema 1g 1 OD 184 2 
 
Pentasa 
suppositories 
1g 1  28 1 
 
Perindopril 4mg 1 OD 184 1  
Perindopril 8mg 1 OD 184 1  
Phenobarbitone 30mg 1 BD 184 1  
Pioglitazone 45mg 1 OD 184 1  
Polycal drink  1  1 1  
Predfoam enema 20mg 1 OD 184 1 
 
Prednisolone  5mg 8 OD 8 1 
 
Prednisolone 5mg 12 OD 15 1 
 
Prednisolone 5mg 10 OD 16 1 
 
Prednisolone 5mg 8 OD 30 1 
 
Prednisolone 5mg 6 OD 8 1 
 
Prednisolone 5mg 4 OD 10 1 
 
Prednisolone 2.5mg 6 OD 8 1 
 
Prednisolone 2.5mg 5 OD 8 1 
 
Prednisolone 2.5mg 4 OD 6 1 
 
Prednisolone 5mg 1 OD 75 1 
 
Prednisolone  5mg 1 OD 184 1 
 
Prednisolone 5mg 4  4 1 
 
Prednisolone 5mg 8  11 1 
 
Prednisolone 5mg 1  39 1 
 
Prednisolone 5mg 8  15 1 
 
Prednisolone 5mg 7  7 1 
 
Prednisolone 5mg 6  21 1 
 
Prednisolone  5mg 1 OD  1 
 
Prednisolone 5mg 1  172 1 
 
Prednisolone 4mg 1  12 1 
 
Prednisolone 2.5mg 3  184 1 
 
Prednisolone  12.5mg 1 OD 184 1 
 
Prednisolone 2.5mg 1  184 1 
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Prednisolone  1mg 4 OD 184 1 
 
Prednisolone 5mg 1  184 1 
 
Prednisolone  5mg 1 OD  1 
 
Prednisolone 5mg 1  38 1 
 
Prednisolone 5mg 8  15 1 
 
Prednisolone 5mg 7  2 1 
 
Prednisolone 5mg 6  7 1 
 
Prednisolone 5mg 5  7 1 
 
Prednisolone 5mg 4  7 1 
 
Prednisolone 5mg 3  7 1 
 
Prednisolone 5mg 2  7 1 
 
Prednisolone 5mg 1  7 1 
 
Questran 4g 1 OD 184 1 
 
Questran  1  43 1 
 
Quinine Sulphate 300mg 1 OD 184 2  
Qvar 100mcg 2 BD 184 1  
Ramipril  5mg 1 OD 184 5  
Ramipril  10mg 1 OD 184 3  
Ramipril 2.5mg  1 OD 184 1  
Ramipril  40mg 1 BD 184 1  
Ranitidine 300mg 1 OD 184 2  
Ropinirole 2mg 1 OD 184 1  
Salazopyrine  500mg 2 BD 184 2 
 
Salazopyrine  500mg 1 BD 184 1 
 
Salbutamol inhaler 100mcg 2 OD 184 1  
Seretide inhaler   2  1 1  
Sertraline 50mg 1 OD 184 1  
Simvastatin  40mg I OD 184 7  
Simvastatin  10mg 1 OD 184 1  
Simvastatin  20mg 1 OD 184 1  
Slo-phyllin 125mg 1 OD 184 1  
Sotalol 80mg 1 OD 184 1  
Sulfasalazine 500mg 2 BD 134 1 
 
Sulphasalazine 500mg 1 TDS 184 1 
 
Symbicort 400/12  2 OD 184 1  
Tamsulosin 400mcg 1  13 1  
Tamsulosin 400mcg 1 OD 184 1  
TED stockings    1 2  
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Thyroxine  125mcg 1 OD 184 1  
Thyroxine  150mcg 1 OD 184 1  
Thyroxine  100mcg 1 OD 184 1  
Tramadol  100mg 4  28 1  
Tramadol 100mg 3  1 1  
Tramadol IV 100mg 5  4 1  
Trimethoprim 200mg 1  6 1  
Vitamin B12  1 3 monthly 184 2 
 
Warfarin 10mg 1  2 1  
Warfarin 3mg 1  1 1  
Warfarin 1mg 1  1 1  
Warfarin 6mg 2 OD 184 1  
Zoton 30mg 1 OD 184 2  
Zoton 15mg 1 OD 184 1  
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Appendix 17. Time taken to produce the ELIJAH intervention 
 
 Time taken in 
minutes 
Frequency Total in minutes 
Requesting notes 1 
2 
3 
4 
5 
25 
30 
18 
11 
6 
2 
1 
1 
1 
126 
Reading notes 2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
17 
19 
21 
24 
2 
4 
3 
5 
3 
2 
1 
2 
1 
2 
1 
1 
3 
3 
2 
1 
2 
2 
398 
Accessing GeneCIS 
information 
1 
2 
3 
4 
6 
8 
11 
17 
11 
15 
9 
1 
1 
1 
1 
1 
114 
Completing ELIJAH 
questionnaire 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
1 
4 
5 
3 
3 
1 
1 
2 
3 
1 
5 
2 
4 
410 
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15 
19 
21 
27 
45 
1 
1 
1 
1 
1 
Printing and sending 
reports 
1 
2 
3 
4 
5 
6 
7 
12 
13 
2 
15 
8 
6 
2 
4 
1 
1 
1 
146 
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Appendix 18. List of ELIJAH Adverse Events 
Adverse Event  Frequency AE 
reported / identified 
Likely linked to 
IBD 
? Diagnosis 1  
? Sebaceous Keratosis 1  
Abdominal pain 1 Yes 
Acne 1  
Adhesive capsulitis 1  
Admission postponed 1  
Admitted unwell 1  
AF 1  
Angina 1  
Ankle pain 1  
Anxiety 2  
AXR & CT 1  
Ba f through 1  
Backache 1  
Banged head 1  
Bheplorins 1  
Blurry vision 1  
Burning in feet 1  
Burning on tongue 1  
Campylobacter 1  
Cataract extraction 2  
Cataracts 1  
Cervicalgia 1  
Chest infection 3  
Circumcision 1  
Coccyx pain 1  
Colectomy 1  
Collapse 2  
Colonoscopy 4  
Conjunctivitis 1  
constipation 2 Yes 
Cough  10  
Cough with blood 1  
CT brain 1  
Declined lung transplant 1  
degenerative hip 1  
DeQuervaim  1  
Diarrhoea & constipation 1 Yes 
Dog bite 1  
Dry mouth 1  
DVT 1  
Dyspepsia 1  
Dysuria 1  
Ear inflammation 1  
ear pain 1  
Ear syringing 1  
Ear wax 1  
Eczema 1  
F/sig 5  
 269 
 
Fall 2  
Fistula burst 1 Yes 
Foot injury 1  
Gout 1  
H breath test 2  
Hands numb 1  
High CRP 1 Yes 
Hypoglycaemia 1  
Increased IBD 11 Yes 
Indigestion 1  
Infection 2  
Inflammation 1 Yes 
Injury L hand 1  
Iritis 2 Yes 
Itchy eyes 2 Yes 
Joint aspiration 1  
Joint pain 1  
L shoulder pain 1  
Laceration R elbow 2  
Lack of taste 1  
Light-headedness 1  
LOC 1  
Loose bowels 1 Yes 
Lower abdo pain 1 Yes 
Lumbago 2  
Lump R groin 1  
Macular degeneration 1  
Medical escalation 1 Yes 
memory loss 1  
Mouth ulcer 2 Yes 
Neuropathic pain 1  
Nocturnal defaecation 1  
Nose bleed 1  
Oral thrush 1  
Osteoarthritis 1  
Otalgia 1  
Pain  1  
Pain neck & arm 1  
Palpitations 2  
Pellety stool 1 Yes 
Penile discharge 1  
Peripheral neuropathy 1  
Plantar fascitis 1  
Pleuritic pain 1  
PR blood 3 Yes 
Pseudomonous 1  
R abdo pain 1  
R groin pain 1  
R hand pain 1  
R hemicolectomy 2  
R hernia repair 1  
Rash 2  
 270 
 
Rectal inflammation 1 Yes 
redness of ear 1  
Retention of urine 1  
Rhinitis 1  
sagittal sinus thrombosis 1  
Shave excision 1  
sinusitis 1  
Skin deterioration 1  
Skin tags 1  
SOB 4  
Sore throat 1  
Start infliximab 1 Yes 
steroids 1  
Swollen eye 1  
Swollen finger 1  
Swollen legs 1  
Syringing ear wax 1  
Testicular pain 1  
TIA 1  
Tingling 1  
Tinnitus 1  
Transferred hospital 1  
TWOC 1  
Unwell 1  
Upper respiratory infection 1  
Urinary incontinence 2  
Urticuria 1  
UTI 7  
Vaginal discomfort 2  
Vaginitis 1  
Watery eye 1  
Weight loss 1 Yes 
Wound discharge 1  
Wound infection 1  
Wound R foot 1  
X-ray foot 1  
X-ray hand 1  
X-ray pelvis 2  
X-ray spine 1  
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Appendix 19:  List of ISSQ Patient free text comments 
 
Intervention patients 
Participant 
number 
Trimester Comment  Positive 
comment 
Negative 
comment 
006 Baseline Very pleased, takes tablets - salazapyrenes. V. Good. 
 
 
019 Baseline Condition varys from day to day have lived with it for many years 
so have come to accept it. 
 
 
 1 Sister/ I am sorry I can not give a date when I was diagnosed, as 
mentioned I had problems when I was in my Teens. Also I am not 
sure what my condition is supposed to be. 
 
 
 2 Sister: sorry for the delay in filling your form. Did have a fall which 
meant I was feeling depressed. As you know I have never 
contacted you concerning my colitis only seen you at clinic. I do 
have bad days it seems when a bit stressed out. But seems to be 
soon ok. I have had this complaint for so long I just take it in my 
stride. Thank you. 
 
 
 3 I have lived with my condition many years. I have my good days 
and bad. I am happy that you are able to keep looking after me 
which is very reassuring.  
 
020 1 Some days I am fine but other days I am in pain and in discomfort 
and feel very bloated. However I have not experienced the nausea 
or sickness that I had a few months ago. I am awaiting result  n a 
food allergy test that my GP did andhope to see a dietician. 
 
 
023 3 I have a follow up appointment to see Prof. j. G. Williams on 
March 7th 2011. 
 
 
024 1 Sometimes I do get a little down but then I buck up 
 
 
 2 Since taking prebiotic low fat yoghurt drink seem to be a lot better 
 
 
 3 I am a little bit anxious when it flares up  
 
032 2 Moderately depressed because I have an ongoing eye infection 
and I have a school inspection due in February which is making me 
feel very stressed. 
 
 
 2 Sorry for delay in returning information. I have a school inspection 
due and paperwork coming out of everywhere! Happy new year. 
 
 
 3 Very satisfied with the care I receive from the staff at the 
Endoscopy Unit at Neath Port Talbot Hospital. 
 
 
036 Baseline Stressful to start with a lot of examinations.  
 
050 3 I suffer badly from constipation. If I take anything things become 
extreme. I only go out once a week to shop as I cant hold my 
water. The surgery are very helpful with necessary equipment. 
Thank you. 
 
 
059 Baseline I hope that if selected I would like electronic contact 
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 2 As for the last question; I am occassionally anxious or depressed. 
 
 
069 Baseline I am diabetic - type 2 
 
 
070 1 Q26 the problems mentioned do not have anything to do with 
chrones PS sorry for the delay 
 
 
 2 Just finished a course of steroids after a flare up over Christmas. I 
simply got a repeat prescription and its now back to normal. 
 
 
075 1 Phedra! Its been a while since I've seen you which isnt a bad thing 
and I mean that in terms of my colitis!! Imogen is growing and 
changing every day - cant believe she is 6 months old - on solids, 
sitting up on her own and has found her voice! Anyway just a 
quick hello, hope all's well with you. Love 
 
 
076 1 The middle box under pain + discomfort has been ticked because 
today I am experiencing mild constipation, I have received advice 
on how to help when this happens , which is useful to me. There is 
also a fatty lump present in the exact place of the  pain (low, left 
side of stomach) I feel that this may be contributing to my 
discomfort and will ask this question in the future 
 
 
 3 From time to time I experience problems at work, some tasks I do 
are difficult to carry out if I am having what I call "flare ups" - I also 
find it awkward to be able to communicate this information at 
work and therefore experience anxiety at times. 
 
 
078 2 The discomfort is merely the excess flatulence. 
 
 
084 Baseline I am not in any pain, on suffering with my mobility at present, 
although I do have flare ups when my joints are quite painful. I 
also get bouts of anxioutus from time to time especially if I have to 
go on long trips I fear I will not be able to access a toilet. 
with regard to questions (14) I put severe because the constant 
need for the toilet and passing blood in my stools which lasted a 
few weeks. (15) the pain I experienced was not to bad its the 
bleeding and urgent need for the toilet that is the worst. (26) I do 
have some problems with mobility when I get a flare up my joints 
go really stiff and inflammed I do get anxious at certain times. I am 
afraid I may not make it to the toilet on time in work or if I am in 
the car. 
 
 
 2 As in the last questionnaire I do experience some anxiety 
especially when I am having a flare up, I worry that I will not be 
able to make it to the toilet on time and I get some joint pain at 
the time of flare up as well as quite a bit of bleeding from bowel. It 
seems to come on quite severe in autumn I am having trouble 
with it at the moment. 
 
 
 3 The pain and discomfort is in the immediate area of the flare up. I 
do feel rather anxious and depressed when the flare up occurs. I 
am quite well otherwise. 
 
 
096 Baseline Excellent care last time in hospital & good aftercare good 
azopyroththese good when help needed call was returned within 
the hour.  
 
117 Baseline My bowel condition is not too much of a problem most of the time 
but my general health is made difficult by emphysema. 
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 1 My bowel condition is manageble most of the time but I have  
emphysema / COPD and so am very limited in what I can  
physically achieve 
 
 
 
 
 3 I have answered the "care" questions with the assumption 'care' 
means that which I receive at the endoscopy unit when my 
condition has worsened. I've been fortunate in not requiring much 
attention and have no care at home - I'm able to look after myself. 
I am still waiting for a bone scan as recommended at my last 
appointment at the endoscopy clinic. 
 
 
133 1 Recently I have had problems which tried to sort out myself; I 
visited my GP to ask for some asacol suppositories which he 
refused to give me saying that yourself recommended that I have 
Predfoam I would it be possible to write to my GP to let me have 
have the asacol suppositories if needed again please, as I had 
some in the house that I found and it cleared it up within a couple 
of days. I tried to explain that I knew what I needed but he refused 
point blank to give me what I knew would clear it. Thank you 
 
 
 2 I dont know if you had my last questionnaire which I sent back 
about 3 wks ago, I did ask if you could inform my GP that if I get 
problems in future that he could give me Asacol suppositories, he 
would only give me Predfoam last time, I find asacol suppositories 
suite my needs better and clear any problems up within days. 
 
 
 
 3 I can usually keep my condition under controll if it comes on I take 
Asacol supp. And at the moment it clears it up in the course of 7 
days if it doesent then I would get in touch with yourselfs but as 
long as I take a fair amount of fruit and fibre based foods it keeps 
it at bay. 
 
 
134 1 My condition is good the last few years with no problems. I try not 
to get stressed with anything anymore. Stress free and slowing 
down my pace of life helps keep this condition at bay.  
 
 2 No problems with my health recently. No symptoms at all. 
 
 
 3 Recently I have experienced "bloatyness" of my stomach and on a 
few occassions extreme pain from trapped wind - much more than 
over the past few years. Not sure if this is due to UC. 
 
 
138 Baseline Following a hernia operation, I have had very troublesome 
diarrhoea, which I reported to the surgeon on my return visit to 
the hospital he referred me to the endoscopy unit and on my 
second visit I was given some tablets which have helped 
 
 
 2 Sister Phedra was very kind and patient. When i saw the doctor on 
my last visit, he seemed to think I did not have Crohn's disease. 
But a condition caused by my diabetes. I have another visit in 
February to see Professor Williams. 
 
 
 3 I have had diarrhoea since August 209 following a hernia 
operation. I also have diabetes and on insulin and metformin since 
around 1994. I did ? The metformin with my GP and he did not 
think it was the tablets because I did not have any symptoms for 
about 4 years before I had the operation. 
 
 
154 2 Been fine for several years now 
 
 
 3 Fit as a fiddle! 
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156 1 some problems related to macular degeneration 
 
 
 3 I have difficulty in completing the form - I am unable to read it due 
to very poor eyesight and I need assistance. 
 
 
 
Control patients 
 
Participant 
Number 
Trimester Comment Positive 
comment 
Negative 
comment 
004 Baseline I was offered medication for my condition. I declined and visited a 
homeopath instead. I noticed an improvement within hours and 
that improvement continued. I have had no symptoms since 2007.  
 
017 Baseline On occasion I am moderately anxious + stressed - work related 
triggers. I suffer from numerous allergies + sometimes find links 
between flare up's + food/ chemicals (laxitives) 
 
 
 1 After my appointment in July I was given the option of when to 
receive a follow-up appointment, this being because I am trying to 
conceive. I chose 3 months. I havent recieved an appointment and 
its been over 4 months. I have had small flare-ups, but have self 
managed the condition. I have been pro-active and com pleted an 
'expert patient programme', through my workplace. It would be 
hugely beneficial if I were able to email regarding flare-ups, for 
advice etc. Sorry this is late, I've been on holiday. Thank you.  
 
 
 2 This is the third questionnaire I have filled out and sent back in 
just over a month, either the mail isnt reaching the department or 
getting to the hospital. 2. I wish I could contact via email - as I can 
only contact during the day/worktime and its an embarrasing 
problem (I work in a male environment). 3. I was given the choice 
of when to have a follow up appointment  - as I was/am trying to 
conceive I chose 3 months, back in June/july - its been more than 
3 months and I haven't heard anything. When I do get treatment / 
advice from my nurse practitioner its always fantastic, but its just 
getting there/contact for advice/ appointments that dissapoint 
me. 
 
 
 3 I am very happy with the care I receive. I did however turn up to 
an appointment that had been made for me to be told that it had 
been rescheduled , however both letters I received hadnt 
mentioned that at all, I received a very cold reception when I was 
unhappy about making a wasted journey. In fact it was quite 
accusational , but I let it go. Just thought it was worth mentioning 
here - even if it is admin and not care. 
 
 
042 1 I have not had a problem for a long time if I should again I would 
get in touch with Sr Phedra Dodds immediately. I concider myself 
very lucky to have a son and daughter and grand children who 
help my husband and I a lot such as helping with housework & 
shopping, my son in law is also a good helper. We are so lucky 
they are true carers. I suffer from rhumatoid arthritis but 
medication keeps it at bay. 
 
 
 1 I have no pain at all, but if I eat too much chocolate or take gravy 
made from juices of a meat joint then I am in trouble and spend a 
lot of time in the toilet. I have learnt to avoid both. Hope this is of 
help for you. 
 
 
044 Baseline Note: spondulitis affects my ability more than the Chrones 
 
 
 275 
 
 3 Please note: I also have spondulitis which is the main cause for 
mobility and usual activities 
 
 
047 1 Mobility. I an very awry of going anywhere if I am not sure about 
the provision of public toilets. 
 
 
 2 Mobility. I would be happier if there were more public 
conveniences open - as there were 20 years ago. 
 
 
 3 Some problems - due to a flare up last week - I was concerned 
about going out due to the 
lack of public toilets. 
 
 
049 1 Since the last time I saw you (Phedra Dodds) believing it to be 
wind and bloatedness. I am extremely tired and lifeless. Relating 
to question 3 I feel I have not recieved enough information on my 
condition and would like reading material to help me understand 
and cope with the symptoms. 
 
 
 2 Dear Phedra, Sorry about the delay in sending this form. I havn't 
been up to standard. Everything seems to be ok at the moment , 
still getting severe stomach cramps at time. Will explain during my 
next appointment with you. Hope my answers are ok. Many 
thanks. 
 
 
 3 Everything is going well at the moment but I know that if needed I 
can contact the department and get an appointment with any 
worries or problems I may have. My usual appointment s are with 
Phedra and my next one is not until July / August. Many thanks 
 
 
090 Baseline I have multiple medical conditions 
 
 
091 1 Pain or discomfort I have only occasional discomfort which I am 
well able to cope with. Many thanks for your continued help and 
support.  
 
 2 Apart fr om the occasional mild flare up I have been able to 
manage my condition by various diet and eating habit changes. 
 
 
 3 I am confident that the support is there if needed. Since my 
condition was diagnosed in March 07 and the initial course of 
medication completed I have experienced mild flare ups. Being of 
a minor nature this has not induced me to seek care. My state of 
health today is very good. 
 
 
104 Baseline Forgot glasses 
 
 
 2 I can only say regarding when I was diagnosed with my condition 
that it was in the "old neath hospital" by Professor Williams 
 
 
105 1 Question 26 answers are for rheumatoid arthritis 
 
 
 2 The above answers are more to do with rheumatoid arthritis 
 
 
 3 The  discomfort and pain I experience is from rheumatoid arthritis 
which I am now on treatment for. 
 
 
109 Baseline My last coloscopy showed no sign of ulcerative colitis after 45 yrs. 
I trust that God has healed me. 
 
 
 1 I am totally satisfied with the care and treatment I have had in the 
past 
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 3 I appreciate very much the excellent care I have received. 
 
 
127 Baseline I have never queried Doctors remarks or made any extra queries 
outside of surgery 
 
 
 1 I have to know where the nearest toilet location is.  
 
 2 Started reducing medication of asathioprine from 3 - 2 on 12 Oct. 
Then from 2 - 1 on 30 Nov. 
 
 
 3 I have never asked for help other than my regular appointment. 
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Appendix 20. ELIJAH budget 
 
Amount awarded  £74,336.00 
 
Type of cost Budgeted (total) £ Spend (total) £ 
Project Manager 0.4 WTE 18,336 18,153 
Project Setup 1,000 0 
Health Economics 5,000 5,000 
Data Management 5,000 6,055 
Travelling 1,000 1,120 
Technical Support 42,000 42000 
User Costs 2,000 1,680 
Incidental 0 
328 
 
Total 74,336 74,336 
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Appendix 21. PRISMA checklist 2009  
 
Section / 
topic 
PRISMA 2009 
No.       Item 
Title  1 Identify the report as a systematic review, meta-analysis, or both 
Abstract 
Structured 
summary 
 
2 Provide a structured summary including , as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions, study 
appraisal and synthesis methods; results; limitations; conclusions & implications of 
key findings; systematic review registration number 
Introduction 
Rationale 
Objectives 
 
3 Describe the rationale for the review in the context of what is already known 
4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS) 
Methods 
Protocol & 
registration 
 
Eligibility 
criteria 
 
Information 
sources 
 
Search 
 
 
Study 
selection 
Data 
collection 
process 
Data items 
 
Risk of bias in 
individual 
studies 
Summary 
measures 
Synthesis of 
results 
Risk of bias 
across studies 
 
Additional 
analyses 
 
5 Indicate if a review protocol exists, if & where it can be accessed (e.g. Web 
address), and, if available, provide registration information including registration 
number 
6 Specify study characteristics (e.g. PICOS, length of follow up) & report 
characteristics (e.g. years considered, language, publication status) used as criteria 
for eligibility, giving rationale 
7 Describe all information sources (e.g. databases with dates of coverage, contact 
with study authors to identify additional studies) in the search and date last 
searched 
8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated 
 
9 State the process for selecting studies (i.e. screening, eligibility, included in 
systematic review, and , if applicable, included in the meta-analysis). 
10 Describe method of data extraction from reports (e.g. piloted forms, 
independently, in duplicate) & any processes for obtaining & confirming data from 
investigators 
11 List & define all variables for which data were sought (e.g. PICOS, funding 
sources) & any assumptions & simplifications made 
12 Describe methods used for assessing risk of bias of individual studies ( including 
specification of whether this was done at the study or outcome level), & how this 
information is to be used in any data synthesis 
13 State the principle summary measures (e.g. risk ration, difference in terms) 
 
14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistence (e.g. I2) for each meta analysis 
15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g. publication bias, selective reporting within studies) 
 
16 Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, 
meta-regression) , if done, indicating which were pre-specified 
Results 
Study 
selection 
 
17 Give numbers of studies screened, assessed for eligibility, & included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram 
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Study 
characteristics 
Risk of bias 
within studies 
Results of 
individual 
studies 
Synthesis of 
results 
Risk of bias 
across studies 
Additional 
analysis 
18 For each study , present characteristics for which data were extracted (e.g. 
study size, PICOS, follow up period) & provide the citations 
19 Present data on risk of bias of each study and , if available, any outcome level 
assessment 
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot 
21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency 
22 Present results of any assessment of risk of bias across studies 
 
Give results of additional analysis, if done (e.g. sensitivity or subgroup analyses, 
meta regression) 
Discussion 
Summary of 
evidence 
 
Limitations 
 
Conclusions 
 
24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g. healthcare providers, users & 
policy makers) 
25 Discuss limitations at study & outcome level (e.g. risk of bias), & at review-level 
(e.g. incomplete retrieval of identified research, reporting bias) 
26 Provide a general interpretation of the results in the context of other evidence, 
& implications for further research 
Funding 
Funding 
 
27 Describe sources of funding for the systematic review & other support (e.g. 
supply of data); role of funders for the systematic review 
 
Ref: Moher D., Liberati A., Tetzlaff J., Altman D., The PRISMA Group. (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-analyses: The PRISMA Statement. PLoS 
Med 6(7): e1000097. Doi:10.1371/journal.pmed.1000097 
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Appendix 22: Search strategy and findings 
Electronic database Number of articles 
identified and appraised 
Number of articles 
included in the 
systematic literature 
review 
AMED 69 0 
BNI 40 0 
CINAHL 35 0 
Cochrane 40 4 
EMBASE 76 0 
EMCARE 27 3 
Google Scholar 13 12 
Medline 559 19 
Other - 5 
Psychinfo 44 2 
TRIP 13 0 
Web of Science 300 20 
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Appendix 23. Quality scoring of articles 
Article 
number 
Author Selection  
bias 
Design Confounders Blinding Data 
collection 
Withdrawals Total 
score 
1.  Al-Sahan A.  0 0 0 0 2 0 2 
2.  Archer J.S. 
et al.  
N/A N/A N/A N/A N/A N/A N/A 
3.  Bartlett C. 
et al.  
0 0 0 0 0 0 0 
4.  Bell S.K. et 
al.  
0 0 0 0 0 0 0 
5.  Bhavnani V. 
et al.  
0 1 0 0 0 1 2 
6.  Bidmead E. 
et al.  
0 0 0 0 0 0 0 
7.  Casey I. et 
al 
0 0 0 0 1 0 1 
8.  Chunchu J.J. 
et al. 
0 1 0 0 1 2 4 
9.  Cimino J.J. 
et al. 
0 0 0 0 0 1 1 
10.  Cimino J.J. 
et al. 
0 0 0 0 1 0 1 
11.  Cimino J.J. 
et al. 
0 0 0 0 0 1 1 
12.  Cruickshank 
J. et al 
0 0 0 0 0 0 0 
13.  Di Marco C. 
et al. 
N/A N/A N/A N/A N/A N/A N/A 
14.  Druss B.G. 
et al. 
2 2 0 0 1 2 7 
15.  Farrelly S. 
et al. 
N/A N/A N/A N/A N/A N/A N/A 
16.  Ferreira A. 
et al. 
N/A N/A N/A N/A N/A N/A N/A 
17.  Fisher B. et 
al. 
0 0 0 0 0 0 0 
18.  Forbes M. 
et al. 
1 2 0 0 1 2 6 
19.  Garcia-
Lizana F. et 
al. 
N/A N/A N/A N/A N/A N/A N/A 
20.  Gee P.M. et 
al. 
N/A N/A N/A N/A N/A N/A N/A 
21.  Gerard M. 
et al. 
0 0 0 0 1 0 1 
22.  Giardina 
T.D. et al. 
N/A N/A N/A N/A N/A N/A N/A 
23.  Greenberg 
A.J. et al. 
1 1 0 0 1 0 3 
24.  Hassol A. et 
al. 
0 1 0 0 1 0 2 
25.  Hemsley B. 
et al. 
N/A N/A N/A N/A N/A N/A N/A 
26.  Honeyman 
A. et al. 
1 1 0 0 1 0 3 
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27.  Jeong D.E. 
et al. 
0 1 0 0 1 0 2 
28.  Kerns J.W. 
et al 
0 0 0 0 1 0 1 
29.  Kelstrup 
A.M. et al.  
2 1 0 0 1 2 6 
30.  Khaneghan 
P.A. et al.  
0 1 0 0 1 0 2 
31.  Ko H. et al. N/A N/A N/A N/A N/A N/A N/A 
32.  Laugesen J. 
et al. 
1 2 0 1 2 1 7 
33.  Masys D. et 
al.  
0 0 0 0 1 1 2 
34.  McKinstry 
B. et al.  
0 2 1 1 2 2 8 
35.  Mold F. et 
al 
N/A N/A N/A N/A N/A N/A N/A 
36.  Muhamma
d R. et al. 
N/A N/A N/A N/A N/A N/A N/A 
37.  Nahm E-S. 
et al. 
1 2 0 1 1 2 7 
38.  Palen T.E. 
et al. 
0 1 0 0 1 0 2 
39.  Papoutsi C. 
et al. 
0 0 0 0 0 0 0 
40.  Pavlik V. et 
al. 
2 2 1 0 1 2 8 
41.  Phelps R.G. 
et al.  
0 1 0 0 1 0 2 
42.  Politi P. et 
al.  
0 1 1 0 1 0 3 
43.  Powell H. et 
al.  
N/A N/A N/A N/A N/A N/A N/A 
44.  Price M. et 
al. 
0 1 0 0 1 0 2 
45.  Price M.M. 
et al. 
N/A N/A N/A N/A N/A N/A N/A 
46.  Riippa I. et 
al. 
0 1 0 0 1 0 2 
47.  Ross S.E. et 
al.  
N/A N/A N/A N/A N/A N/A N/A 
48.  Ross S.E. et 
al.  
1 1 0 0 1 1 4 
49.  Royal 
College of 
Physicians 
0 0 0 0 1 2 3 
50.  Royal 
College of 
Physicians 
N/A N/A N/A N/A N/A N/A N/A 
51.  Royal 
College of 
Physicians 
N/A N/A N/A N/A N/A N/A N/A 
52.  Royal 
College of 
Physicians 
N/A N/A N/A N/A N/A N/A N/A 
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53.  Royal 
College of 
Physicians 
N/A N/A N/A N/A N/A N/A N/A 
54.  Royal 
College of 
Physicians 
N/A N/A N/A N/A N/A N/A N/A 
55.  Royal 
College of 
Physicians 
0 0 0 0 2 2 4 
56.  Sartain S.A. 
et al.  
N/A N/A N/A N/A N/A N/A N/A 
57.  Showell C. N/A N/A N/A N/A N/A N/A N/A 
58.  Somner 
J.E.A. et al. 
0 1 0 0 0 1 2 
59.  Tenforde 
M. et al.  
N/A N/A N/A N/A N/A N/A N/A 
60.  Wagner P.J. 
et al. 
0 2 0 0 2 1 5 
61.  Wells S. et 
al. 
0 1 0 0 0 0 1 
62.  Wells S. et 
al. 
0 1 0 0 0 0 1 
63.  Williams 
J.G. et al.  
0 2 0 0 2 1 5 
64.  Winkleman 
W.J. et al.  
N/A N/A N/A N/A N/A N/A N/A 
65.  Zarcadoolas 
C. et al. 
0 1 0 0 1 0 2 
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